




(12) **DEMANDE DE BREVET CANADIEN
CANADIAN PATENT APPLICATION**

(13) **A1**

(86) Date de dépôt PCT/PCT Filing Date: 2019/08/01
(87) Date publication PCT/PCT Publication Date: 2020/02/06
(85) Entrée phase nationale/National Entry: 2021/02/02
(86) N° demande PCT/PCT Application No.: US 2019/044575
(87) N° publication PCT/PCT Publication No.: 2020/028608
(30) Priorités/Priorities: 2018/08/03 (US62/714,238);
2019/07/31 (US16/527,802)

(51) Cl.Int./Int.Cl. *C07D 487/04* (2006.01),
A61K 31/519 (2006.01), *A61P 35/00* (2006.01)
(71) Demandeur/Applicant:
BRISTOL-MYERS SQUIBB COMPANY, US
(72) Inventeurs/Inventors:
POUDEL, YAM B., US;
GANGWAR, SANJEEV, US;
HE, LIQI, US;
SIVAPRAKASAM, PRASANNA, US;
BROEKEMA, MATTHIAS, US;
CHOWDARI, NAIDU S., US;
...
(74) Agent: GOWLING WLG (CANADA) LLP

(54) Titre : COMPOSES DE 1H-PYRAZOLO[4,3-D]PYRIMIDINE UTILISES EN TANT QU'AGONISTES DU RECEPTEUR 7 DE TYPE TOLL (TLR7) ET PROCEDES ET UTILISATIONS ASSOCIES
(54) Title: 1H-PYRAZOLO[4,3-D]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS AND METHODS AND USES THEREFOR



(57) Abrégé/Abstract:

Compounds according to formula I are useful as agonists of Toll-like receptor 7 (TLR7). Such compounds can be used in cancer treatment, especially in combination with an anti-cancer immunotherapy agent, or as a vaccine adjuvant.

(72) Inventeurs(suite)/Inventors(continued): COX, MATTHEW, US; TARBY, CHRISTINE M., US; ZHANG, QIAN, US

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property

Organization

International Bureau

(43) International Publication Date

06 February 2020 (06.02.2020)



(10) International Publication Number

WO 2020/028608 A1

(51) International Patent Classification:

C07D 487/04 (2006.01) A61K 31/519 (2006.01)
A61P 35/00 (2006.01)

(21) International Application Number:

PCT/US2019/044575

(22) International Filing Date:

01 August 2019 (01.08.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/714,238 03 August 2018 (03.08.2018) US
16/527,802 31 July 2019 (31.07.2019) US

(71) Applicant: BRISTOL-MYERS SQUIBB COMPANY

[US/US]; Route 206 and Province Line Road, Princeton,
New Jersey 08543 (US).

(72) Inventors: POUDEL, Yam B.; c/o Bristol-Myers Squibb

Company, 700 Bay Road, Redwood City, California 94063 (US). GANGWAR, Sanjeev; c/o Bristol-Myers Squibb Company, 700 Bay Road, Redwood City, California 94063 (US). HE, Liqi; c/o Bristol-Myers Squibb Company, 700 Bay Road, Redwood City, California 94063 (US). SI-VAPRAKASAM, Prasanna; c/o Bristol-Myers Squibb Company, Route 206 and Province Line Road, Princeton, New Jersey 08543 (US). BROEKEMA, Matthias; c/o Bristol-Myers Squibb Company, Route 206 and Province Line Road, Princeton, New Jersey 08543 (US). CHOWDARI, Naidu S.; c/o Bristol-Myers Squibb Company, 700 Bay Road, Redwood City, California 94063 (US). COX, Matthew; c/o Bristol-Myers Squibb Company, 700 Bay Road, Redwood City, California 94063 (US). TARBY, Christine M.; c/o Bristol-Myers Squibb Company, Route 206 and Province Line Road, Princeton, New Jersey 08543 (US). ZHANG, Qian; c/o Bristol-Myers Squibb Company, 700 Bay Road, Redwood City, California 94063 (US).

(74) Agent: CHAO, Yuan et al.; Bristol-Myers Squibb Company,

Route 206 and Province Line Road, Princeton, New Jersey 08543 (US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))
- of inventorship (Rule 4.17(iv))

Published:

- with international search report (Art. 21(3))

(54) Title: 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS AND METHODS AND USES THEREFOR



(57) Abstract: Compounds according to formula I are useful as agonists of Toll-like receptor 7 (TLR7). Such compounds can be used in cancer treatment, especially in combination with an anti-cancer immunotherapy agent, or as a vaccine adjuvant.

WO 2020/028608 A1

1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7)
AGONISTS AND METHODS AND USES THEREFOR

CROSS-REFERENCE TO RELATED APPLICATIONS

5 [0001] This application claims the benefit under 35 U.S.C. §119(e) of US Provisional Application Ser. No. 62/714,238, filed August 3, 2018; the disclosure of which is incorporated herein by reference.

BACKGROUND OF THE DISCLOSURE




[0002] This disclosure relates to Toll-like receptor 7 (“TLR7”) agonists and conjugates
10 thereof, and methods for the preparation and use of such agonists and their conjugates.

[0003] Toll-like receptors (“TLRs”) are receptors that recognize pathogen-associated molecular patterns (“PAMPs”), which are small molecular motifs conserved in certain classes of pathogens. TLRs can be located either on a cell’s surface or intracellularly. Activation of a TLR by the binding of its cognate PAMP signals the presence of the associated pathogen inside the
15 host – *i.e.*, an infection – and stimulates the host’s immune system to fight the infection. Humans have 10 TLRs, named TLR1, TLR2, TLR3, and so on.


[0004] The activation of a TLR – with TLR7 being the most studied – by an agonist can have a positive effect on the action of vaccines and immunotherapy agents in treating a variety of conditions other than actual pathogen infection, by stimulating the immune response overall.
20 Thus, there is considerable interest in the use of TLR7 agonists as vaccine adjuvants or as enhancers in cancer immunotherapy. See, for example, Vasilakos and Tomai 2013, Sato-Kaneko *et al.* 2017, Smits *et al.* 2008, and Ota *et al.* 2019.

[0005] TLR7, an intracellular receptor located on the membrane of endosomes, recognizes PAMPs associated with single-stranded RNA viruses. Its activation induces secretion of Type I
25 interferons such as IFN α and IFN β (Lund *et al.* 2004). TLR7 has two binding sites, one for single stranded RNA ligands (Berghöfer *et al.* 2007) and one for small molecules such as guanosine (Zhang *et al.* 2016).


[0006] TLR7 can bind to, and be activated by, guanosine-like synthetic agonists such as imiquimod, resiquimod, and gardiquimod, which are based on a 1H-imidazo[4,5-c]quinoline
30 scaffold. For a review of small-molecule TLR7 agonists, see Cortez and Va 2018.



[0007] Synthetic TLR7 agonists based on a pteridinone molecular scaffold are also known, as exemplified by vesatolimod (Desai *et al.* 2015).



- 5 [0008] Other synthetic TLR7 agonists based on a purine-like scaffold have been disclosed, frequently according to the general formula (A):



where R, R', and R'' are structural variables, with R'' typically containing an unsubstituted or substituted aromatic or heteroaromatic ring.

- 10 [0009] Disclosures of bioactive molecules having a purine-like scaffold and their uses in treating conditions such as fibrosis, inflammatory disorders, cancer, or pathogenic infections include: Akinbobuyi *et al.* 2015 and 2016; Barberis *et al.* 2012; Carson *et al.* 2014; Ding *et al.* 2016, 2017a, and 2017b; Graupe *et al.* 2015; Hashimoto *et al.* 2009; He *et al.* 2019a and 2019b; Holldack *et al.* 2012; Isobe *et al.* 2009a and 2012; Poudel *et al.* 2019a and 2019b; Pryde 2010; and Young *et al.* 2019.

[0010] The group R'' can be pyridyl: Bonfanti *et al.* 2015a and 2015b; Halcomb *et al.* 2015; Hirota *et al.* 2000; Isobe *et al.* 2002, 2004, 2006, 2009a, 2009b, 2011, and 2012; Kasibhatla *et al.* 2007; Koga-Yamakawa *et al.* 2013; Musmuca *et al.* 2009; Nakamura 2012; Ogita *et al.* 2007; and Yu *et al.* 2013.

[0011] There are disclosures of related molecules in which the 6,5-fused ring system of formula (A) – a pyrimidine six member ring fused to an imidazole five member ring – is modified. (a) Dellaria *et al.* 2007, Jones *et al.* 2010 and 2012, and Pilatte *et al.* 2017 disclose compounds in which the pyrimidine ring is replaced by a pyridine ring. (b) Chen *et al.* 2011, Coe
 5 *et al.* 2017, and Zhang *et al.* 2018 disclose compounds in which the imidazole ring is replaced by a pyrazole ring. (c) Cortez *et al.* 2017 and 2018; Li *et al.* 2018; and McGowan *et al.* 2016a, 2016b, and 2017 disclose compounds in which the imidazole ring is replaced by a pyrrole ring.

[0012] Bonfanti *et al.* 2015b and 2016 and Purandare *et al.* 2019 disclose TLR7 modulators in which the two rings of a purine moiety are spanned by a macrocycle:

10 [0013] A TLR7 agonist can be conjugated to a partner molecule, which can be, for example, a phospholipid, a poly(ethylene glycol) (“PEG”), an antibody, or another TLR (commonly TLR2). Exemplary disclosures include: Carson *et al.* 2013, 2015, and 2016, Chan *et al.* 2009 and 2011, Cortez *et al.* 2017, Gadd *et al.* 2015, Lioux *et al.* 2016, Maj *et al.* 2015, Vernejoul *et al.* 2014, and Zurawski *et al.* 2012. A frequent conjugation site is at the R” group of formula (A).


15 [0014] Jensen *et al.* 2015 discloses the use of cationic lipid vehicles for the delivery of TLR7 agonists.

[0015] Some TLR7 agonists, including resiquimod are dual TLR7/TLR8 agonists. See, for example, Beesu *et al.* 2017, Embrechts *et al.* 2018, Lioux *et al.* 2016, and Vernejoul *et al.* 2014.


[0016] Full citations for the documents cited herein by first author or inventor and year are
 20 listed at the end of this specification.

BRIEF SUMMARY OF THE DISCLOSURE

[0017] This specification relates to compounds having a 1*H*-pyrazolo[4,3-*d*]pyrimidine aromatic system, having activity as TLR7 agonists.



25 [0018] In one aspect, there is provided a compound with a structure according to formula I




wherein

each X^1 is independently N or CR^2 ;

X^2 is O, CH_2 , NH, S, or $N(C_1-C_3 \text{ alkyl})$;


- 5 R^1 is H, $CH_3(CH_2)_{1-3}$, $CH_3(CH_2)_{0-1}O(CH_2)_{2-3}$, $CH_3(CH_2)_{0-3}C(=O)$, $CH_3(CH_2)_{0-1}O(CH_2)_{2-3}C(=O)$,



R^2 is H, $O(C_1-C_3 \text{ alkyl})$, $C_1-C_3 \text{ alkyl}$, Cl, F, or CN;

R^3 is H, halo, OH, CN, NH_2 , $NH(C_1-C_5 \text{ alkyl})$, $N(C_1-C_5 \text{ alkyl})_2$, $NH(CH_2)_{0-1}(C_3-C_6 \text{ cycloalkyl})$,

- 10 $NH(C_4-C_8 \text{ bicycloalkyl})$, $NH(C_6-C_{10} \text{ spirocycloalkyl})$, $N(C_3-C_6 \text{ cycloalkyl})_2$, $NH(CH_2)_{1-3}(\text{aryl})$, $N((CH_2)_{1-3}(\text{aryl}))_2$, a cyclic amine moiety having the structure



wherein

- 15 an alkyl, cycloalkyl, bicycloalkyl, spirocycloalkyl, cyclic amine, 6-membered aromatic or heteroaromatic, or 5-membered heteroaromatic moiety is optionally substituted with one or more substituents selected from OH, halo, CN, $(C_1-C_3 \text{ alkyl})$, $O(C_1-C_3 \text{ alkyl})$, $C(=O)(Me)$, $SO_2(C_1-C_3 \text{ alkyl})$, $C(=O)(Et)$, NH_2 , $NH(Me)$, $N(Me)_2$, $NH(Et)$, $N(Et)_2$, and $N(C_1-C_3 \text{ alkyl})$, $(CH_2)_{1-2}OH$, $(CH_2)_{1-2}OMe$; and
- 20 a cycloalkyl, bicycloalkyl, spirocycloalkyl, or cyclic amine moiety may have a CH_2 group replaced by O, S, NH, $N(C_1-C_3 \text{ alkyl})$, or $N(Boc)$;

m is 0 or 1;

and

n is 1, 2, or 3;

- 25 or a pharmaceutically acceptable salt thereof.

[0019] Compounds disclosed herein have activity as TLR7 agonists and some can be conjugated to an antibody for targeted delivery to a target tissue or organ of intended action. They can also be PEGylated, to modulate their pharmaceutical properties.

[0020] Compounds disclosed herein, or their conjugates or their PEGylated derivatives, can be used in the treatment of a subject suffering from a condition amenable to treatment by activation of the immune system, by administering to such subject a therapeutically effective amount of such a compound or a conjugate thereof or a PEGylated derivative thereof, especially in combination with a vaccine or a cancer immunotherapy agent.

BRIEF DESCRIPTION OF THE DRAWING(S)

[0021] FIGs. 1, 2A, 2B, 3A, 3B, 4A, 4B, 5, 6A, 6B, 7, 8, 9, 10, 11, 12, 13 and 14 show reaction schemes for preparing compounds disclosed herein.

[0022] FIGs. 15 and 16 show schemes for the attachment of linkers to compounds of this disclosure, rendering them suitable for conjugation.

DETAILED DESCRIPTION OF THE INVENTION

15 DEFINITIONS

[0023] “Antibody” means whole antibodies and any antigen binding fragment (*i.e.*, “antigen-binding portion”) or single chain variants thereof. A whole, or full length, antibody is a protein comprising at least two heavy (H) chains and two light (L) chains inter-connected by disulfide bonds. Each heavy chain comprises a heavy chain variable region (V_H) and a heavy chain constant region comprising three domains, CH_1 , CH_2 and CH_3 . Each light chain comprises a light chain variable region (V_L or V_k) and a light chain constant region comprising one single domain, CL . The V_H and V_L regions can be further subdivided into regions of hypervariability, termed complementarity determining regions (CDRs), interspersed with more conserved framework regions (FRs). Each V_H and V_L comprises three CDRs and four FRs, arranged from amino- to carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4. The variable regions contain a binding domain that interacts with an antigen. The constant regions may mediate the binding of the antibody to host tissues or factors, including various cells of the immune system (*e.g.*, effector cells) and the first component (Clq) of the classical complement system. An antibody is said to “specifically bind” to an antigen X if the antibody binds to antigen X with a K_D of 5×10^{-8} M or less, more preferably 1×10^{-8} M or less, more preferably 6×10^{-9} M or less, more preferably 3×10^{-9} M or less, even more preferably 2×10^{-9} M or less. The antibody

can be chimeric, humanized, or, preferably, human. The heavy chain constant region can be engineered to affect glycosylation type or extent, to extend antibody half-life, to enhance or reduce interactions with effector cells or the complement system, or to modulate some other property. The engineering can be accomplished by replacement, addition, or deletion of one or more amino acids or by replacement of a domain with a domain from another immunoglobulin type, or a combination of the foregoing.

[0024] “Antigen binding fragment” and “antigen binding portion” of an antibody (or simply “antibody portion” or “antibody fragment”) mean one or more fragments of an antibody that retain the ability to specifically bind to an antigen. It has been shown that the antigen-binding function of an antibody can be performed by fragments of a full-length antibody, such as (i) a Fab fragment, a monovalent fragment consisting of the V_L , V_H , C_L and C_{H1} domains; (ii) a $F(ab')_2$ fragment, a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region; (iii) a Fab' fragment, which is essentially an Fab with part of the hinge region (see, for example, Abbas *et al.*, *Cellular and Molecular Immunology*, 6th Ed., Saunders Elsevier 2007); (iv) a Fd fragment consisting of the V_H and C_{H1} domains; (v) a Fv fragment consisting of the V_L and V_H domains of a single arm of an antibody, (vi) a dAb fragment (Ward *et al.*, (1989) *Nature* 341:544-546), which consists of a V_H domain; (vii) an isolated complementarity determining region (CDR); and (viii) a nanobody, a heavy chain variable region containing a single variable domain and two constant domains. Preferred antigen binding fragments are Fab, $F(ab')_2$, Fab' , Fv, and Fd fragments. Furthermore, although the two domains of the Fv fragment, V_L and V_H , are encoded by separate genes, they can be joined, using recombinant methods, by a synthetic linker that enables them to be made as a single protein chain in which the V_L and V_H regions pair to form monovalent molecules (known as single chain Fv, or scFv); see, e.g., Bird *et al.* (1988) *Science* 242:423-426; and Huston *et al.* (1988) *Proc. Natl. Acad. Sci. USA* 85:5879-5883). Such single chain antibodies are also encompassed within the term “antigen-binding portion” of an antibody.

[0025] Unless indicated otherwise – for example by reference to the linear numbering in a SEQ ID NO: listing – references to the numbering of amino acid positions in an antibody heavy or light chain variable region (V_H or V_L) are according to the Kabat system (Kabat *et al.*, "Sequences of proteins of immunological interest, 5th ed., Pub. No. 91-3242, U.S. Dept. Health & Human Services, NIH, Bethesda, Md., 1991, hereinafter “Kabat”) and references to the numbering of amino acid positions in an antibody heavy or light chain constant region (C_{H1} , C_{H2} ,

CH₃, or CL) are according to the EU index as set forth in Kabat. See Lazar *et al.*, US 2008/0248028 A1, the disclosure of which is incorporated herein by reference, for examples of such usage. Further, the ImMunoGeneTics Information System (IMGT) provides at its website a table entitled “IMGT Scientific Chart: Correspondence between C Numberings” showing the correspondence between its numbering system, EU numbering, and Kabat numbering for the heavy chain constant region.

[0026] An “isolated antibody” means an antibody that is substantially free of other antibodies having different antigenic specificities (*e.g.*, an isolated antibody that specifically binds antigen X is substantially free of antibodies that specifically bind antigens other than antigen X). An isolated antibody that specifically binds antigen X may, however, have cross-reactivity to other antigens, such as antigen X molecules from other species. In certain embodiments, an isolated antibody specifically binds to human antigen X and does not cross-react with other (non-human) antigen X antigens. Moreover, an isolated antibody may be substantially free of other cellular material and/or chemicals.

[0027] “Monoclonal antibody” or “monoclonal antibody composition” means a preparation of antibody molecules of single molecular composition, which displays a single binding specificity and affinity for a particular epitope.

[0028] “Human antibody” means an antibody having variable regions in which both the framework and CDR regions (and the constant region, if present) are derived from human germline immunoglobulin sequences. Human antibodies may include later modifications, including natural or synthetic modifications. Human antibodies may include amino acid residues not encoded by human germline immunoglobulin sequences (*e.g.*, mutations introduced by random or site-specific mutagenesis *in vitro* or by somatic mutation *in vivo*). However, “human antibody” does not include antibodies in which CDR sequences derived from the germline of another mammalian species, such as a mouse, have been grafted onto human framework sequences.

[0029] “Human monoclonal antibody” means an antibody displaying a single binding specificity, which has variable regions in which both the framework and CDR regions are derived from human germline immunoglobulin sequences. In one embodiment, human monoclonal antibodies are produced by a hybridoma that includes a B cell obtained from a transgenic nonhuman animal, *e.g.*, a transgenic mouse, having a genome comprising a human heavy chain transgene and a light chain transgene fused to an immortalized cell.

[0030] “Aliphatic” means a straight- or branched-chain, saturated or unsaturated, non-aromatic hydrocarbon moiety having the specified number of carbon atoms (*e.g.*, as in “C₃ aliphatic,” “C₁₋₅ aliphatic,” “C_{1-C5} aliphatic,” or “C₁ to C₅ aliphatic,” the latter three phrases being synonymous for an aliphatic moiety having from 1 to 5 carbon atoms) or, where the number of carbon atoms is not explicitly specified, from 1 to 4 carbon atoms (2 to 4 carbons in the instance of unsaturated aliphatic moieties). A similar understanding is applied to the number of carbons in other types, as in C₂₋₄ alkene, C_{4-C7} cycloaliphatic, etc. In a similar vein, a term such as “(CH₂)₁₋₃” is to be understood as shorthand for the subscript being 1, 2, or 3, so that such term represents CH₂, CH₂CH₂, and CH₂CH₂CH₂.

[0031] “Alkyl” means a saturated aliphatic moiety, with the same convention for designating the number of carbon atoms being applicable. By way of illustration, C₁-C₄ alkyl moieties include, but are not limited to, methyl, ethyl, propyl, isopropyl, isobutyl, *t*-butyl, 1-butyl, 2-butyl, and the like. “Alkylene” means a divalent counterpart of an alkyl group, such as CH₂CH₂, CH₂CH₂CH₂, and CH₂CH₂CH₂CH₂.

[0032] “Alkenyl” means an aliphatic moiety having at least one carbon-carbon double bond, with the same convention for designating the number of carbon atoms being applicable. By way of illustration, C₂-C₄ alkenyl moieties include, but are not limited to, ethenyl (vinyl), 2-propenyl (allyl or prop-2-enyl), *cis*-1-propenyl, *trans*-1-propenyl, *E*- (or *Z*-) 2-butenyl, 3-butenyl, 1,3-butadienyl (but-1,3-dienyl) and the like.

[0033] “Alkynyl” means an aliphatic moiety having at least one carbon-carbon triple bond, with the same convention for designating the number of carbon atoms being applicable. By way of illustration, C₂-C₄ alkynyl groups include ethynyl (acetylenyl), propargyl (prop-2-ynyl), 1-propynyl, but-2-ynyl, and the like.

[0034] “Cycloaliphatic” means a saturated or unsaturated, non-aromatic hydrocarbon moiety having from 1 to 3 rings, each ring having from 3 to 8 (preferably from 3 to 6) carbon atoms. “Cycloalkyl” means a cycloaliphatic moiety in which each ring is saturated. “Cycloalkenyl” means a cycloaliphatic moiety in which at least one ring has at least one carbon-carbon double bond. “Cycloalkynyl” means a cycloaliphatic moiety in which at least one ring has at least one carbon-carbon triple bond. By way of illustration, cycloaliphatic moieties include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, cyclooctyl, and adamantyl. Preferred cycloaliphatic moieties are cycloalkyl ones, especially cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl. “Cycloalkylene” means a

divalent counterpart of a cycloalkyl group. Similarly, “bicycloalkylene” and “spirocycloalkylene” (or “spiroalkylene”) refer to divalent counterparts of a bicycloalkyl and spirocycloalkyl/spiroalkyl group.

[0035] “Heterocycloaliphatic” means a cycloaliphatic moiety wherein, in at least one ring thereof, up to three (preferably 1 to 2) carbons have been replaced with a heteroatom independently selected from N, O, or S, where the N and S optionally may be oxidized and the N optionally may be quaternized. Preferred cycloaliphatic moieties consist of one ring, 5- to 6-membered in size. Similarly, “heterocycloalkyl,” “heterocycloalkenyl,” and “heterocycloalkynyl” means a cycloalkyl, cycloalkenyl, or cycloalkynyl moiety, respectively, in which at least one ring thereof has been so modified. Exemplary heterocycloaliphatic moieties include aziridinyl, azetidiny, 1,3-dioxanyl, oxetanyl, tetrahydrofuryl, pyrrolidinyl, piperidinyl, piperazinyl, tetrahydropyranyl, tetrahydrothiopyranyl, tetrahydrothiopyranyl sulfone, morpholinyl, thiomorpholinyl, thiomorpholinyl sulfoxide, thiomorpholinyl sulfone, 1,3-dioxolanyl, tetrahydro-1,1-dioxothienyl, 1,4-dioxanyl, thietanyl, and the like.

[0036] “Heterocycloalkylene” means a divalent counterpart of a heterocycloalkyl group.

[0037] “Alkoxy,” “aryloxy,” “alkylthio,” and “arylthio” mean –O(alkyl), –O(aryl), –S(alkyl), and –S(aryl), respectively. Examples are methoxy, phenoxy, methylthio, and phenylthio, respectively.

[0038] “Halogen” or “halo” means fluorine, chlorine, bromine or iodine, unless a narrower meaning is indicated.

[0039] “Aryl” means a hydrocarbon moiety having a mono-, bi-, or tricyclic ring system (preferably monocyclic) wherein each ring has from 3 to 7 carbon atoms and at least one ring is aromatic. The rings in the ring system may be fused to each other (as in naphthyl) or bonded to each other (as in biphenyl) and may be fused or bonded to non-aromatic rings (as in indanyl or cyclohexylphenyl). By way of further illustration, aryl moieties include, but are not limited to, phenyl, naphthyl, tetrahydronaphthyl, indanyl, biphenyl, phenanthryl, anthracenyl, and acenaphthyl. “Arylene” means a divalent counterpart of an aryl group, for example 1,2-phenylene, 1,3-phenylene, or 1,4-phenylene.

[0040] “Heteroaryl” means a moiety having a mono-, bi-, or tricyclic ring system (preferably 5- to 7-membered monocyclic) wherein each ring has from 3 to 7 carbon atoms and at least one ring is an aromatic ring containing from 1 to 4 heteroatoms independently selected from N,

O, or S, where the N and S optionally may be oxidized and the N optionally may be quaternized. Such at least one heteroatom containing aromatic ring may be fused to other types of rings (as in benzofuranyl or tetrahydroisoquinolyl) or directly bonded to other types of rings (as in phenylpyridyl or 2-cyclopentylpyridyl). By way of further illustration, heteroaryl moieties include

5 pyrrolyl, furanyl, thiophenyl (thienyl), imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, triazolyl, tetrazolyl, pyridyl, N-oxopyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, quinolinyl, isoquinolynyl, quinazolinyl, cinnolynyl, quinoxalyl, naphthyridinyl, benzofuranyl, indolyl, benzothiophenyl, oxadiazolyl, thiadiazolyl, phenothiazolyl, benzimidazolyl, benzotriazolyl, dibenzofuranyl, carbazolyl, dibenzothiophenyl, acridinyl, and the like.

10 “Heteroarylene” means a divalent counterpart of a heteroaryl group.

[0040] Where it is indicated that a moiety may be substituted, such as by use of “unsubstituted or substituted” or “optionally substituted” phrasing as in “unsubstituted or substituted C₁-C₅ alkyl” or “optionally substituted heteroaryl,” such moiety may have one or more independently selected substituents, preferably one to five in number, more preferably one

15 or two in number. Substituents and substitution patterns can be selected by one of ordinary skill in the art, having regard for the moiety to which the substituent is attached, to provide compounds that are chemically stable and that can be synthesized by techniques known in the art as well as the methods set forth herein. Where a moiety is identified as being “unsubstituted or substituted” or “optionally substituted,” in a preferred embodiment such moiety is unsubstituted.

20 **[0041]** “Arylalkyl,” (heterocycloaliphatic)alkyl,” “arylalkenyl,” “arylalkynyl,” “biarylalkyl,” and the like mean an alkyl, alkenyl, or alkynyl moiety, as the case may be, substituted with an aryl, heterocycloaliphatic, biaryl, etc., moiety, as the case may be, with the open (unsatisfied) valence at the alkyl, alkenyl, or alkynyl moiety, for example as in benzyl, phenethyl, N-imidazoylethyl, N-morpholinoethyl, and the like. Conversely, “alkylaryl,” “alkenylcycloalkyl,”

25 and the like mean an aryl, cycloalkyl, etc., moiety, as the case may be, substituted with an alkyl, alkenyl, etc., moiety, as the case may be, for example as in methylphenyl (tolyl) or allylcyclohexyl. “Hydroxyalkyl,” “haloalkyl,” “alkylaryl,” “cyanoaryl,” and the like mean an alkyl, aryl, etc., moiety, as the case may be, substituted with one or more of the identified substituent (hydroxyl, halo, etc., as the case may be).

30 **[0042]** For example, permissible substituents include, but are not limited to, alkyl (especially methyl or ethyl), alkenyl (especially allyl), alkynyl, aryl, heteroaryl, cycloaliphatic, heterocycloaliphatic, halo (especially fluoro), haloalkyl (especially trifluoromethyl), hydroxyl, hydroxyalkyl

(especially hydroxyethyl), cyano, nitro, alkoxy, -O(hydroxyalkyl), -O(haloalkyl) (especially -OCF₃), -O(cycloalkyl), -O(heterocycloalkyl), -O(aryl), alkylthio, arylthio, =O, =NH, =N(alkyl), =NOH, =NO(alkyl), -C(=O)(alkyl), -C(=O)H, -CO₂H, -C(=O)NHOH, -C(=O)O(alkyl), -C(=O)O(hydroxyalkyl), -C(=O)NH₂, -C(=O)NH(alkyl), -C(=O)N(alkyl)₂, -OC(=O)(alkyl),
 5 -OC(=O)(hydroxyalkyl), -OC(=O)O(alkyl), -OC(=O)O(hydroxyalkyl), -OC(=O)NH₂,
 -OC(=O)NH(alkyl), -OC(=O)N(alkyl)₂, azido, -NH₂, -NH(alkyl), -N(alkyl)₂, -NH(aryl),
 -NH(hydroxyalkyl), -NHC(=O)(alkyl), -NHC(=O)H, -NHC(=O)NH₂, -NHC(=O)NH(alkyl),
 -NHC(=O)N(alkyl)₂, -NHC(=NH)NH₂, -OSO₂(alkyl), -SH, -S(alkyl), -S(aryl), -S(cycloalkyl),
 -S(=O)alkyl, -SO₂(alkyl), -SO₂NH₂, -SO₂NH(alkyl), -SO₂N(alkyl)₂, and the like.

- 10 **[0043]** Where the moiety being substituted is an aliphatic moiety, preferred substituents are aryl, heteroaryl, cycloaliphatic, heterocycloaliphatic, halo, hydroxyl, cyano, nitro, alkoxy, -O(hydroxyalkyl), -O(haloalkyl), -O(cycloalkyl), -O(heterocycloalkyl), -O(aryl), alkylthio, arylthio, =O, =NH, =N(alkyl), =NOH, =NO(alkyl), -CO₂H, -C(=O)NHOH, -C(=O)O(alkyl), -C(=O)O(hydroxyalkyl), -C(=O)NH₂, -C(=O)NH(alkyl), -C(=O)N(alkyl)₂, -OC(=O)(alkyl),
 15 -OC(=O)(hydroxyalkyl), -OC(=O)O(alkyl), -OC(=O)O(hydroxyalkyl), -OC(=O)NH₂,
 -OC(=O)NH(alkyl), -OC(=O)N(alkyl)₂, azido, -NH₂, -NH(alkyl), -N(alkyl)₂, -NH(aryl),
 -NH(hydroxyalkyl), -NHC(=O)(alkyl), -NHC(=O)H, -NHC(=O)NH₂, -NHC(=O)NH(alkyl),
 -NHC(=O)N(alkyl)₂, -NHC(=NH)NH₂, -OSO₂(alkyl), -SH, -S(alkyl), -S(aryl), -S(=O)alkyl,
 -S(cycloalkyl), -SO₂(alkyl), -SO₂NH₂, -SO₂NH(alkyl), and -SO₂N(alkyl)₂. More preferred
 20 substituents are halo, hydroxyl, cyano, nitro, alkoxy, -O(aryl), =O, =NOH, =NO(alkyl),
 -OC(=O)(alkyl), -OC(=O)O(alkyl), -OC(=O)NH₂, -OC(=O)NH(alkyl), -OC(=O)N(alkyl)₂, azido,
 -NH₂, -NH(alkyl), -N(alkyl)₂, -NH(aryl), -NHC(=O)(alkyl), -NHC(=O)H, -NHC(=O)NH₂,
 -NHC(=O)NH(alkyl), -NHC(=O)N(alkyl)₂, and -NHC(=NH)NH₂. Especially preferred are
 25 phenyl, cyano, halo, hydroxyl, nitro, C₁-C₄alkoxy, O(C₂-C₄ alkylene)OH, and O(C₂-C₄
 alkylene)halo.

- [0044]** Where the moiety being substituted is a cycloaliphatic, heterocycloaliphatic, aryl, or heteroaryl moiety, preferred substituents are alkyl, alkenyl, alkynyl, halo, haloalkyl, hydroxyl, hydroxyalkyl, cyano, nitro, alkoxy, -O(hydroxyalkyl), -O(haloalkyl), -O(aryl), -O(cycloalkyl), -O(heterocycloalkyl), alkylthio, arylthio, -C(=O)(alkyl), -C(=O)H, -CO₂H, -C(=O)NHOH,
 30 -C(=O)O(alkyl), -C(=O)O(hydroxyalkyl), -C(=O)NH₂, -C(=O)NH(alkyl), -C(=O)N(alkyl)₂,
 -OC(=O)(alkyl), -OC(=O)(hydroxyalkyl), -OC(=O)O(alkyl), -OC(=O)O(hydroxyalkyl),
 -OC(=O)NH₂, -OC(=O)NH(alkyl), -OC(=O)N(alkyl)₂, azido, -NH₂, -NH(alkyl), -N(alkyl)₂,

-NH(aryl), -NH(hydroxyalkyl), -NHC(=O)(alkyl), -NHC(=O)H, -NHC(=O)NH₂,
 -NHC(=O)NH(alkyl), -NHC(=O)N(alkyl)₂, -NHC(=NH)NH₂, -OSO₂(alkyl), -SH, -S(alkyl),
 -S(aryl), -S(cycloalkyl), -S(=O)alkyl, -SO₂(alkyl), -SO₂NH₂, -SO₂NH(alkyl), and -SO₂N(alkyl)₂.

More preferred substituents are alkyl, alkenyl, halo, haloalkyl, hydroxyl, hydroxyalkyl, cyano,
 5 nitro, alkoxy, -O(hydroxyalkyl), -C(=O)(alkyl), -C(=O)H, -CO₂H, -C(=O)NHOH,
 -C(=O)O(alkyl), -C(=O)O(hydroxyalkyl), -C(=O)NH₂, -C(=O)NH(alkyl), -C(=O)N(alkyl)₂,
 -OC(=O)(alkyl), -OC(=O)(hydroxyalkyl), -OC(=O)O(alkyl), -OC(=O)O(hydroxyalkyl),
 -OC(=O)NH₂, -OC(=O)NH(alkyl), -OC(=O)N(alkyl)₂, -NH₂, -NH(alkyl), -N(alkyl)₂, -NH(aryl),
 -NHC(=O)(alkyl), -NHC(=O)H, -NHC(=O)NH₂, -NHC(=O)NH(alkyl), -NHC(=O)N(alkyl)₂, and
 10 -NHC(=NH)NH₂. Especially preferred are C₁-C₄ alkyl, cyano, nitro, halo, and C₁-C₄alkoxy.

[0045] Where a range is stated, as in “C₁-C₅ alkyl” or “5 to 10%,” such range includes the
 end points of the range, as in C₁ and C₅ in the first instance and 5% and 10% in the second
 instance.

[0046] Unless particular stereoisomers are specifically indicated (e.g., by a bolded or dashed
 15 bond at a relevant stereocenter in a structural formula, by depiction of a double bond as having E
 or Z configuration in a structural formula, or by use stereochemistry-designating nomenclature or
 symbols), all stereoisomers are included within the scope of the invention, as pure compounds as
 well as mixtures thereof. Unless otherwise indicated, racemates, individual enantiomers (whether
 optically pure or partially resolved), diastereomers, geometrical isomers, and combinations and
 20 mixtures thereof are all encompassed by this invention.

[0047] Those skilled in the art will appreciate that compounds may have tautomeric forms
 (e.g., keto and enol forms), resonance forms, and zwitterionic forms that are equivalent to those
 depicted in the structural formulae used herein and that the structural formulae encompass such
 tautomeric, resonance, or zwitterionic forms.

[0048] “Pharmaceutically acceptable ester” means an ester that hydrolyzes *in vivo* (for
 25 example in the human body) to produce the parent compound or a salt thereof or has *per se*
 activity similar to that of the parent compound. Suitable esters include C₁-C₅ alkyl, C₂-C₅ alkenyl
 or C₂-C₅ alkynyl esters, especially methyl, ethyl or n-propyl.


[0049] “Pharmaceutically acceptable salt” means a salt of a compound suitable for
 30 pharmaceutical formulation. Where a compound has one or more basic groups, the salt can be an
 acid addition salt, such as a sulfate, hydrobromide, tartrate, mesylate, maleate, citrate, phosphate,

acetate, pamoate (embonate), hydroiodide, nitrate, hydrochloride, lactate, methylsulfate, fumarate, benzoate, succinate, mesylate, lactobionate, suberate, tosylate, and the like. Where a compound has one or more acidic groups, the salt can be a salt such as a calcium salt, potassium salt, magnesium salt, meglumine salt, ammonium salt, zinc salt, piperazine salt, tromethamine salt, lithium salt, choline salt, diethylamine salt, 4-phenylcyclohexylamine salt, benzathine salt, sodium salt, tetramethylammonium salt, and the like. Polymorphic crystalline forms and solvates are also encompassed within the scope of this invention.

[0050] “Subject” refers to an animal, including, but not limited to, a primate (*e.g.*, human), monkey, cow, pig, sheep, goat, horse, dog, cat, rabbit, rat, or mouse. The terms “subject” and “patient” are used interchangeably herein in reference, for example, to a mammalian subject, such as a human.


[0051] The terms “treat,” “treating,” and “treatment,” in the context of treating a disease or disorder, are meant to include alleviating or abrogating a disorder, disease, or condition, or one or more of the symptoms associated with the disorder, disease, or condition; or to slowing the progression, spread or worsening of a disease, disorder or condition or of one or more symptoms thereof. The “treatment of cancer”, refers to one or more of the following effects: (1) inhibition, to some extent, of tumor growth, including, (i) slowing down and (ii) complete growth arrest; (2) reduction in the number of tumor cells; (3) maintaining tumor size; (4) reduction in tumor size; (5) inhibition, including (i) reduction, (ii) slowing down or (iii) complete prevention, of tumor cell infiltration into peripheral organs; (6) inhibition, including (i) reduction, (ii) slowing down or (iii) complete prevention, of metastasis; (7) enhancement of anti-tumor immune response, which may result in (i) maintaining tumor size, (ii) reducing tumor size, (iii) slowing the growth of a tumor, (iv) reducing, slowing or preventing invasion and/or (8) relief, to some extent, of the severity or number of one or more symptoms associated with the disorder.

[0052] In the formulae of this specification, a wavy line (~~~~~) transverse to a bond or an asterisk (*) at the end of the bond denotes a covalent attachment site. For instance, a statement that R is





[0053] In the formulae of this specification, a bond traversing an aromatic ring between two carbons thereof means that the group attached to the bond may be located at any of the positions

of the aromatic ring made available by removal of the hydrogen that is implicitly there. By way of illustration, the formula




[0054] In other illustrations,




[0055] Those skilled in the art will appreciate that certain structures can be drawn in one tautomeric form or another – for example, keto versus enol – and that the two forms are equivalent.

COMPOUNDS


[0056] In one embodiment, either each X^1 is CR^2 or not more than two X^1 's are N in the moiety



15 Examples of such are





[0057] A preferred example is




[0058] Suitable groups R^1 include:





5




10 [0059] Preferably the group R^1 is




[0060] Examples of suitable groups R^3 include Cl, OH,




15







[0061] Examples of where the group R^3 has the structure



15 (including instances with one or more methylene (CH_2) groups optionally replaced by one or more of O, S, SO_2 , NH, $\text{C}(=\text{O})$, $\text{N}(\text{C}_1\text{-C}_3 \text{ alkyl})$, $\text{NC}(=\text{O})(\text{C}_1\text{-C}_3 \text{ alkyl})$, or $\text{N}(\text{Boc})$, or has another ring fused thereto, as disclosed hereinabove) are:




[0062] In another embodiment, R^3 is selected from the group consisting of




5

[0063] In one embodiment of formula I, m is 0, in which case the formula simplifies to formula I':




[0064] Another embodiment of compounds according to formula I is represented by formula

10 Ia:






where R^1 and R^3 are as defined in respect of formulae I hereinabove.

[0065] An embodiment of compounds according to formula I wherein m is 1 is represented by formula Ib, wherein R^1 , R^3 and X^1 are as defined in respect of formula I hereinabove.




15


[0066] Preferably, in formula Ib



or




, more preferably










[0067] Specific examples of compounds per in this specification are listed following.

5 Methods for their preparation and their properties are provided in the experimental sections hereinbelow.







No. Structure









No. Structure









No. Structure









No. Structure









No. Structure









No. Structure









No. Structure









No. Structure









No. Structure









No. Structure









No. Structure









No. Structure



No. Structure



No. Structure




CONJUGATES

General

5 [0068] TLR7 agonists disclosed herein can be delivered to the site of intended action by localized administration or by targeted delivery in a conjugate with a targeting moiety. Preferably, the targeting moiety is an antibody or antigen binding portion thereof and its antigen is found at the locality of intended action, for example a tumor associated antigen if the intended site of action is at a tumor (cancer). Preferably, the tumor associated antigen is uniquely
10 expressed or overexpressed by the cancer cell, compared to a normal cell. The tumor associated antigen can be located on the surface of the cancer cell or secreted by the cancer cell into its environs.

[0069] In one aspect, there is provided a conjugate comprising compound of this invention and a ligand, represented by formula (IV)



where Z is a targeting moiety, D is an agonist of this invention, and $-(X^D)_a(C)_c(X^Z)_b-$ are collectively referred to as a “linker moiety” or “linker” because they link Z and D. Within the linker, C is a cleavable group designed to be cleaved at or near the site of intended biological action of D; X^D and X^Z are spacer moieties (or “spacers”) that space apart D and C and C and Z,
20 respectively; subscripts a, b, and c are independently 0 or 1 (that is, the presence of X^D , X^Z and C are optional). Subscript m is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 (preferably 1, 2, 3, or 4). D, X^D , C, X^Z and Z are more fully described hereinbelow.

[0070] By binding to a target tissue or cell where its antigen or receptor is located, Z directs the conjugate there. Cleavage of group C at the target tissue or cell releases D to exert its effect
25 locally. In this manner, precise delivery of D is achieved at the site of intended action, reducing the dosage needed. Also, D is normally biologically inactive (or significantly less active) in its conjugated state, thereby reducing off-target effects.

[0071] As reflected by the subscript m, each Z can conjugate with more than one D, depending on the number of sites Z has available for conjugation and the experimental
30 conditions employed. Those skilled in the art will appreciate that, while each individual Z is conjugated to an integer number of Ds, a preparation of the conjugate may analyze for a non-

integer ratio of D to Z, reflecting a statistical average. This ratio is referred to as the substitution ratio (“SR”) or the drug-antibody ratio (“DAR”).

Targeting moiety Z

[0072] Preferably, targeting moiety Z is an antibody. For convenience and brevity and not by way of limitation, the detailed discussion in this specification about Z and its conjugates is written in the context of its being an antibody, but those skilled in the art will understand that other types of Z can be conjugated, *mutatis mutandis*. For example, conjugates with folic acid as the targeting moiety can target cells having the folate receptor on their surfaces (Leamon *et al.*, Cancer Res. **2008**, 68 (23), 9839). For the same reasons, the detailed discussion in this specification is primarily written in terms of a 1:1 ratio of Z to D ($m = 1$).

[0073] Antibodies that can be used in conjugates of this invention include those recognizing the following antigens: mesothelin, prostate specific membrane antigen (PSMA), CD19, CD22, CD30, CD70, B7H3, B7H4 (also known as O8E), protein tyrosine kinase 7 (PTK7), glypican-3, RG1, fucosyl-GM1, CTLA-4, and CD44. The antibody can be animal (*e.g.*, murine), chimeric, humanized, or, preferably, human. The antibody preferably is monoclonal, especially a monoclonal human antibody. The preparation of human monoclonal antibodies against some of the aforementioned antigens is disclosed in Korman *et al.*, US 8,609,816 B2 (2013; B7H4, also known as O8E; in particular antibodies 2A7, 1G11, and 2F9); Rao-Naik *et al.*, 8,097,703 B2 (2012; CD19; in particular antibodies 5G7, 13F1, 46E8, 21D4, 21D4a, 47G4, 27F3, and 3C10); King *et al.*, US 8,481,683 B2 (2013; CD22; in particular antibodies 12C5, 19A3, 16F7, and 23C6); Keler *et al.*, US 7,387,776 B2 (2008; CD30; in particular antibodies 5F11, 2H9, and 17G1); Terrett *et al.*, US 8,124,738 B2 (2012; CD70; in particular antibodies 2H5, 10B4, 8B5, 18E7, and 69A7); Korman *et al.*, US 6,984,720 B1 (2006; CTLA-4; in particular antibodies 10D1, 4B6, and 1E2); Korman *et al.*, US 8,008,449 B2 (2011; PD-1; in particular antibodies 17D8, 2D3, 4H1, 5C4, 4A11, 7D3, and 5F4); Huang *et al.*, US 2009/0297438 A1 (2009; PSMA; in particular antibodies 1C3, 2A10, 2F5, 2C6); Cardarelli *et al.*, US 7,875,278 B2 (2011; PSMA; in particular antibodies 4A3, 7F12, 8C12, 8A11, 16F9, 2A10, 2C6, 2F5, and 1C3); Terrett *et al.*, US 8,222,375 B2 (2012; PTK7; in particular antibodies 3G8, 4D5, 12C6, 12C6a, and 7C8); Harkins *et al.*, US 7,335,748 B2 (2008; RG1; in particular antibodies A, B, C, and D); Terrett *et al.*, US 8,268,970 B2 (2012; mesothelin; in particular antibodies 3C10, 6A4, and 7B1); Xu *et al.*, US 2010/0092484 A1 (2010; CD44; in particular antibodies 14G9.B8.B4, 2D1.A3.D12, and 1A9.A6.B9); Deshpande *et al.*, US 8,258,266 B2 (2012; IP10; in particular antibodies 1D4, 1E1,

2G1, 3C4, 6A5, 6A8, 7C10, 8F6, 10A12, 10A12S, and 13C4); Kuhne *et al.*, US 8,450,464 B2 (2013; CXCR4; in particular antibodies F7, F9, D1, and E2); and Korman *et al.*, US 7,943,743 B2 (2011; PD-L1; in particular antibodies 3G10, 12A4, 10A5, 5F8, 10H10, 1B12, 7H1, 11E6, 12B7, and 13G4); the disclosures of which are incorporated herein by reference. Preferably, the antibody is an anti-mesothelin antibody.

[0074] In addition to being an antibody, Z can also be an antibody fragment (such as Fab, Fab', F(ab')₂, Fd, or Fv) or antibody mimetic, such as an affibody, a domain antibody (dAb), a nanobody, a unibody, a DARPin, an anticalin, a versabody, a duocalin, a lipocalin, or an avimer.

[0075] Any one of several different reactive groups on Z can be a conjugation site, including ε-amino groups in lysine residues, pendant carbohydrate moieties, carboxylic acid groups on aspartic or glutamic acid side chains, cysteine-cysteine disulfide groups, and cysteine thiol groups. For reviews on antibody reactive groups suitable for conjugation, see, *e.g.*, Garnett, *Adv. Drug Delivery Rev.* **2001**, 53, 171-216 and Dubowchik and Walker, *Pharmacology & Therapeutics* **1999**, 83, 67-123, the disclosures of which are incorporated herein by reference.

[0076] Most antibodies have multiple lysine residues, which can be conjugated via their ε-amino groups via amide, urea, thiourea, or carbamate bonds.

[0077] A thiol (-SH) group in the side chain of a cysteine can be used to form a conjugate by several methods. It can be used to form a disulfide bond between it and a thiol group on the linker. Another method is via its Michael addition to a maleimide group on the linker.

[0078] Typically, although antibodies have cysteine residues, they lack free thiol groups because all their cysteines are engaged in intra- or inter-chain disulfide bonds. To generate a free thiol group, a native disulfide group can be reduced. See, *e.g.*, Packard *et al.*, *Biochemistry* **1986**, 25, 3548; King *et al.*, *Cancer Res.* **1994**, 54, 6176; and Doronina *et al.*, *Nature Biotechnol.* **2003**, 21, 778. Alternatively, a cysteine having a free -SH group can be introduced by mutating the antibody, substituting a cysteine for another amino acid or inserting one into the polypeptide chain. See, for example, Eigenbrot *et al.*, US 7,521,541 B2 (2009); Chilkoti *et al.*, *Bioconjugate Chem.* **1994**, 5, 504; Urnovitz *et al.*, US 4,698,420 (1987); Stimmel *et al.*, *J. Biol. Chem.* **2000**, 275, 30445; Bam *et al.*, US 7,311,902 B2 (2007); Kuan *et al.*, *J. Biol. Chem.* **1994**, 269, 7610; Poon *et al.*, *J. Biol. Chem.* **1995**, 270, 8571; Junutula *et al.*, *Nature Biotechnology* **2008**, 26, 925 and Rajpal *et al.*, US Provisional Application No. 62/270245, filed Dec. 21, 2015. In yet another approach, a cysteine is added to the C-terminus of the heavy or light chain. See, *e.g.*, Liu *et al.*,

US 8,865,875 B2 (2014); Cumber *et al.*, *J. Immunol.* **1992**, 149, 120; King *et al.*, *Cancer Res.* **1994**, 54, 6176; Li *et al.*, *Bioconjugate Chem.* **2002**, 13, 985; Yang *et al.*, *Protein Engineering* **2003**, 16, 761; and Olafson *et al.*, *Protein Engineering Design & Selection* **2004**, 17, 21. The disclosures of the documents cited in this paragraph are incorporated herein by reference.

5 *Linkers and Their Components*

[0079] As noted above, the linker comprises up to three elements: a cleavable group C and optional spacers X^Z and X^D .

[0080] Group C is cleavable under physiological conditions. Preferably it is relatively stable while the conjugate is in circulation in the blood, but is readily cleaved once the conjugate
10 reaches its site of intended action.

[0081] A preferred group C is a peptide that is cleaved selectively by a protease inside the target cell, as opposed to by a protease in the serum. Typically, the peptide comprises from 1 to 20 amino acids, preferably from 1 to 6 amino acids, more preferably from 2 to 3 amino acids. The amino acid(s) can be natural and/or non-natural α -amino acids. Natural amino acids are
15 those encoded by the genetic code, as well as amino acids derived therefrom, *e.g.*, hydroxyproline, γ -carboxyglutamate, citrulline, and O-phosphoserine. In this specification, the term "amino acid" also includes amino acid analogs and mimetics. Analogs are compounds having the same general $H_2N(R)CHCO_2H$ structure of a natural amino acid, except that the R group is not one found among the natural amino acids. Examples of analogs include homoserine,
20 norleucine, methionine-sulfoxide, and methionine methyl sulfonium. An amino acid mimetic is a compound that has a structure different from the general chemical structure of an α -amino acid but functions in a manner similar to one. The amino acid can be of the "L" stereochemistry of the genetically encoded amino acids, as well as of the enantiomeric "D" stereochemistry.

[0082] Preferably, C contains an amino acid sequence that is a cleavage recognition
25 sequence for a protease. Many cleavage recognition sequences are known in the art. *See, e.g.*, Matayoshi *et al. Science* 247: 954 (1990); Dunn *et al. Meth. Enzymol.* 241: 254 (1994); Seidah *et al. Meth. Enzymol.* 244: 175 (1994); Thornberry, *Meth. Enzymol.* 244: 615 (1994); Weber *et al. Meth. Enzymol.* 244: 595 (1994); Smith *et al. Meth. Enzymol.* 244: 412 (1994); and Bouvier *et al. Meth. Enzymol.* 248: 614 (1995); the disclosures of which are incorporated herein by reference.

[0083] A group C can be chosen such that it is cleaved by a protease present in the
30 extracellular matrix in the vicinity of a cancer, *e.g.*, a protease released by nearby dying cancer

cells or a tumor-associated protease secreted by cancer cells. Exemplary extracellular tumor-associated proteases are plasmin, matrix metalloproteases (MMP), thimet oligopeptidase (TOP) and CD10. See, *e.g.*, Trouet *et al.*, US 7,402,556 B2 (2008); Dubois *et al.*, US 7,425,541 B2 (2008); and Bebbington *et al.*, US 6,897,034 B2 (2005). Cathepsin D, normally lysosomal
 5 enzyme found inside cells, is sometimes found in the environs of a tumor, possibly released by dying cancer cells.

[0084] For conjugates designed to be by an enzyme, C preferably comprises an amino acid sequence selected for cleavage by proteases such cathepsins B, C, D, H, L and S, especially cathepsin B. Exemplary cathepsin B cleavable peptides include Val-Ala, Val-Cit, Val-Lys, Lys-
 10 Val-Ala, Asp-Val-Ala, Val-Ala, Lys-Val-Cit, Ala-Val-Cit, Val-Gly, Val-Gln, and Asp-Val-Cit. (Herein, amino acid sequences are written in the N-to-C direction, as in H₂N-AA²-AA¹-CO₂H, unless the context clearly indicates otherwise.) See Dubowchik *et al.*, *Bioorg. Med. Chem. Lett.* **1998**, 8, 3341; Dubowchik *et al.*, *Bioorg. Med. Chem. Lett.* **1998**, 8, 3347; and Dubowchik *et al.*, *Bioconjugate Chem.* **2002**, 13, 855; the disclosures of which are incorporated by reference.

[0085] Another enzyme that can be utilized for cleaving peptidyl linkers is legumain, a lysosomal cysteine protease that preferentially cleaves at Ala-Ala-Asn.


[0086] In one embodiment, Group C is a peptide comprising a two-amino acid sequence -AA²-AA¹- wherein AA¹ is lysine, arginine, or citrulline and AA² is phenylalanine, valine, alanine, leucine or isoleucine. In another embodiment, C consists of a sequence of one to three
 20 amino acids, selected from the group consisting of Val-Cit, Ala-Val, Val-Ala-Val, Lys-Lys, Ala-Asn-Val, Val-Leu-Lys, Cit-Cit, Val-Lys, Ala-Ala-Asn, Lys, Cit, Ser, and Glu. More preferably, it is a two to three amino acid peptide from the foregoing group.

[0087] The preparation and design of cleavable groups C consisting of a single amino acid is disclosed in Chen *et al.*, US 8,664,407 B2 (2014), the disclosure of which is incorporated herein
 25 by reference.


[0088] Group C can be bonded directly to Z or D; *i.e.* spacers X^Z or X^D, as the case may be, can be absent.

[0089] When present, spacer X^Z provides spatial separation between C and Z, lest the former sterically interfere with antigen binding by latter or the latter sterically interfere with cleavage of
 30 the former. Further, spacer X^Z can be used to confer increased solubility or decreased aggregation properties to conjugates. A spacer X^Z can comprise one or more modular segments,

which can be assembled in any number of combinations. Examples of suitable segments for a spacer X^Z are:



where the subscript g is 0 or 1 and the subscript h is 1 to 24, preferably 2 to 4. These segments can be combined, such as illustrated below:



- 10 **[0090]** Spacer X^D , if present, provides spatial separation between C and D, lest the latter interfere sterically or electronically with cleavage of the former. Spacer X^D also can serve to introduce additional molecular mass and chemical functionality into a conjugate. Generally, the additional mass and functionality will affect the serum half-life and other properties of the conjugate. Thus, through judicious selection of spacer groups, the serum half-life of a conjugate
- 15 can be modulated. Spacer X^D also can be assembled from modular segments, analogously to the description above for spacer X^Z .

[0091] Spacers X^Z and/or X^D , where present, preferably provide a linear separation of from 4 to 25 atoms, more preferably from 4 to 20 atoms, between Z and C or D and C, respectively.


- [0092]** The linker can perform other functions in addition to covalently linking the antibody
- 20 and the drug. For instance, the linker can contain a poly(ethylene glycol) ("PEG") group. Since the conjugation step typically involves coupling a drug-linker to an antibody in an aqueous medium, a PEG group may enhance the aqueous solubility of the drug-linker. Also, a PEG group may enhance the solubility or reduce aggregation in the resulting ADC. Where a PEG group is present, it may be incorporated into either spacer X^Z or X^D , or both. The number of
- 25 repeat units in a PEG group can be from 2 to 20, preferably between 4 and 10.

[0093] Either spacer X^Z or X^D , or both, can comprise a self-immolating moiety. A self-immolating moiety is a moiety that (1) is bonded to C and either Z or D and (2) has a structure

such that cleavage from group C initiates a reaction sequence resulting in the self-immolating moiety disbonding itself from Z or D, as the case may be. In other words, reaction at a site distal from Z or D (cleavage from group C) causes the X^Z -Z or the X^D -D bond to rupture as well. The presence of a self-immolating moiety is desirable in the case of spacer X^D because, if, after


5 cleavage of the conjugate, spacer X^D or a portion thereof were to remain attached to D, the biological activity of D may be impaired. The use of a self-immolating moiety is especially desirable where cleavable group C is a polypeptide, in which instance the self-immolating moiety typically is located adjacent thereto, in order to prevent D from sterically or electronically interfering with peptide cleavage.

10 **[0094]** Exemplary self-immolating moieties (i)-(v) bonded to a hydroxyl or amino group of D are shown below:



[0095] The self-immolating moiety is the structure between dotted lines a and b (or dotted lines b and c), with adjacent structural features shown to provide context. Self-immolating moieties (i) and (v) are bonded to a D-NH₂ (*i.e.*, conjugation is via an amino group), while self-immolating moieties (ii), (iii), and (iv) are bonded to a D-OH (*i.e.*, conjugation is via a hydroxyl or carboxyl group). Cleavage of the bond at dotted line b by an enzyme – a peptidase in the

instance of structures (i)-(v) and a β -glucuronidase in the instance of structure (vi) – initiates a self-immolating reaction sequence that results in the cleavage of the bond at dotted line a and the consequent release of D-OH or D-NH₂, as the case may be. By way of illustration, self-immolating mechanisms for structures (i) and (iv) are shown below:




[0096] In other words, cleavage of a first chemical bond at one part of a self-immolating group initiates a sequence of steps that results in the cleavage of a second chemical bond – the one connecting the self-immolating group to the drug – at a different part of the self-immolating group, thereby releasing the drug.

[0097] In some instances, self-immolating groups can be used in tandem, as shown by structure (vii). In such case, cleavage at dotted line c triggers self-immolation of the moiety between dotted lines b and c by a 1,6-elimination reaction, followed by self-immolation of the moiety between dotted lines a and b by a cyclization-elimination reaction. For additional disclosures regarding self-immolating moieties, see Carl *et al.*, *J. Med. Chem.* **1981**, 24, 479; Carl *et al.*, WO 81/01145 (1981); Dubowchik *et al.*, *Pharmacology & Therapeutics* **1999**, 83, 67; Firestone *et al.*, US 6,214,345 B1 (2001); Toki *et al.*, *J. Org. Chem.* **2002**, 67, 1866; Doronina *et al.*, *Nature Biotechnology* **2003**, 21, 778 (erratum, p. 941); Boyd *et al.*, US 7,691,962 B2; Boyd *et al.*, US 2008/0279868 A1; Sufi *et al.*, WO 2008/083312 A2; Feng, US 7,375,078 B2; Jeffrey *et al.*, US 8,039,273; and Senter *et al.*, US 2003/0096743 A1; the disclosures of which are incorporated by reference.


[0098] In another embodiment, Z and D are linked by a non-cleavable linker, *i.e.*, C is absent. Metabolism of D eventually reduces the linker to a small appended moiety that does not interfere with the biological activity of D.

Conjugation Techniques

[0099] Conjugates of TLR7 agonists disclosed herein preferably are made by first preparing a compound comprising D and linker $(X^D)_a(C)(X^Z)_b$ (where X^D , C, X^Z , a, b, and c are as defined for formula (II)) to form drug-linker compound represented by formula (V):




where R^{31} is a functional group suitable for reacting with a complementary functional group on Z to form the conjugate. Examples of suitable groups R^{31} include amino, azide, thiol, cyclooctyne,



where R^{32} is Cl, Br, F, mesylate, or tosylate and R^{33} is Cl, Br, I, F, OH, -O-N-succinimidyl, -O-(4-nitrophenyl), -O-pentafluorophenyl, or -O-tetrafluorophenyl. Chemistry generally usable for the preparation of suitable moieties $D-(X^D)_aC(X^Z)_b-R^{31}$ is disclosed in Ng *et al.*, US 7,087,600 B2 (2006); Ng *et al.*, US 6,989,452 B2 (2006); Ng *et al.*, US 7,129,261 B2 (2006); Ng *et al.*, WO 02/096910 A1; Boyd *et al.*, US 7,691,962 B2; Chen *et al.*, US 7,517,903 B2 (2009); Gangwar *et al.*, US 7,714,016 B2 (2010); Boyd *et al.*, US 2008/0279868 A1; Gangwar *et al.*, US 7,847,105 B2 (2010); Gangwar *et al.*, US 7,968,586 B2 (2011); Sufi *et al.*, US 8,461,117 B2 (2013); and Chen *et al.*, US 8,664,407 B2 (2014); the disclosures of which are incorporated herein by reference.

20 [00100] Preferably reactive functional group $-R^{31}$ is $-NH_2$, $-OH$, $-CO_2H$, $-SH$, maleimido, cyclooctyne, azido ($-N_3$), hydroxylamino ($-ONH_2$) or N-hydroxysuccinimido. Especially preferred functional groups $-R^{31}$ are:




[00101] An $-OH$ group can be esterified with a carboxy group on the antibody, for example, on an aspartic or glutamic acid side chain.

[00102] A $\text{-CO}_2\text{H}$ group can be esterified with a -OH group or amidated with an amino group (for example on a lysine side chain) on the antibody.

[00103] An N-hydroxysuccinimide group is functionally an activated carboxyl group and can conveniently be amidated by reaction with an amino group (*e.g.*, from lysine).

5 [00104] A maleimide group can be conjugated with an -SH group on the antibody (*e.g.*, from cysteine or from the chemical modification of the antibody to introduce a sulfhydryl functionality), in a Michael addition reaction.


[00105] Where an antibody does not have a cysteine -SH available for conjugation, an ϵ -amino group in the side chain of a lysine residue can be reacted with 2-iminothiolane or N-succinimidyl-3-(2-pyridyldithio)propionate (“SPDP”) to introduce a free thiol (-SH) group –
 10 creating a cysteine surrogate, as it were. The thiol group can react with a maleimide or other nucleophile acceptor group to effect conjugation. The mechanism is illustrated below with 2-iminothiolane.



[00106] Typically, a thiolation level of two to three thiols per antibody is achieved. For a representative procedure, see Cong *et al.*, US 8,980,824 B2 (2015), the disclosure of which is incorporated herein by reference.

20 [00107] In a reversed arrangement, an antibody Z can be modified with N-succinimidyl 4-(maleimidomethyl)-cyclohexanecarboxylate (“SMCC”) or its sulfonated variant sulfo-SMCC, both of which are available from Sigma-Aldrich, to introduce a maleimide group thereto. Then, conjugation can be effected with a drug-linker compound having an -SH group on the linker.


[00108] An alternative conjugation method employs copper-free “click chemistry,” in which an azide group adds across a strained cyclooctyne to form an 1,2,3-triazole ring. See, *e.g.*, Agard *et al.*, *J. Amer. Chem. Soc.* **2004**, 126, 15046; Best, *Biochemistry* **2009**, 48, 6571, the disclosures of which are incorporated herein by reference. The azide can be located on the antibody and the cyclooctyne on the drug-linker moiety, or vice-versa. A preferred cyclooctyne group is dibenzocyclooctyne (DIBO). Various reagents having a DIBO group are available from Invitrogen/Molecular Probes, Eugene, Oregon. The reaction below illustrates click chemistry conjugation for the instance in which the DIBO group is attached to the antibody (Ab):



[00109] Yet another conjugation technique involves introducing a non-natural amino acid into an antibody, with the non-natural amino acid providing a functionality for conjugation with a reactive functional group in the drug moiety. For instance, the non-natural amino acid *p*-acetylphenylalanine can be incorporated into an antibody or other polypeptide, as taught in Tian *et al.*, WO 2008/030612 A2 (2008). The ketone group in *p*-acetylphenylalanine can be a conjugation site via the formation of an oxime with a hydroxylamino group on the linker-drug moiety. Alternatively, the non-natural amino acid *p*-azidophenylalanine can be incorporated into an antibody to provide an azide functional group for conjugation via click chemistry, as discussed above. Non-natural amino acids can also be incorporated into an antibody or other polypeptide using cell-free methods, as taught in Goerke *et al.*, US 2010/0093024 A1 (2010) and Goerke *et al.*, *Biotechnol. Bioeng.* **2009**, 102 (2), 400-416. The foregoing disclosures are incorporated herein by reference. Thus, in one embodiment, an antibody that is used for making a conjugate has one or more amino acids replaced by a non-natural amino acid, which preferably is *p*-acetylphenylalanine or *p*-azidophenylalanine, more preferably *p*-acetylphenylalanine.

[00110] Still another conjugation technique uses the enzyme transglutaminase (preferably bacterial transglutaminase from *Streptomyces mobaraensis* or BTG), per Jeger *et al.*, *Angew. Chem. Int. Ed.* **2010**, 49, 9995. BTG forms an amide bond between the side chain carboxamide of a glutamine (the amine acceptor) and an alkyleneamino group (the amine donor), which can be, for example, the ϵ -amino group of a lysine or a 5-amino-n-pentyl group. In a typical

conjugation reaction, the glutamine residue is located on the antibody, while the alkyleneamino group is located on the linker-drug moiety, as shown below:



5 Conjugate


[00111] The positioning of a glutamine residue on a polypeptide chain has a large effect on its susceptibility to BTG mediated transamidation. None of the glutamine residues on an antibody are normally BTG substrates. However, if the antibody is deglycosylated – the glycosylation site being asparagine 297 (N297; numbering per EU index as set forth in Kabat et al., “Sequences of
 10 proteins of immunological interest,” 5th ed., Pub. No. 91-3242, U.S. Dept. Health & Human Services, NIH, Bethesda, Md., 1991; hereinafter “Kabat”) of the heavy chain – nearby glutamine 295 (Q295) is rendered BTG susceptible. An antibody can be deglycosylated enzymatically by treatment with PNGase F (Peptide-N-Glycosidase F). Alternatively, an antibody can be synthesized glycoside free by introducing an N297A mutation in the constant region, to eliminate
 15 the N297 glycosylation site. Further, it has been shown that an N297Q substitution not only eliminates glycosylation, but also introduces a second glutamine residue (at position 297) that too is an amine acceptor. Thus, in one embodiment, the antibody is deglycosylated. In another embodiment, the antibody has an N297Q substitution. Those skilled in the art will appreciate that deglycosylation by post-synthesis modification or by introducing an N297A mutation generates
 20 two BTG-reactive glutamine residues per antibody (one per heavy chain, at position 295), while an antibody with an N297Q substitution will have four BTG-reactive glutamine residues (two per heavy chain, at positions 295 and 297).

[00112] An antibody can also be rendered susceptible to BTG-mediated conjugation by introducing into it a glutamine containing peptide, or “tag,” as taught, for example, in Pons *et al.*,
 25 US 2013/0230543 A1 (2013) and Rao-Naik *et al.*, WO 2016/144608 A1.

[00113] In a complementary approach, the substrate specificity of BTG can be altered by varying its amino acid sequence, such that it becomes capable of reacting with glutamine 295 in an unmodified antibody, as taught in Rao-Naik *et al.*, WO 2017/059158 A1 (2017).


[00114] While the most commonly available bacterial transglutaminase is that from *S. mobaraensis*, transglutaminase from other bacteria, having somewhat different substrate specificities, can be considered, such as transglutaminase from *Streptovorticillium ladakanum* (Hu *et al.*, US 2009/0318349 A1 (2009), US 2010/0099610 A1 (2010), and US 2010/0087371 A1 (2010)).

[00115] TLR7 agonists of this disclosure having a primary or secondary alkyl amine are particularly suitable for use in conjugates, as the secondary amine provides a functional group for attachment of the linker. An example of such a TLR7 agonist-linker compound is compound **41**, which contains an enzymatically cleavable linker. FIG. 15 shows a scheme according to which compound **41** can be prepared.



41

[00116] An example of a TLR7 agonist-linker compound that contains a non-enzymatically cleavable linker is compound **43**. FIG. 16 shows a pathway for synthesizing compound **43**.



43


[00117] Both compounds **41** and **43** contain a primary alkylamino group, rendering them amenable to conjugation with transglutaminase. A suitable conjugation procedure is described in the Examples hereinbelow.

[00118] Conjugation can also be effected using the enzyme Sortase A, as taught in Levary *et al.*, *PLoS One* **2011**, 6(4), e18342; Proft, *Biotechnol. Lett.* **2010**, 32, 1-10; Ploegh *et al.*, WO 2010/087994 A2 (2010); and Mao *et al.*, WO 2005/051976 A2 (2005). The Sortase A recognition motif (typically LPXTG, where X is any natural amino acid) may be located on the


ligand Z and the nucleophilic acceptor motif (typically GGG) may be the group R³¹ in formula (III), or vice-versa.

TLR7 Agonist Conjugates

[00119] Applying the fore-described techniques, TLR7 agonist conjugates such as the ones
5 shown below can be prepared:



Conjugate 1



Conjugate 2

where m is 1, 2, 3, or 4 and Ab is an antibody.


10 PEGYLATION

[00120] Attachment of a poly(ethylene glycol) (PEG) chain to a drug (“PEGylation”) can improve the latter’s pharmacokinetic properties. The circulation half-life of the drug is increased, sometimes by over an order of magnitude, concomitantly reducing the dosage needed to achieve a desired therapeutic effect. PEGylation can also decrease metabolic degradation of a drug and
15 reduce its immunogenicity. For a review, see Kolate *et al.*, *J. Controlled Release* **2014**, 192, 167.


[00121] Initially, PEGylation was applied to biologic drugs. As of 2016, over ten PEGylated biologics had been approved. Turecek *et al.*, *J. Pharmaceutical Sci.* **2016**, 105, 460. More recently, stimulated by the successful application of the concept to biologics, attention has turned towards its application to small molecule drugs. In addition to the aforementioned benefits,


PEGylated small molecule drugs may have increased solubility and cause fewer toxic effects. Li *et al. Prog. Polymer Sci.* **2013**, 38, 421.

[00122] The compounds disclosed herein can be PEGylated. Where a compound has an aliphatic primary or secondary amine or an aliphatic hydroxyl, such as the case of the compounds shown below (arrows), it can be PEGylated via an ester, amide, carbonate, or carbamate group with a carboxy-containing PEG molecule utilizing conventional techniques such as dicyclohexylcarbodiimide, HATU, N-hydroxysuccinimide esters, and the like. Various other methods for PEGylating pharmaceutical molecules are disclosed in Alconcel *et al.*, *Polymer Chem.* **2011**, 2, 1442, the disclosure of which is incorporated herein by reference.



[00123] If desired, a TLR7 agonist disclosed herein can be PEGylated via an enzymatically cleavable linker comprising a self-immolating moiety, to allow release of the un-PEGylated agonist in a designed manner. Further, PEGylation can be combined with conjugation to a protein such as an antibody, if the PEG-containing molecule has a suitable functional group such as an amine for attachment to the protein. The protein can provide an additional therapeutic function or, if an antibody, can provide a targeting function. These concepts are illustrated in the following reaction sequence, where TLR7-NH-R generically represents a TLR7 agonist:





5

[00124] In the above reaction sequence, the valine-citrulline (Val-Cit) dipeptide is cleavable by the enzyme cathepsin B, with a *p*-aminobenzyl oxycarbonyl (PABC) group serving as a self-immolating spacer. The functional group for conjugation is an amine group, which is temporarily protected by an Fmoc group. Conjugation is effected by the enzyme transglutaminase, with a glutamine (Gln) side chain acting as the acyl acceptor. The subscript *x*, denoting the number of PEG repeat units, can vary widely, depending on the purpose of the PEGylation, as discussed below. For some purposes, *x* can be relatively small, such as 2, 4, 8, 12, or 24. For other purposes, *x* is large, for example between about 45 and about 910.

10

[00125] Those skilled in the art will understand that the sequence is illustrative and that other elements – peptide, self-immolating group, conjugation method, PEG length, etc. – may be employed, as is well known in the art. They will also understand that, while the above sequence combines PEGylation and conjugation, PEGylation does not require conjugation, and *vice-versa*.

15

[00126] Where the compound lacks aliphatic hydroxyl or aliphatic primary or secondary amine, it still can be PEGylated at the aromatic amine on the pyrimidine ring. A method for PEGylating at this position is disclosed by Zarraga, US 2017/0166384 A1 (2007), the disclosure of which is incorporated by reference.

5 [00127] In some embodiments, it may be desirable to have multiple PEGylated agonists linked in a single molecule. For instance, four PEGylated arms can be constructed on pentaerythritol ($C(CH_2OH)_4$) and a TLR7 agonist can be attached to each PEGylated arm. See Gao *et al.*, US 2013/0028857 A1 (2013), the disclosure of which is incorporated by reference.

10 [00128] For modulating pharmacokinetics, it is generally preferred that the PEG moiety have a formula weight of between about 2 kDa (corresponding to about 45 $-(CH_2CH_2O)-$ repeating units) and between about 40 kDa (corresponding to about 910 $-(CH_2CH_2O)-$ repeating units), more preferably between about 5 kDa and about 20 kDa. That is, the range of the subscript x in the above formulae is from about 45 to about 910. It is to be understood that PEG compositions are not 100% homogeneous but, rather, exhibit a distribution of molecular weights. Thus, a
15 reference to, for example, “20kDa PEG” means PEG having an average molecular weight of 20 kDa.

[00129] PEGylation can also be used for improving the solubility of an agonist. In such instances a shorter PEG chain can be used, for example comprising 2, 4, 8, 12, or 24 repeating units.

20 PHARMACEUTICAL COMPOSITIONS AND ADMINISTRATION

[00130] In another aspect, there is provided a pharmaceutical composition comprising a compound of as disclosed herein, or of a conjugate thereof, formulated together with a pharmaceutically acceptable carrier or excipient. It may optionally contain one or more additional pharmaceutically active ingredients, such as a biologic or a small molecule drug. The
25 pharmaceutical compositions can be administered in a combination therapy with another therapeutic agent, especially an anti-cancer agent.

[00131] The pharmaceutical composition may comprise one or more excipients. Excipients that may be used include carriers, surface active agents, thickening or emulsifying agents, solid binders, dispersion or suspension aids, solubilizers, colorants, flavoring agents, coatings,
30 disintegrating agents, lubricants, sweeteners, preservatives, isotonic agents, and combinations

thereof. The selection and use of suitable excipients is taught in Gennaro, ed., *Remington: The Science and Practice of Pharmacy*, 20th Ed. (Lippincott Williams & Wilkins 2003).

[00132] Preferably, a pharmaceutical composition is suitable for intravenous, intramuscular, subcutaneous, parenteral, spinal or epidermal administration (*e.g.*, by injection or infusion).

5 Depending on the route of administration, the active compound may be coated in a material to protect it from the action of acids and other natural conditions that may inactivate it. The phrase “parenteral administration” means modes of administration other than enteral and topical administration, usually by injection, and includes, without limitation, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, 10 transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal, epidural and intrasternal injection and infusion. Alternatively, the pharmaceutical composition can be administered via a non-parenteral route, such as a topical, epidermal or mucosal route of administration, for example, intranasally, orally, vaginally, rectally, sublingually or topically.

[00133] Pharmaceutical compositions can be in the form of sterile aqueous solutions or 15 dispersions. They can also be formulated in a microemulsion, liposome, or other ordered structure suitable to achieve high drug concentration. The compositions can also be provided in the form of lyophilates, for reconstitution in water prior to administration.

[00134] The amount of active ingredient which can be combined with a carrier material to produce a single dosage form will vary depending upon the subject being treated and the 20 particular mode of administration and will generally be that amount of the composition which produces a therapeutic effect. Generally, out of one hundred per cent, this amount will range from about 0.01 per cent to about ninety-nine percent of active ingredient, preferably from about 0.1 per cent to about 70 per cent, most preferably from about 1 per cent to about 30 per cent of active ingredient in combination with a pharmaceutically acceptable carrier.

25 [00135] Dosage regimens are adjusted to provide a therapeutic response. For example, a single bolus may be administered, several divided doses may be administered over time, or the dose may be proportionally reduced or increased as indicated by the exigencies of the situation. It is especially advantageous to formulate parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. “Dosage unit form” refers to physically discrete units 30 suited as unitary dosages for the subjects to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic response, in association with the required pharmaceutical carrier.

[00136] The dosage ranges from about 0.0001 to 100 mg/kg, and more usually 0.01 to 5 mg/kg, of the host body weight. For example dosages can be 0.3 mg/kg body weight, 1 mg/kg body weight, 3 mg/kg body weight, 5 mg/kg body weight or 10 mg/kg body weight or within the range of 1-10 mg/kg, or alternatively 0.1 to 5 mg/kg. Exemplary treatment regimens are administration once per week, once every two weeks, once every three weeks, once every four weeks, once a month, once every 3 months, or once every three to 6 months. Preferred dosage regimens include 1 mg/kg body weight or 3 mg/kg body weight via intravenous administration, using one of the following dosing schedules: (i) every four weeks for six dosages, then every three months; (ii) every three weeks; (iii) 3 mg/kg body weight once followed by 1 mg/kg body weight every three weeks. In some methods, dosage is adjusted to achieve a plasma antibody concentration of about 1-1000 µg/mL and in some methods about 25-300 µg /mL.

[00137] A “therapeutically effective amount” of a compound of the invention preferably results in a decrease in severity of disease symptoms, an increase in frequency and duration of disease symptom-free periods, or a prevention of impairment or disability due to the disease affliction. For example, for the treatment of tumor-bearing subjects, a “therapeutically effective amount” preferably inhibits tumor growth by at least about 20%, more preferably by at least about 40%, even more preferably by at least about 60%, and still more preferably by at least about 80% relative to untreated subjects. A therapeutically effective amount of a therapeutic compound can decrease tumor size, or otherwise ameliorate symptoms in a subject, which is typically a human but can be another mammal. Where two or more therapeutic agents are administered in a combination treatment, “therapeutically effective amount” refers to the efficacy of the combination as a whole, and not each agent individually.

[00138] The pharmaceutical composition can be a controlled or sustained release formulation, including implants, transdermal patches, and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. See, *e.g.*, *Sustained and Controlled Release Drug Delivery Systems*, J.R. Robinson, ed., Marcel Dekker, Inc., New York, 1978.

[00139] Therapeutic compositions can be administered via medical devices such as (1) needleless hypodermic injection devices; (2) micro-infusion pumps; (3) transdermal devices; (4) infusion devices; and (5) osmotic devices.

[00140] In certain embodiments, the pharmaceutical composition can be formulated to ensure proper distribution *in vivo*. For example, to ensure that the therapeutic compounds of the

invention cross the blood-brain barrier, they can be formulated in liposomes, which may additionally comprise targeting moieties to enhance selective transport to specific cells or organs.

INDUSTRIAL APPLICABILITY

[00141] TLR7 agonist compounds disclosed herein can be used for the treatment of a disease
5 or condition that can be ameliorated by activation of TLR7.

[00142] In one embodiment, the TLR7 agonist is used in combination with an anti-cancer immunotherapy agent – also known as an immuno-oncology agent. An anti-cancer immunotherapy agent works by stimulating a body's immune system to attack and destroy cancer cells, especially through the activation of T cells. The immune system has numerous
10 checkpoint (regulatory) molecules, to help maintain a balance between its attacking legitimate target cells and preventing it from attacking healthy, normal cells. Some are stimulators (up-regulators), meaning that their engagement promotes T cell activation and enhances the immune response. Others are inhibitors (down-regulators or brakes), meaning that their engagement inhibits T cell activation and abates the immune response. Binding of an agonistic
15 immunotherapy agent to a stimulatory checkpoint molecule can lead to the latter's activation and an enhanced immune response against cancer cells. Reciprocally, binding of an antagonistic immunotherapy agent to an inhibitory checkpoint molecule can prevent down-regulation of the immune system by the latter and help maintain a vigorous response against cancer cells. Examples of stimulatory checkpoint molecules are B7-1, B7-2, CD28, 4-1BB (CD137), 4-1BBL,
20 ICOS, CD40, ICOS-L, OX40, OX40L, GITR, GITRL, CD70, CD27, CD40, DR3 and CD28H. Examples of inhibitory checkpoint molecules are CTLA-4, PD-1, PD-L1, PD-L2, LAG-3, TIM-3, Galectin 9, CEACAM-1, BTLA, CD69, Galectin-1, CD113, GPR56, VISTA, 2B4, CD48, GARP, PD1H, LAIR1, TIM-1, CD96 and TIM-4.

[00143] Whichever the mode of action of an anti-cancer immunotherapy agent, its
25 effectiveness can be increased by a general up-regulation of the immune system, such as by the activation of TLR7. Thus, in one embodiment, this specification provides a method of treating a cancer, comprising administering to a patient suffering from such cancer a therapeutically effective combination of an anti-cancer immunotherapy agent and a TLR7 agonist as disclosed herein. The timing of administration can be simultaneous, sequential, or alternating. The mode of
30 administration can be systemic or local. The TLR7 agonist can be delivered in a targeted manner, via a conjugate.

[00144] Cancers that could be treated by a combination treatment as described above include acute myeloid leukemia, adrenocortical carcinoma, Kaposi sarcoma, lymphoma, anal cancer, appendix cancer, teratoid/rhabdoid tumor, basal cell carcinoma, bile duct cancer, bladder cancer, bone cancer, brain cancer, breast cancer, bronchial tumor, carcinoid tumor, cardiac tumor, cervical cancer, chordoma, chronic lymphocytic leukemia, chronic myeloproliferative neoplasm, colon cancer, colorectal cancer, craniopharyngioma, bile duct cancer, endometrial cancer, ependymoma, esophageal cancer, esthesioneuroblastoma, Ewing sarcoma, eye cancer, fallopian tube cancer, gallbladder cancer, gastrointestinal carcinoid tumor, gastrointestinal stromal tumor, germ cell tumor, hairy cell leukemia, head and neck cancer, heart cancer, liver cancer, hypopharyngeal cancer, pancreatic cancer, kidney cancer, laryngeal cancer, chronic myelogenous leukemia, lip and oral cavity cancer, lung cancer, melanoma, Merkel cell carcinoma, mesothelioma, mouth cancer, oral cancer, osteosarcoma, ovarian cancer, penile cancer, pharyngeal cancer, prostate cancer, rectal cancer, salivary gland cancer, skin cancer, small intestine cancer, soft tissue sarcoma, testicular cancer, throat cancer, thyroid cancer, urethral cancer, uterine cancer, vaginal cancer, and vulvar cancer.

[00145] Anti-cancer immunotherapy agents that can be used in combination therapies as disclosed herein include: AMG 557, AMP-224, atezolizumab, avelumab, BMS 936559, cemiplimab, CP-870893, dacetuzumab, durvalumab, enoblituzumab, galiximab, IMP321, ipilimumab, lucatumumab, MEDI-570, MEDI-6383, MEDI-6469, muromonab-CD3, nivolumab, pembrolizumab, pidilizumab, spartalizumab, tremelimumab, urelumab, utomilumab, varlilumab, vonlerolizumab. Table A below lists their alternative name(s) (brand name, former name, research code, or synonym) and the respective target checkpoint molecule.

Table A		
Immunotherapy Agent	Alternative Name(s)	Target
AMG 557		B7RP-1 (ICOSL)
AMP-224		PD-1
Atezolizumab	MPDL3280A, RO5541267, TECENTRIQ®	PD-L1
Avelumab	BAVENCIO®	PD-L1
BMS 936559		PD-L1
Cemiplimab	LIBTAYO®	PD-1
CP-870893		CD40

Table A		
Immunotherapy Agent	Alternative Name(s)	Target
Dacetuzumab		CD40
Durvalumab	IMFINZI®	PD-L1
Enoblituzumab	MGA271	B7-H3
Galiximab		B7-1 (CD80)
IMP321		LAG-3
Ipilimumab	YERVOY®	CTLA-4
Lucatumumab		CD40
MEDI-570		ICOS (CD278)
MEDI-6383		OX40
MEDI-6469		OX40
Muromonab-CD3		CD3
Nivolumab	OPDIVO®	PD-1
Pembrolizumab	KEYTRUDA®	PD-1
Pidilizumab	MDV9300	PD-1
Spartalizumab	PDR001	PD-1
Tremelimumab	Ticilimumab, CP-675, CP-675,206	CTLA-4
Urelumab	BMS-663513	CD137
Utomilumab	PF-05082566	CD137
Varlilumab	CDX 1127	CD27
Vonlerolizumab	RG7888, MOXR0916, pogalizumab	OX40

[00146] In one embodiment of a combination treatment with a TLR7 agonist, the anti-cancer immunotherapy agent is an antagonistic anti-CTLA-4, anti-PD-1, or anti-PD-L1 antibody. The cancer can be lung cancer (including non-small cell lung cancer), pancreatic cancer, kidney cancer, head and neck cancer, lymphoma (including Hodgkin's lymphoma), skin cancer (including melanoma and Merkel skin cancer), urothelial cancer (including bladder cancer), gastric cancer, hepatocellular cancer, or colorectal cancer.

[00147] In another embodiment of a combination treatment with a TLR7 agonist, the anti-cancer immunotherapy agent is an antagonistic anti-CTLA-4 antibody, preferably ipilimumab.

[00148] In another embodiment of a combination treatment with a TLR7 agonist, the anti-cancer immunotherapy agent is an antagonistic anti-PD-1 antibody, preferably nivolumab or pembrolizumab.

[00149] The TLR7 agonists disclosed herein also are useful as vaccine adjuvants.

5 BIOLOGICAL ACTIVITY

[00150] The biological activity of compounds disclosed herein as TLR7 agonists can be assayed by the procedures following.

Human TLR7 Agonist Activity Assay

[00151] This procedure describes a method for assaying human TLR7 (hTLR7) agonist
10 activity of the compounds disclosed in this specification.

[00152] Engineered human embryonic kidney blue cells (HEK-Blue™ TLR cells; Invivogen) possessing a human TLR7-secreted embryonic alkaline phosphatase (SEAP) reporter transgene were suspended in a non-selective, culture medium (DMEM high-glucose (Invitrogen), supplemented with 10% fetal bovine serum (Sigma)). HEK-Blue™ TLR7 cells were added to
15 each well of a 384-well tissue-culture plate (15,000 cells per well) and incubated 16-18 h at 37 °C, 5% CO₂. Compounds (100 nl) were dispensed into wells containing the HEK-Blue™ TLR cells and the treated cells were incubated at 37 °C, 5% CO₂. After 18 h treatment ten microliters of freshly-prepared Quanti-Blue™ reagent (Invivogen) was added to each well, incubated for 30 min (37 °C, 5% CO₂) and SEAP levels measured using an Envision plate reader (OD = 620 nm).
20 The half maximal effective concentration values (EC₅₀; compound concentration which induced a response halfway between the assay baseline and maximum) were calculated.

Induction of Type I Interferon Genes (MX-1) and CD69 in Human Blood

[00153] The induction of Type I interferon (IFN) MX-1 genes and the B-cell activation marker CD69 are downstream events that occur upon activation of the TLR7 pathway. The
25 following is a human whole blood assay that measures their induction in response to a TLR7 agonist.

[00154] Heparinized human whole blood was harvested from human subjects and treated with test TLR7 agonist compounds at 1mM. The blood was diluted with RPMI 1640 media and Echo was used to predot 10 nL per well giving a final concentration of 1uM (10nL in 10uL of blood).
30 After mixing on a shaker for 30 sec, the plates were covered and placed in a 37 °C chamber for

o/n=17hrs. Fixing/lysis buffer was prepared (5x->1x in H₂O, warm at 37 °C; Cat# BD 558049) and kept the perm buffer (on ice) for later use.

[00155] For surface markers staining (CD69): prepared surface Abs: 0.045ul hCD14-FITC (ThermoFisher Cat # MHCD1401) + 0.6ul hCD19-ef450 (ThermoFisher Cat # 48-0198-42) +
5 1.5ul hCD69-PE (cat# BD555531) + 0.855ul FACS buffer. Added 3ul/well, spin1000rpm for 1min and mixed on shaker for 30sec, put on ice for 30 mins. Stop stimulation after 30 minutes with 70uL of prewarmed 1x fix/lysis buffer and use Felix mate to resuspend (15 times, change tips for each plate) and incubate at 37C for 10 minutes.

[00156] Centrifuge at 2000 rpm for 5 minutes aspirate with HCS plate washer, mix on shaker
10 for 30sec and then wash with 70uL in dPBS and pelleted 2xs (2000rpm for 5 min) and 50ul wash in FACS buffer pelleted 1xs(2000rpm for 5 min). Mix on shaker for 30sec. For Intracellular markers staining (MX-1): Add 50ul of BD Perm buffer III and mix on shaker for 30sec. Incubate on ice for 30 minutes (in the dark). Wash with 50uL of FACS buffer 2X (spin @2300rpm x 5min after perm) followed by mixing on shaker for 30sec. Resuspended in 20ul of FACS buffer
15 containing MX1 antibody (4812)-Alexa 647: Novus Biologicals #NBP2-43704AF647) 20ul FACS bf + 0.8ul hIgG + 0.04ul MX-1. Spin 1000rpm for 1 min, mix on shaker for 30se and the samples were incubated at RT in the dark for 45 minutes followed by washing 2x FACS buffer (spin @2300rpm x 5min after perm). Resuspend 20ul (35uL total per well) of FACS buffer and cover with foil and place in 4°C to read the following day. Plates were read on iQuePlus. The
20 results were loaded into toolset and IC50 curves are generated in curve master. The y-axis 100% is set to 1uM of resiquimod.

Induction of TNF-alpha and Type I IFN Response Genes in Mouse Blood

[00157] The induction of TNF-alpha and Type I IFN response genes are downstream events that occur upon activation of the TLR7 pathway. The following is an assay that measures their
25 induction in whole mouse blood in response to a TLR7 agonist.

[00158] Heparinized mouse whole blood was diluted with RPMI 1640 media with Pen-Strep in the ratio of 5:4 (50 uL whole blood and 40 uL of media). A volume of 90 uL of the diluted blood was transferred to wells of Falcon flat bottom 96-well tissue culture plates, and the plates were incubated at 4 °C for 1 h. Test compounds in 100% DMSO stocks were diluted 20-fold in
30 the same media for concentration response assays, and then 10 uL of the diluted test compounds were added to the wells, so that the final DMSO concentration was 0.5%. Control wells received

10 uL media containing 5% DMSO. The plates were then incubated at 37°C in a 5% CO₂ incubator for 17 h. Following the incubation, 100 uL of the culture medium was added to each well. The plates were centrifuged and 130 uL of supernatant was removed for use in assays of TNFa production by ELISA (Invitrogen, Catalog Number 88-7324 by Thermo-Fisher Scientific). A 70 uL volume of mRNA catcher lysis buffer (1x) with DTT from the Invitrogen mRNA Catcher Plus kit (Cat#K1570-02) was added to the remaining 70 uL sample in the well, and was mixed by pipetting up and down 5 times. The plate was then shaken at room temperature for 5 - 10 min, followed by addition of 2 uL of proteinase K (20 mg/mL) to each well. Plates were then shaken for 15 - 20 min at RT. The plates were then stored at -80 °C until further processing.

[00159] The frozen samples were thawed and mRNA was extracted using the Invitrogen mRNA Catcher Plus kit (Cat# K1570-02) according to the manufacturer's instructions. Half yield of mRNA from RNA extraction were used to synthesize cDNA in 20 µL reverse transcriptase reactions using Invitrogen SuperScript IV VILO Master Mix (Cat# 11756500). TaqMan® real-time PCR was performed using QuantStudio Real-Time PCR system from ThermoFisher (Applied Biosystems). All real-time PCR reactions were run in duplicate using commercial predesigned TaqMan assays for mouse IFIT1, IFIT3, MX1 and PPIA gene expression and TaqMan Master Mix. PPIA was utilized as the housekeeping gene. The recommendations from the manufacturer were followed. All raw data (Ct) were normalized by average housekeeping gene (Ct) and then the comparative Ct ($\Delta\Delta Ct$) method were utilized to quantify relative gene expression (RQ) for experimental analysis.

GENERAL PROCEDURES

[00160] The following general procedures were used for liquid chromatography (preparative or analytical) and nuclear magnetic resonance.

Liquid Chromatography

[00161] Unless noted otherwise, the following general conditions were used for high pressure liquid chromatography (HPLC) purification or for liquid chromatography-mass spectrometry (LC-MS):

Preparative HPLC/MS conditions A-1: Column: XBridge C18, 200 mm x 19 mm, 5-µm particles; Mobile Phase A: 5:95 acetonitrile: water with 0.05% trifluoroacetic acid; Mobile Phase B: 95:5 acetonitrile: water with 0.05% trifluoroacetic acid; Gradient: a 0-

minute hold at 0% B, 0-40% B over 20 minutes, then a 0-minute hold at 100% B; Flow Rate: 20 mL/min; Column Temperature: 25 °C.

Preparative HPLC/MS conditions A-2: Column: XBridge C18, 200 mm x 19 mm, 5-µm particles; Mobile Phase A: 5:95 acetonitrile: water with 10 mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile: water with 10 mM ammonium acetate; Gradient: a 0-minute hold at 7% B, 7-47% B over 20 minutes, then a 0-minute hold at 100% B; Flow Rate: 20 mL/min; Column Temperature: 25 °C.

Preparative HPLC/MS conditions A-3: Column: XBridge Shield RP18 OBD Column, 19x150mm, 5 µm; Mobile phase A: water with 0.05% TFA; Mobile phase B acetonitrile with 0.05% TFA; Flow rate: 18.9 mL/min; Gradient: 0% B for 2 min, 0-35% B for 20 min, 100% B for 3 min; Detector, UV 254/210nm; Column Temperature: 25 °C.

LC/MS conditions B: Column: Aquity UPLC BEH C18, 2.1 mm x 50 mm, 1.7 µm particles; Mobile Phase A: 100% water with 0.05% TFA; Mobile Phase B: 100% acetonitrile with 0.05% TFA; Gradient: 2 %B to 98 %B over 1 min, then a 0.50 min hold at 98 %B; Flow: 0.8 mL/min.

LC/MS conditions C: Column: Waters XBridge C18, 2.1 mm x 50 mm, 1.7 µm particles; Mobile Phase A: 5:95 acetonitrile:water with 0.1 % trifluoroacetic acid; Mobile Phase B: 95:5 acetonitrile:water with 0.1 % trifluoroacetic acid; Temperature: 50 °C; Gradient: 0 %B to 100 %B over 3 min, then a 0.50 min hold at 100 %B; Flow: 1 mL/min; Detection: MS and UV (220 nm).

LC/MS conditions D: LC/MS conditions: Column: Aquity UPLC BEH C18, 2.1 mm x 50 mm, 1.7 µm particles; Mobile Phase A: 95:5 water:acetonitrile with 10 mM NH₄OH; Mobile Phase B: 95:5 acetonitrile:water with 10 mM NH₄OH; Gradient: 5 %B to 95 %B over 1 min, then a 0.50 min hold at 95 %B; Flow: 0.8 mL/min to 95 %B over 1 min, then a 0.50 min hold at 95 %B; Flow: 0.8 mL/min.

LC/MS conditions E: LC/MS conditions: Column: Waters XBridge C18, 2.1 mm x 50 mm, 1.7 µm particles; Mobile Phase A: water with 0.1% TFA; Mobile Phase B: acetonitrile with 0.1% TFA; Temperature: 40 °C; Gradient: 5%B to 95%B over 2.6 min, then a 0.20 min hold at 95%B; Flow rate: 0.6 mL/min;

NMR



[00162] The following conditions were used for obtaining proton nuclear magnetic resonance (NMR) spectra: NMR spectra were taken in either 400 Mz or 500 Mhz Bruker instrument using either DMSO-d₆ or CDCl₃ as solvent and internal standard. The crude NMR data was analyzed
 5 by using either ACD Spectrus version 2015-01 by ADC Labs or MestReNova software.

[00163] Chemical shifts are reported in parts per million (ppm) downfield from internal tetramethylsilane (TMS) or from the position of TMS inferred by the deuterated NMR solvent. Apparent multiplicities are reported as: singlet-s, doublet-d, triplet-t, quartet-q, or multiplet-m. Peaks that exhibit broadening are further denoted as br. Integrations are approximate. It should
 10 be noted that integration intensities, peak shapes, chemical shifts and coupling constants can be dependent on solvent, concentration, temperature, pH, and other factors. Further, peaks that overlap with or exchange with water or solvent peaks in the NMR spectrum may not provide reliable integration intensities. In some cases, NMR spectra may be obtained using water peak suppression, which may result in overlapping peaks not being visible or having altered shape
 15 and/or integration.

SYNTHESIS

[00164] The practice of this invention can be further understood by reference to the following examples, which are provided by way of illustration and not of limitation.

[00165] Generally, the procedures disclosed herein produce a mixture of regioisomers,
 20 alkylated at the 1*H* or 2*H* position of the pyrazolopyrimidine ring system (which are also referred to as N1 and N2 regioisomers, respectively, alluding to the nitrogen that is alkylated). In the figures, sometimes the N2 regioisomers are not shown for convenience, but it is to be understood that they are present in the initial product mixture and separated at a later time, for example by preparative HPLC.

1*H*-pyrazolo[4,3-*d*]pyrimidine2*H*-pyrazolo[4,3-*d*]pyrimidine

[00166] The mixture of regioisomers can be separated at an early stage of the synthesis and the remaining synthetic steps carried out with the 1*H* regioisomer or, alternatively, the synthesis

can be progressed carrying the mixture of regioisomers and separation effected at a later stage, as desired.

Procedure 1 – Compounds per FIG. 1

[00167] This procedure and companion **FIG. 1** illustrate a method for making compounds disclosed herein, using compound **800** as an exemplar.

[00168] *Compound 3.* Methyl 4-amino-1H-pyrazole-5-carboxylate **2** (4 g, 28.3 mmol) and methyl (Z)-4-(2,3-bis(methoxycarbonyl)guanidino)-1H-pyrazole-5-carboxylate **1** in methanol (50 mL) was treated with acetic acid (8.11 mL, 142 mmol) at which time a precipitate formed. The reaction mixture was stirred overnight. Sodium methoxide (64.8 mL, 283 mmol) was added and stirring was continued overnight. LCMS showed completion of the reaction. The pH was adjusted to 5 by the slow addition of acetic acid, whereby a precipitate formed that was washed with water and then acetonitrile and dried to provide 5.2 g of compound **3** as an off white solid. LCMS ESI: calculated for $C_7H_7N_5O_3 = 210.16$ ($M+H^+$), found 210.0 ($M+H^+$).

[00169] *Compound 4.* Compound **3** (2g, 9.56 mmol), butan-1-amine (1.8 mL, 9 mmol), and DBU (1.6 mL, 10 mmol) in DMSO (10 mL) was slowly treated with BOP (5 g, 11 mmol). The reaction mixture was heated at 60 °C for 2 h at which time LCMS showed completion of the reaction. The reaction was directly purified on reverse phase COMBIFLASH™ apparatus using 80 g C-18 column eluting with 0-100% acetonitrile/water (0.1% formic acid) to yield compound **4** as a white solid. LCMS ESI: calculated for $C_{11}H_{16}N_6O_2 = 265.28$ ($M+H^+$), found 265.2 ($M+H^+$). ^1H NMR (400 MHz, $dmsO-d_6$) δ 8.02 (s, 1H), 3.97 (s, 3H), 1.74 – 1.66 (m, 2H), 1.49 – 1.38 (m, 2H), 1.25 (s, 1H), 0.95 (t, $J = 7.4$ Hz, 3H).

[00170] *Compound 6.* A mixture of methyl 4-(bromomethyl)-2-methoxybenzoate **5** (1g, 3.86 mmol) and cyclobutanamine **5a** (0.659 mL, 7.72 mmol) in DMF (2 mL) was heated at 70 °C over 30 min at which point LCMS showed the formation of an amine product. The excess base was evaporated and Hunig's Base (1.348 mL, 7.72 mmol) was added, followed by addition of Boc-anhydride (0.896 mL, 3.86 mmol). LCMS showed the completion of reaction. The solvent was evaporated and the crude product was purified by COMBIFLASH™ apparatus using EtOAc/hexanes to provide 0.82g desired product **6** as a colorless oil. LCMS ESI: calculated for $C_{19}H_{27}NO_5 = 350.42$ ($M+H^+$), found 350.1 ($M+H^+$).

[00171] *Compound 7.* A solution of compound **6** (0.82g, 2.347 mmol) in THF (5 mL) at 0 °C was treated slowly with $LiAlH_4$ (2 M in THF, 1.173 mL, 2.347 mmol) and stirred for 30 min, at

which point LCMS showed completion of the reaction. The reaction was quenched by the slow addition of methanol and stirred with Rochelle salt solution for 2 h. The organic layers were separated and the crude product **7** was purified on a COMBIFLASH™ apparatus using EtOAc/hexanes, silica gel column. LCMS ESI: calculated for C₁₈H₂₇NO₄ = 322.41 (M+H⁺),
 5 found 322.1 (M+H⁺).

[00172] *Compounds 8 and 9.* A mixture of compound **4** (100 mg, 0.378 mmol), compound **7** (182 mg, 0.568 mmol) and triphenylphosphine (248 mg, 0.946 mmol) in THF (3 mL) was slowly treated with DIAD (0.110 mL, 0.568 mmol) over 5 min and stirred at RT for 30 min under N₂ at which point LCMS showed the completion of the reaction. The solvent was evaporated and the
 10 crude product was purified on reverse phase COMBIFLASH™ apparatus using 80 g C-18 column eluting with 0-100% acetonitrile/water (1 mM TEAA) to provide a mixture of compounds **8** and **9** as a white solid. LCMS ESI: calculated for C₂₉H₄₁N₇O₅ = 566.69 (M-H⁺), found 566.3 (M-H⁺).

[00173] The isomers were separated by chiral supercritical fluid chromatography using
 15 Column: Kromasil 5-CelluCoat, 21 x 250 mm, 5 micron, Mobile Phase: 15% MeOH-DEA / 85% CO₂, Flow Conditions: 45 mL/min, 150 Bar, 40°C, Detector Wavelength: 230 nm, Injection Details: 0.5 mL of ~25mg/mL in MeOH to provide 17 mg of compound **8** and 25 mg of compound **9**.

Analytical data for compound 8: ¹H NMR (400 MHz, DMSO-*d*₆) δ 9.61 (s, 2H), 7.86 (s, 2H), 6.94 (s, 2H), 6.83 (s, 2H), 6.63 (d, *J* = 7.9 Hz, 2H), 6.51 (d, *J* = 7.5 Hz, 2H), 5.69 (s, 4H), 4.39 (s, 4H), 3.79 (s, 6H), 3.63 (s, 6H), 3.48 (d, *J* = 6.2 Hz, 4H), 3.33 (s, 20H), 3.18 (d, *J* = 5.3 Hz, 1H), 2.05 – 1.95 (m, 8H), 1.53 (t, *J* = 7.5 Hz, 7H), 1.35 (s, 11H), 1.23 (q, *J* = 7.2 Hz, 6H), 0.86 (t, *J* = 7.4 Hz, 6H).
 20

Analytical data for compound 9: ¹H NMR (400 MHz, DMSO-*d*₆) δ 9.37 (s, 1H), 8.08 (s, 1H), 6.90 (s, 1H), 6.84 (s, 1H), 6.71 (d, *J* = 7.7 Hz, 1H), 5.48 (s, 2H), 4.42 (s, 3H), 3.78 (d, *J* = 18.0 Hz, 4H), 3.69 (s, 1H), 3.61 (s, 3H), 3.51 – 3.42 (m, 3H), 2.06 – 1.97 (m, 6H), 1.61 – 1.47 (m, 6H), 1.36 (s, 8H), 1.34 – 1.26 (m, 6H), 0.99 (t, *J* = 7.1 Hz, 3H), 0.94 – 0.85 (m, 4H).
 25

[00174] *Compound 800.* A solution of compound **8** (13 mg, 0.023 mmol) was dissolved in
 30 THF (0.5 mL) and was treated with TFA (0.018 mL, 0.229 mmol). LCMS in 30 min showed Boc deprotection. The TFA was evaporated and this mixture was treated with sodium hydroxide (9.16 mg, 0.229 mmol) and heated at 60 °C for 2 h, at which point LCMS showed completion of

the reaction. The base was neutralized by the slow addition of 6M HCl and worked up with EtOAc/water. The crude material was purified via preparative HPLC under HPLC/MS conditions A-2.

[00175] Other compounds of this disclosure can be analogously made, *mutatis mutandis*, by using another amine instead of cyclobutanamine **5a**.

Procedure 2 – Compounds per FIGs. 2A-2B

[00176] This procedure and companion **FIGs. 2A-2B** illustrate another method for making compounds disclosed herein, using compounds **801** and **818** as exemplars.

[00177] *Compounds 12 and 13.* A solution of methyl 4-nitro-1H-pyrazole-5-carboxylate **10** (3.27 g, 19.11 mmol) in DMF (20 mL) was treated with K₂CO₃ (2.90 g, 21.02 mmol) and methyl 4-(bromomethyl)-3-methoxybenzoate **11** (5 g, 19.30 mmol). The reaction was started at 0 °C and allowed to proceed for 1 h, at which point LCMS showed completion of the reaction with ~1:5 mixture of products. The base was filtered and the reaction was diluted with EtOAc and washed with water 2 times. The solvent was evaporated and the crude product was taken to next step as-is. LCMS ESI: calculated for C₁₅H₁₅N₃O₇ = 350.2 (M-H⁺), found 350.0 (M-H⁺).

[00178] For characterization purpose, a small amount of the mixture of products was separated using silica gel column chromatography using 0-50% EtOAc/hexanes.

Analytical data for compound 12: ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.40 (s, 1H), 7.57 (dd, *J* = 7.8, 1.5 Hz, 1H), 7.50 (d, *J* = 1.6 Hz, 1H), 7.27 (d, *J* = 7.9 Hz, 1H), 5.53 (s, 2H), 3.96 (s, 3H), 3.84 (d, *J* = 16.2 Hz, 6H).

Analytical data for compound 13: ¹H NMR (400 MHz, DMSO-*d*₆) δ 9.05 (s, 1H), 7.62 – 7.51 (m, 2H), 7.28 (d, *J* = 7.9 Hz, 1H), 5.47 (s, 2H), 3.87 (s, 8H), 3.31 (s, 1H).

[00179] *Compounds 14 and 15.* A solution of compounds **12** and **13** (2g, 5.73 mmol), zinc and ammonium formate was stirred at RT for 2 h, after which LCMS showed completion of the reaction. Filtration and concentration yielded a crude mixture of compounds **14** and **15**. LCMS ESI: calculated for C₁₅H₁₇N₃O₅ = 320.3 (M+H⁺), found 320.2 (M+H⁺).

[00180] *Compounds 16 and 17.* A mixture of compounds **14** and **15** (1.830 g, 5.73 mmol) and compound **1** in MeOH (20 mL) was treated with acetic acid (1.640 mL, 28.7 mmol) and stirred overnight. The solution was treated with sodium methoxide (13.11 mL, 57.3 mmol) and stirred overnight. LCMS showed conversion to the product. The pH was adjusted to 5 and the resulting

precipitate was washed with water. The residue was dried to afford a mixture of compounds **16** and **17**. LCMS ESI: calculated for $C_{17}H_{17}N_5O_6 = 388.3$ ($M+H^+$), found 388.1 ($M+H^+$).

[00181] *Compounds 18 and 19*. A mixture of compounds **16** and **17** (1 g, 2.58 mmol) in DMSO (10 mL) was treated with butan-1-amine (0.510 mL, 5.16 mmol), DBU (0.428 mL, 2.84 mmol) followed slowly by BOP (1.370 g, 3.10 mmol). The reaction was heated at 70 °C for 2 h, at which point LCMS showed completion of the reaction. The reaction was diluted with water and extracted with EtOAc. The combined organic phases were dried over Na_2SO_4 and taken as-is to the next step. LCMS ESI: calculated for $C_{21}H_{26}N_6O_5 = 443.4$ ($M+H^+$), found 443.2 ($M+H^+$). ^1H NMR (400 MHz, DMSO- d_6) δ 9.41 (s, 1H), 8.20 (s, 1H), 8.08 (s, 1H), 7.57 – 7.42 (m, 3H), 6.93 (d, $J = 8.1$ Hz, 1H), 5.80 (s, 1H), 5.60 (s, 2H), 4.04 (q, $J = 7.1$ Hz, 1H), 3.95 – 3.82 (m, 10H), 3.62 (d, $J = 6.1$ Hz, 4H), 3.45 (q, $J = 7.0$ Hz, 3H), 2.68 (d, $J = 9.9$ Hz, 1H), 2.57 – 2.50 (m, 6H), 2.00 (s, 1H), 1.59 (p, $J = 7.3$ Hz, 3H), 1.54 – 1.48 (m, 1H), 1.39 – 1.26 (m, 3H), 1.18 (t, $J = 7.1$ Hz, 2H), 0.86 (dt, $J = 29.5, 7.3$ Hz, 5H).

[00182] *Compound 818*. A solution of compounds **18** and **19** (1.142 g, 2.58 mmol) in THF (2.58 mL, 5.16 mmol) at 0 °C was treated with $LiAlH_4$ (THF, 2.58 mL, 5.16 mmol) and stirred for 1 h, after which LCMS showed completion of the reaction. The reaction was quenched with MeOH and stirred with Rochelle salt solution overnight. The product was extracted with EtOAc and taken to next step as a mixture of crude compounds reduced intermediate. LCMS ESI: calculated for $C_{20}H_{26}N_6O_4 = 415.4$ ($M+H^+$), found 415.2 ($M+H^+$).

[00183] A mixture of the reduced intermediates (1069 mg, 2.58 mmol) in 1,4-dioxane (10 mL) was treated with aqueous sodium hydroxide (2.58 mL, 25.8 mmol) and heated at 80 °C for 5 h, after which LCMS showed formation of product. The base was neutralized with 6M HCl and the solvent was evaporated. The residue was taken up in 5 mL DMF and syringe filtered. The solvent was evaporated to afford a 3:1 mixture of compounds **818** and its regioisomer **19a**.

[00184] *Compound 801 and 19b*. A solution of compounds **818** and **19a** (420 mg, 1.178 mmol) in THF (1 mL) was treated with thionyl chloride (0.172 mL, 2.357 mmol) and stirred for 30 min, after which LCMS showed completion of the reaction. The solvent was evaporated and the crude benzyl chloride intermediate was taken to next step as-is. LCMS ESI: calculated for $C_{18}H_{23}ClN_6O = 375.8$ ($M+H^+$), found 375.2 ($M+H^+$).

[00185] A mixture of the preceding crude product mixture (20 mg, 0.053 mmol) and tetrahydro-2H-pyran-4-amine **22** (5.40 mg, 0.053 mmol) in DMF (1 mL) was heated at 70 °C for

1 h, after which LCMS showed completion of the reaction. The reaction was syringe filtered and the crude products were purified and separated via preparative LC/MS with the following conditions: Column: XBridge C18, 200 mm x 19 mm, 5- μ m particles; Mobile Phase A: 5:95 acetonitrile: water with 0.1% trifluoroacetic acid; Mobile Phase B: 95:5 acetonitrile: water with 0.1% trifluoroacetic acid; Gradient: a 2-minute hold at 6% B, 6-27% B over 25 minutes, then a 2-minute hold at 100% B; Flow Rate: 20 mL/min; Column Temperature: 25 C. Fraction collection was triggered by MS signals. Fractions containing the desired product were combined and dried via centrifugal evaporation.

[00186] If desired, the separation of 1*H* and 2*H* regioisomers can be effected earlier in the synthetic process, for example at the mixture of compounds **12** and **13** and synthetic steps carried out only with the 1*H* regioisomer.

[00187] Other compounds of this disclosure can be analogously prepared, *mutatis mutandis*, for example by using another amine instead of tetrahydro-2*H*-pyran-4-amine **22**.

Procedure 3 – Compounds per FIGs. 3A-3B

[00188] This procedure and companion **FIGs. 3A-3B** illustrate another method for making compounds disclosed herein, using compounds **844**, **817**, and **861** as exemplars.

[00189] *Compound 24*. To a mixture of compound **16** (400 mg, 1.033 mmol) and (S)-3-aminohexan-1-ol **23** (242 mg, 2.065 mmol) in DMSO (5 mL) was added DBU (0.463 mL, 3.10 mmol) followed by the slow addition of BOP (502 mg, 1.136 mmol). The reaction mixture was heated at 70 °C for 2 h, at which point LCMS showed completion of the reaction. The reaction mixture was diluted with EtOAc and washed with water. The organic layer was concentrated to leave a crude product, which was used in the next step.

[00190] The crude product was treated with tert-butylchlorodiphenylsilane (0.295 mL, 1.136 mmol) and imidazole (141 mg, 2.065 mmol) in DMF (5 mL). The reaction mixture was stirred overnight. The reaction mixture was diluted with water and worked up with EtOAc. Purification was performed with a COMBIFLASHTM apparatus using EtOAc/hexane to afford compound **24**. LCMS ESI: calculated for C₃₈H₄₈N₆O₆Si = 725.9 (M+H⁺), found 725.3 (M+H⁺). ¹H NMR (400 MHz, DMSO-*d*₆) δ 9.53 (s, 1H), 7.94 (s, 1H), 7.57 – 7.50 (m, 2H), 7.50 – 7.30 (m, 7H), 7.25 – 7.14 (m, 3H), 6.31 (d, *J* = 7.9 Hz, 1H), 6.24 (d, *J* = 8.4 Hz, 1H), 5.78 (d, *J* = 17.2 Hz, 2H), 4.56 (s, 1H), 3.92 – 3.82 (m, 4H), 3.78 (s, 3H), 3.59 (s, 3H), 3.55 – 3.43 (m, 2H), 3.31 (s, 2H), 1.86 – 1.68 (m, 2H), 1.47 (q, *J* = 8.7, 7.9 Hz, 2H), 1.18 (t, *J* = 7.1 Hz, 5H), 0.91 (s, 9H).

[00191] *Compound 25*. A solution of compound **24** (408 mg, 0.563 mmol) in THF (5 mL) was treated slowly with LiAlH₄ (0.563 mL, 1.126 mmol) and the reaction was stirred at 0 °C for 1 h, at which point LCMS showed completion of the reaction. The reaction was quenched with MeOH and stirred with Rochelle salt solution overnight. Extraction with EtOAc and purification with a COMBIFLASH™ apparatus, 0-50% MeOH in DCM gradient afforded compound **25**.
LCMS ESI: calculated for C₃₈H₄₈N₆O₅Si: 697.9 (M+H⁺), found 679.4 (M+H⁺).

[00192] *Compound 26*. A solution of compound **25** (150 mg, 0.215 mmol) in THF (0.5 mL) was treated slowly with thionyl chloride (0.031 mL, 0.430 mmol) and stirred for 1 h. LCMS showed completion of the reaction. The solvent was evaporated and the crude product **26** was taken to next step. LCMS ESI: calculated for C₃₈H₄₇ClN₆O₄Si= 715.3 (M+H⁺), found 715.4 (M+H⁺).

[00193] *Compound 844*. Compound **26** (15 mg) was dissolved in DMF (0.5 mL) and treated with 1,2,3,4-tetrahydro-2,6-naphthyridine **27** (5.78 mg, 0.043 mmol) and heated at 70 °C for 2 h after which LCMS showed completion of the reaction. A solution of the intermediate product (0.018 g, 0.022 mmol) was dissolved in dioxane (0.5 mL) and treated with triethylamine trihydrofluoride (0.018 mL, 0.110 mmol). After stirring at RT overnight, LCMS showed removal of the TBDPS protecting group. Neutralization to pH 7, evaporation of solvent and purification on a reverse phase ISCO using TEAA as modifier afforded the deprotected intermediate product.

[00194] The deprotected intermediate product from above was dissolved in dioxane (0.5 mL), treated with sodium hydroxide (0.220 mL, 0.220 mmol) and heated at 80 °C for 2 h. LCMS showed completion of the reaction. The reaction mixture was neutralized to pH 7 with aqueous HCl and the solvent was evaporated. The residue was dissolved in DMF and syringe-filtered and purified by preparative LC/MS using following conditions: Column: XBridge C18, 200 mm x 19 mm, 5-μm particles; Mobile Phase A: 5:95 acetonitrile: water with 10-mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile: water with 10 mM ammonium acetate; Gradient: a 0-minute hold at 15% B, 15-55% B over 20 minutes, then a 4-minute hold at 100% B; Flow Rate: 20 mL/min; Column Temperature: 25 °C. Fraction collection was triggered by MS signals. Fractions containing the desired product were combined and dried via centrifugal evaporation to yield compound **844** (4.7 mg, 40% yield).

[00195] *Compound 817*. Compound **25** was treated with trimethylamine trihydrofluoride and then sodium hydroxide, generally following the above procedure, to afford compound **817**.

[00196] **FIG. 3B** shows a variation of the scheme of **FIG. 3A**, in which the steps subsequent to the preparation of compound **26** are varied. The scheme of **FIG. 3B** is illustrated by particular reference to compound **861**.

[00197] *Compound 26b.* Compound **26** (22 mg, 0.031 mmol) was dissolved in DMF (0.6 mL) at RT and was treated with DIEA (27 μ L, 0.15 mmol) and 3-methoxyazetidine (**26a**) as its hydrochloride (11 mg, 0.093 mmol). After stirring for 2 h at 70 °C, the reaction mixture was concentrated *in vacuo* to give compound **26b**, which was used without further purification. LC/MS conditions B: LC RT: 0.88 min. LCMS (M+H) = 766.9.

[00198] *Compound 861.* A solution of compound **26a** (24 mg, 0.031 mmol) in dioxane (0.3 mL) at RT was treated with NaOH (10M aq. Solution, 0.1 mL, 1.0 mmol) and the reaction was heated at 70 °C for 60 min, before the addition of another portion of NaOH (10M aq. solution, 0.1 mL, 1.0 mmol). After 2 h, the reaction mixture concentrated *in vacuo*. The residue was treated with MeOH (0.3 mL) and HCl (37% aq. solution, 0.3 mL, 3.7 mmol), stirred at RT for 30 min and concentrated. The crude product was dissolved in DMF, filtered through a PTFE frit, and purified via preparative HPLC conditions A-1. Fraction collection was triggered by MS signals. Fractions containing the desired product were combined and dried via centrifugal evaporation to give compound **861** as its TFA salt (8.4 mg, 46%). LC/MS conditions C: LC RT: 0.82 min. LCMS (M+H) = 470.3.

[00199] Other compounds of this disclosure can be analogously prepared, *mutatis mutandis*, for example by using amines other than those shown in **FIGs. 3A-3B**.

Procedure 4 – Compounds per FIGs. 4A-4B

[00200] This procedure and companion **FIGs. 4A-4B** illustrate another method of making compounds disclosed herein.

[00201] *Compound 30.* A suspension of compound **4** (400 mg, 1.513 mmol) in dioxane (5 mL) was treated with sodium hydroxide (10 N in water, 1.513 mL, 15.13 mmol) and stirred at 60 °C for 45 min. The reaction mixture was concentrated. The crude product was dissolved into water and purified by reverse phase chromatography on a COMBIFLASH™ unit using a 150 g C-18 column eluting with 10 mM TEAA in acetonitrile:10mM in water, 0-70% gradient. The desired fractions were frozen and lyophilized to yield compound **30** (150 mg, 0.727 mmol, 48.1 % yield). LCMS ESI: calculated for $C_9H_{15}N_6$ = 207.1 (M+H⁺), found 207.2 (M+H⁺). ¹H NMR

(400 MHz, DMSO- d_6) δ 7.56 (br s, 1H), 5.53 (br s, 2H), 3.43 (br d, $J=6.2$ Hz, 2H), 1.57 (t, $J=7.2$ Hz, 2H), 1.44 - 1.29 (m, 2H), 0.95 - 0.76 (m, 3H).

[00202] *Compound 33.* A suspension of 6-fluoronicotinaldehyde **31** (1.809 g, 14.46 mmol), methyl 4-hydroxybenzoate **32** (2 g, 13.15 mmol), and K_2CO_3 (1.998 g, 14.46 mmol) in DMF (26.3 ml) was stirred at 110 °C for 4 h. LCMS indicated the reaction was complete. Upon cooling, the reaction was quenched with water. The resulting solid was collected by filtration and rinsed with water and dried in vacuo to yield compound **33** (3.30 g, 12.84 mmol, 95.1 % yield). LCMS ESI: calculated for $C_{14}H_{11}NO_4 = 258.1$ ($M+H^+$), found 258.0($M+H^+$). ^1H NMR (400 MHz, CHLOROFORM- d) δ 10.01 (s, 1H), 8.63 (d, $J=2.4$ Hz, 1H), 8.23 (dd, $J=8.6, 2.4$ Hz, 1H), 8.17 - 7.97 (m, 2H), 7.27 - 7.22 (m, 2H), 7.10 (d, $J=8.6$ Hz, 1H), 3.93 (s, 3H).

[00203] *Compound 34.* A solution of compound **33** (3.76 g, 14.62 mmol) in MeOH (100 ml) was treated with $NaBH_4$ (0.553 g, 14.62 mmol) portionwise at 0 °C and then stirred for 10 min with continued cooling. LCMS indicated the reaction was complete. Reaction was quenched by slowly adding half saturated NH_4Cl . Stirring was continued for 30 min at RT. The reaction mixture was extracted with ethyl acetate. The organic extracts were dried over Na_2SO_4 , filtered, and concentrated. The crude solid was slurried into water and collected by filtration and dried in vacuo to yield compound **34** (3.37 g, 13.00 mmol, 89 % yield). LCMS ESI: calculated for $C_{14}H_{13}NO_4 = 260.1$ ($M+H^+$), found 260.0($M+H^+$). ^1H NMR (400 MHz, CHLOROFORM- d) δ 8.21 (d, $J=2.2$ Hz, 1H), 8.12 - 8.04 (m, 2H), 7.81 (dd, $J=8.4, 2.4$ Hz, 1H), 7.21 - 7.13 (m, 2H), 6.99 (d, $J=8.4$ Hz, 1H), 4.71 (s, 2H), 3.91 (s, 3H).

[00204] *Compound 35.* Compound **34** (7.9 g, 30.5 mmol) in DCM (75 mL) was treated with $MsCl$ (2.61 mL, 33.5 mmol) at 0 °C. After stirring at RT for 16 h, the reaction was done. The reaction was quenched with water. After extraction with DCM (3 x 20 mL), the combined organic extracts were dried over Na_2SO_4 , filtered and concentrated. The crude product was purified on an ISCO silica column (80g), eluting with ethyl acetate:hexanes, 0-70% gradient. The desired fractions were concentrated to yield compound **35** (7.47g, 26.9 mmol, 88 % yield). LCMS ESI: calculated for $C_{14}H_{13}ClNO_3 = 278.1$ ($M+H^+$), found 278.0($M+H^+$). ^1H NMR (400 MHz, CHLOROFORM- d) δ 8.19 (d, $J=2.2$ Hz, 1H), 8.13 - 8.02 (m, 2H), 7.79 (dd, $J=8.5, 2.5$ Hz, 1H), 7.22 - 7.14 (m, 2H), 6.99 (d, $J=8.6$ Hz, 1H), 4.57 (s, 2H), 3.92 (s, 3H).

[00205] *Compounds 36 and 37.* Compound **30** (70 mg, 0.339 mmol) in DMF (1 mL) was treated with cesium carbonate (332 mg, 1.018 mmol), followed by compound **35** (94 mg, 0.339 mmol). After stirring for 5 h at RT, the reaction was complete. After quenching with water and

extraction with ethyl acetate (3x10mL), the combined organic extracts were dried over Na₂SO₄, filtered and concentrated. The crude product was purified on an ISCO silica column (24g), eluted with 20% MeOH in DCM:DCM, 0-60% gradient. The desired fractions were concentrated to yield a mixture of compounds **36** and **37** (120 mg, 0.080 mmol, 79 % yield), in a 1:4 ratio.

5 LCMS ESI: calculated for C₂₃H₂₆N₇O₃ = 448.2 (M+H⁺), found 448.3 (M+H⁺).

[00206] *Compounds 37a and 37b.* A mixture of compounds **36** and **37** (60 mg, 0.114 mmol) in THF (2 mL) was treated with LiAlH₄ (1.0 M in THF, 0.22 mL, 0.22 mmol) slowly at 0 °C under N₂. The reaction mixture was stirred at 0 °C for 1 h, at which point LCMS showed completion of the reaction. Reaction was quenched by adding Na₂SO₄•10 H₂O slowly, followed by MeOH and stirring at RT for 3 h. The solid was filtered off. The filtrate was concentrated. 10 The residue dissolved in DMF and the products were purified via preparative LC/MS with the following conditions: Column: XBridge C18, 200 mm x 19 mm, 5-μm particles; Mobile Phase A: 5:95 acetonitrile: water with 0.1% trifluoroacetic acid; Mobile Phase B: 95:5 acetonitrile: water with 0.1% trifluoroacetic acid; Gradient: a 0-minute hold at 10% B, 10-45% B over 20 15 minutes, then a 4-minute hold at 100% B; Flow Rate: 20mL/min. Fraction collection was triggered by MS and UV signals. Fractions containing desired product were combined and dried via centrifugal evaporation.

[00207] *Compounds 38a and 38b.* A mixture of compound **37a** and compound **37b** (40 mg, 0.095 mmol) in THF (1 mL) was treated with thionyl chloride (0.14 mL, 1.9 mmol). After 20 stirring at RT for 3 h, LCMS showed completion of the reaction. The solvent was evaporated and the excess thionyl chloride was azeotropically removed with DCM. The crude chloride material was directly carried over to next step without further purification. LCMS ESI: calculated for C₂₂H₂₅N₇O = 438.2 (M+H⁺), found 438.1 (M+H⁺).

[00208] A mixture of the preceding chlorides (40 mg, 0.091 mmol) from preceding paragraph 25 was dissolved in DMF (1.0 mL) and treated with 2-aminoethan-1-ol (55.0 μL, 0.91 mmol), followed by stirring at RT for 16 h. LCMS showed completion of the reaction. The mixture was purified via preparative LC/MS with the following conditions: Column: XBridge C18, 200 mm x 19 mm, 5-μm particles; Mobile Phase A: 5:95 acetonitrile: water with 10 mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile: water with 10 mM ammonium acetate; Gradient: a 0-minute hold at 8% B, 8-48% B over 25 minutes, then a 4-min hold at 100% B; Flow Rate: 20 30 mL/min; Column Temperature: 25 °C. Fraction collection was triggered by MS signals. Fractions containing the desired product were combined and dried via centrifugal evaporation.

[00209] Replacing 6-fluoronicotinaldehyde **31** with 4-fluoro-2-methoxybenzaldehyde in the scheme of **FIGs. 4A-4B** and generally following the procedures above, the other compounds of this disclosure can be prepared, for example: **802, 803, 808, 809, and 810**.

Procedure 5 – Compounds per FIG. 5

5 [00210] This procedure and companion **FIG. 5** relate to the synthesis of (*S*)-N-(3-aminohexyl)acetamide **54**, which can be used as an intermediate for the synthesis of compounds disclosed herein.

[00211] *Compound 51*. A solution of (*S*)-3-aminohexan-1-ol **50** (1g, 8.53 mmol) in DCM (10 mL) was treated with Hunig's base (4.47 mL, 25.6 mmol) and Boc-anhydride (2.377 mL, 10.24 mmol) and stirred for 3 h, after which LCMS showed completion of the reaction. The solvent and base were stripped off *in vacuo*. The crude product was purified on an ISCO machine with N₂ detector using 80 g silica gel gold column with using 0-100% EtOAc/hexanes to provide fractions with the desired product, which were combined and concentrated to provide compound **51** (1.05 g, 56.6 % yield). LCMS ESI: calculated for C₁₁H₂₃NO₃ = 218.3 (M+H⁺), found 218.2
10
15 ¹H NMR (400 MHz, Chloroform-*d*) δ 3.76 (s, 1H), 3.63 (dd, *J* = 7.6, 3.0 Hz, 2H), 1.90 – 1.77 (m, 1H), 1.46 – 1.44 (m, 10H), 1.44 – 1.17 (m, 4H), 1.00 – 0.81 (m, 5H).

[00212] *Compound 52*. To a solution of compound **51** (1050 mg, 4.83 mmol), triphenylphosphine (1648 mg, 6.28 mmol) and isoindoline-1,3-dione (924 mg, 6.28 mmol) in THF (10 mL) was slowly added DIAD (1.221 mL, 6.28 mmol). After stirring overnight at RT, LCMS showed completion of the reaction. Stripping off the solvent in a rotary evaporator and purification on an ISCO machine using 80 g silical gold column eluting with 0-50% EtOAc/hexanes provided fractions with the dsired product, which were concentrated to provide compound **52** (1.6 g, 96 % yield) as a pale yellow solid. LCMS ESI: calculated for C₁₉H₂₆NO₄ = 347.4 (M+H⁺), found 247.2 (M-Boc+H⁺). δ 7.83 (dd, *J* = 5.4, 3.1 Hz, 2H), 7.70 (dd, *J* = 5.5, 3.0 Hz, 2H), 4.40 (s, 1H), 3.75 (dd, *J* = 8.4, 7.0 Hz, 2H), 3.64 (s, 1H), 1.69 (dq, *J* = 15.8, 7.9 Hz, 1H), 1.52 – 1.44 (m, 2H), 1.42 (s, 9H), 1.39 – 1.28 (m, 3H), 0.91 (t, *J* = 7.1 Hz, 3H).
20
25

[00213] *Compound 53*. Compound **52** (1.6g, 4.62 mmol) was treatd with methylamine in MeOH (15.59 g, 92 mmol). The reaction mixture was stirred for 1 h, after which LCMS showed phthalimide deprotection. The solvent and base were evaporated and the residue was dissoled in THF (5 mL) and treated with Hunig'sbase (1.613 mL, 9.24 mmol), followed by acetyl chloride (0.394 mL, 5.54 mmol). The reaction mixture was stirred for 1 h at RT and the solvent was
30

evaporated. The crude product was purified on reverse phase ISCO using 80 g C-18 column eluting with 0-95% acetonitrile in water (0.05% formic acid) to provide fractions with the desired product, which were lyophilized to provide compound **53** as pale yellow paste (0.8g). LCMS ESI: calculated for $C_{13}H_{26}N_2O_3 = 259.3$ ($M+H^+$), found 159.1 ($M-Boc+H^+$). δ 6.65 (s, 2H), 4.30 (d, $J = 9.4$ Hz, 2H), 3.75 – 3.67 (m, 2H), 3.60 (s, 2H), 2.84 (t, $J = 12.7$ Hz, 2H), 2.00 (s, 3H), 1.75 (dddd, $J = 14.1, 10.7, 5.3, 3.6$ Hz, 1H), 1.44 – 1.24 (m, 9H), 0.91 (t, $J = 6.8$ Hz, 3H).

[00214] *Compound 54.* Compound **53** (0.8g, 3.10 mmol) was treated with TFA (4.7 mL, 61.9 mmol). LCMS after 30 min shows completion of reaction. TFA was evaporated. The residue was dried in a lyophilizer overnight to give compound **54** (322 mg, 65.7% yield) as pale yellow paste. LCMS ESI: calculated for $C_8H_{18}N_2O = 159.2$ ($M+H^+$), found 159.1 ($M+H^+$). δ 8.08 (s, 2H), 6.71 (s, 1H), 3.49 (s, 1H), 3.38 – 3.32 (m, 2H), 3.30 (s, 1H), 3.18 (d, $J = 9.7$ Hz, 1H), 2.04 (s, 3H), 1.96 – 1.83 (m, 2H), 1.67 (ddq, $J = 36.7, 14.4, 7.5, 7.0$ Hz, 1H), 1.40 (dq, $J = 15.6, 7.7$ Hz, 1H), 0.94 (t, $J = 7.3$ Hz, 3H).

[00215] Compound **54** can be used to make compounds such as **846** and **847**, generally following the Procedure 3 and **FIGs. 3A-3B**, using compound **16**.

Procedure 6 – Compounds per FIGs. 6a-6B

[00216] This procedure and companion **FIGs. 6A-6B** illustrate another method of making compounds disclosed herein, using compound **857** as an exemplar.

[00217] *Compound 55.* To a suspension of compound **30** (1.50 g, 7.27 mmol) in DMF (25 mL) was added NBS (1.29 g, 7.27 mmol) in three portions (color changed from red to light yellow). After 10 min stirring at RT, LCMS indicated that the reaction was complete. The mixture was poured onto a small portion of ice and stirred for 16 h. The resulting solid was collected by filtration and dried in high vacuum to yield compound **55** (1.96 g, 6.9 mmol, 95 % yield).

[00218] *Compound 57.* A suspension of 4-fluoro-2-methoxybenzaldehyde **56** (1.5 g, 9.73 mmol), methyl 4-hydroxybenzoate **32** (1.777 g, 11.68 mmol) and K_2CO_3 (2.69 g, 19.46 mmol) in DMF (19.46 mL) was stirred at 105 °C for three days, LCMS indicated that reaction was complete. It was quenched with water. The resulting precipitate of a creamy colored solid was collected by filtration and dried *in vacuo* to yield compound **57** (2.6 g, 9.08 mmol, 93 % yield). LCMS ESI: calculated for $C_{16}H_{15}O_5 = 287.1$ ($M+H^+$), found 287.1 ($M+H^+-18$).

[00219] *Compound 58.* To a stirred suspension of compound **57** (2.6 g, 9.08 mmol) in MeOH (25 mL) was added NaBH₄ (0.344 g, 9.08 mmol) in portions. The reaction mixture turned clear. After 1 h, the reaction was complete. The reaction mixture was concentrated to half-volume. Water was added, followed by stirring for 30 min. The resulting solid was collected by filtration and air dried to yield compound **58** (2.50g, 8.67 mmol, 95 % yield) as a white solid, which was pure enough for use in the next step. LCMS ESI: calculated for C₁₆H₁₇O₅ = 289.1 (M+H⁺), found 271.1 (M+H⁺-18).

[00220] *Compound 59.* Compound **58** (730 mg, 2.53 mmol) in THF (10 mL) was treated, with stirring, with SOCl₂ (0.924 mL, 12.66 mmol). Stirring was continued at RT for 16 h. Concentration on a rotary evaporator yielded compound **59**. The extra SOCl₂ was removed azeotropically with DCM (3X). The resulting solid was pure enough to carry over to next step without further purification. ¹H NMR (400 MHz, DMSO-d₆) δ 8.07 - 7.83 (m, 2H), 7.46 (d, J=8.1 Hz, 1H), 7.16 - 7.01 (m, 2H), 6.87 (d, J=2.2 Hz, 1H), 6.66 (dd, J=8.3, 2.3 Hz, 1H), 4.73 (s, 2H), 3.84 (d, J=5.3 Hz, 6H).

[00221] *Compound 60.* To a stirred mixture of compound **55** (300 mg, 1.052 mmol) in DMF (1 mL) was added compound **59** (323 mg, 1.052 mmol). After stirring at RT for 3 h, no starting material **59** was detected. The reaction mixture was quenched with brine, extracted with DCM (3x20 mL). The combined organic extracts were dried with Na₂SO₄ and filtered. The filtrate was concentrated. The crude mixture was purified by ISCO silica column (40g), eluting with EtOAc/hexanes =0-100%. The desired fractions were concentrated to yield compound **60** (166 mg, 0.299 mmol, 28.4 % yield). LCMS ESI: calculated for C₂₂H₂₈BrN₆O₄ = 555.1, 557.1(M+H⁺), found 555.2, 557.2 (M+H⁺). ¹H NMR (400 MHz, DMSO-d₆) δ 7.96 (d, J=8.8 Hz, 2H), 7.55 - 7.55 (m, 1H), 7.12 - 6.98 (m, 2H), 6.87 (d, J=2.2 Hz, 1H), 6.76 (t, J=5.4 Hz, 1H), 6.71 (d, J=8.1 Hz, 1H), 6.62 (dd, J=8.3, 2.3 Hz, 1H), 5.97 (s, 2H), 5.62 (s, 2H), 3.83 (s, 3H), 3.79 (s, 3H), 3.50 - 3.39 (m, 2H), 1.59 - 1.46 (m, 2H), 1.31 - 1.21 (m, 2H), 0.87 (t, J=7.4 Hz, 3H).

[00222] *Compound 61.* To a stirred mixture of compound **60** (160 mg, 0.288 mmol) in THF (10 mL) was added LiAlH₄ (2.5M in THF) (10.93 mg, 0.288 mmol) under nitrogen at RT. After 10 mins, LCMS indicated that reaction was complete. The reaction mixture was quenched with Rochelle salt solution carefully, and stirred at RT for 18 h. The organic layer was separated and the aqueous layer was further extracted with ethyl acetate (2x50 mL). The combined organic extracts were dried over Na₂SO₄ and filtered. The filtrate was concentrated to yield compound **61** (140 mg, 0.265 mmol, 92.2 % yield). LCMS ESI: calculated for C₂₄H₂₈BrN₆O₃ = 527.1,

529.1(M+H⁺), found 527.2, 529.2 (M+H⁺). ¹H NMR (400 MHz, DMSO-d₆) δ 7.32 (d, J=8.6 Hz, 2H), 6.96 (d, J=8.6 Hz, 2H), 6.77 - 6.65 (m, 3H), 6.43 (dd, J=8.3, 2.3 Hz, 1H), 5.95 (s, 2H), 5.57 (s, 2H), 5.15 (t, J=5.6 Hz, 1H), 4.47 (d, J=5.7 Hz, 2H), 3.76 (s, 3H), 3.45 (br d, J=5.7 Hz, 2H), 1.53 (t, J=7.2 Hz, 2H), 1.31 - 1.20 (m, 2H), 0.88 (t, J=7.4 Hz, 3H).

5 [00223] *Compound 62*. A suspension of compound **61** (165 mg, 0.313 mmol) in MeOH (10 mL) and ethyl acetate (3 mL) was purged with N₂. Pd-C 5% (40 mg, 0.019 mmol) was added, purged with H₂, and stirred under H₂ balloon for 18 h. The catalyst was then removed by filtration through a CELITE® pad. The filtrate was concentrated to yield compound **62** (157 mg, 0.350 mmol, 112 % yield). LCMS ESI: calculated for C₂₄H₂₉N₆O₃ = 449.2 (M+H⁺), found
10 449.3 (M+H⁺). ¹H NMR (400 MHz, DMSO-d₆) δ 8.13 (br d, J=4.0 Hz, 1H), 7.75 (s, 1H), 7.61 (br s, 2H), 7.33 (d, J=8.6 Hz, 2H), 6.97 (d, J=8.6 Hz, 2H), 6.83 (d, J=8.6 Hz, 1H), 6.74 (d, J=2.2 Hz, 1H), 6.42 (dd, J=8.3, 2.3 Hz, 1H), 5.68 (s, 2H), 5.26 - 5.03 (m, 1H), 4.48 (d, J=5.3 Hz, 2H), 3.73 (s, 3H), 3.58 (br d, J=6.2 Hz, 2H), 1.59 (br t, J=7.3 Hz, 2H), 1.35 - 1.18 (m, 2H), 0.90 (t, J=7.4 Hz, 3H).

15 [00224] *Compound 857*. A suspension of compound **62** (100 mg, 0.223 mmol) in THF (4 mL) was treated with SOCl₂ (0.081 mL, 1.115 mmol), followed by stirring at RT for 1 h. The reaction mixture was then concentrated on a rotary evaporator. The excess SOCl₂ was azeotropically removed with DCM (3x), the resulting solid was pure enough for use in the next step. LCMS ESI: calculated for C₂₄H₂₈ClN₆O₂ = 467.2 (M+H⁺), found 467.2 (M+H⁺). The
20 resulting solid (20 mg, 0.043 mmol) was dissolved in DMF (0.5 mL). 1-Amino-2-methylpropan-2-ol (19.09 mg, 0.214 mmol) was added to the reaction mixture and the solution was stirred at RT for 16 hrs. The reaction mixture was syringe-filtered and the crude material was purified via preparative LC/MS with the following conditions: Column: XBridge C18, 200 mm x 19 mm, 5-μm particles; Mobile Phase A: 5:95 acetonitrile: water with 0.1% trifluoroacetic acid; Mobile
25 Phase B: 95:5 acetonitrile: water with 0.1% trifluoroacetic acid; Gradient: a 0-minute hold at 19% B, 19-59% B over 20 minutes, then a 0-minute hold at 100% B; Flow Rate: 20mL/min; Column Temperature: 25 C. Fraction collection was triggered by MS and UV signals. Fractions containing the desired product were combined and dried via centrifugal evaporation to yield compound **857** as a TFA salt (6.9 mg, 10.63 μmol, 24.81 % yield).

30 [00225] This Procedure 6 and prior Procedure 4 can be used to make similar compounds. We have observed that alkylation of 3-bromo compound **55** yields a higher proportion of the 1*H* regioisomer (2*H* regioisomer not shown in **FIG. 6A**) than the alkylation of counterpart

compound **36** in Procedure 4. Thus, where the *1H* regioisomer is the more desired one, this Procedure 6 may be the preferable one, even though it entails the extra bromination and de-bromination steps. Table B below lists some compounds that were made by either Procedure 4 or 6. Also, 3-bromo compound **55** can be an intermediate in other synthetic pathways, as shown in
5 Procedures hereinbelow.

Procedure 7 – Compounds per FIG. 7

[00226] This Procedure and companion **FIG. 7** illustrate another method for making compounds disclosed herein, using compound **864** as an exemplar.

[00227] *Compound 64.* A solution of compound **16** (48.5 mg, 0.125 mmol) in THF (1.8 mL) was cooled to 0 °C and treated with LiAlH₄ (1M in THF, 219 µL, 0.219 mmol). After 10 min, an additional portion of LiAlH₄ (1M in THF, 200 µL, 0.200 mmol) was added and the reaction was stirred for another 20 min at 0 °C. The reaction mixture was quenched with MeOH and Rochelle's salt (sat. aq. solution) and stirred at RT for 30 min. The mixture was extracted with EtOAc (3x). The combined organic layers were washed with H₂O, dried over Na₂SO₄, filtered
15 and concentrated *in vacuo* to give compound **64** (38 mg, 84%). ¹H NMR (400 MHz, DMSO-d₆) δ 11.60 - 11.12 (m, 2H), 7.85 - 7.83 (m, 1H), 6.97 (s, 1H), 6.77 (d, *J*=8.0 Hz, 1H), 6.59 (d, *J*=7.7 Hz, 1H), 5.66 (s, 2H), 5.15 (t, *J*=5.7 Hz, 1H), 4.44 (d, *J*=5.6 Hz, 2H), 3.79 (s, 3H), 3.74 (s, 3H). LC/MS conditions B: LC RT: 0.61 min. LCMS (M+H)=360.1.

[00228] *Compound 65.* A solution of compound **64** (402 mg, 1.12 mmol) in DCM (15 mL) was treated with thionyl chloride (1.6 mL, 22 mmol). After 15 min, the reaction mixture concentrated *in vacuo*. The residue was redissolved in DCM and concentrated *in vacuo* again to yield compound **65** (422 mg, 100%). ¹H NMR (400 MHz, DMSO-d₆) δ 11.25 - 11.02 (m, 1H), 7.89 - 7.88 (m, 1H), 7.11 (d, *J*=1.5 Hz, 1H), 6.92 (dd, *J*=7.8, 1.5 Hz, 1H), 6.62 (d, *J*=7.7 Hz, 1H), 5.69 (s, 2H), 4.72 (s, 2H), 3.82 (s, 3H), 3.75 (s, 3H). One proton was not visible, likely due to
25 overlap with water peak or proton exchange. LC/MS conditions B: LC RT: 0.80 min. LCMS (M+H)=378.0.

[00229] *Compound 66.* A solution of cyclobutanamine **5a** (0.84 mL, 9.9 mmol) in THF (11 mL) was treated a solution of compound **65** (249 mg, 0.659 mmol) in THF (8 mL). The reaction mixture was stirred for 16 h at 60 °C and then concentrated *in vacuo*. The residue was dissolved
30 in DCM/MeOH, absorbed onto CELITE® and purified via column chromatography (50g C18 gold column; Mobile Phase A: 10:90 methanol:water with 0.1 % trifluoroacetic acid; Mobile

Phase B: 90:10 methanol:water with 0.1 % trifluoroacetic acid; Flow Rate: 40 mL/min) to give compound **66** as its TFA salt (168 mg, 48% yield). ¹H NMR (400 MHz, DMSO-d₆) δ 11.55 (br s, 1H), 11.18 - 11.12 (m, 1H), 9.04 - 8.93 (m, 2H), 7.91 - 7.89 (m, 1H), 7.19 (d, *J*=1.4 Hz, 1H), 6.95 (dd, *J*=7.7, 1.3 Hz, 1H), 6.68 (d, *J*=7.7 Hz, 1H), 5.71 (s, 2H), 4.02 - 3.97 (m, 2H), 3.85 (s, 3H), 3.76 (s, 3H), 3.72 - 3.63 (m, 1H), 2.20 - 2.10 (m, 4H), 1.85 - 1.72 (m, 2H). LC/MS conditions B: LC RT: 0.63 min. LCMS (M+H) =413.3.

[00230] *Compound 864.* A solution of compound **66** (15 mg, 0.036 mmol) in DMF (1 mL) was treated with BOP (161 mg, 0.364 mmol), 2-ethoxyethan-1-amine **6a** (32.4 mg, 0.364 mmol) and DBU (73 μL, 0.49 mmol) and stirred at RT for 18 h. The reaction mixture was concentrated under a stream of nitrogen. A solution of the crude product **67** in dioxane (0.5 mL) was treated with NaOH (10 M aq soln, 0.05 mL, 0.5 mmol) and heated to 75 °C. After 1 h, the reaction mixture was neutralized with HOAc (0.03 mL, 0.5 mmol) and concentrated under a stream of nitrogen. The residue was dissolved in DMF, filtered through a PTFE frit, and the crude material was purified via preparative LC/MS with the following conditions: Column: XBridge C18, 200 mm x 19 mm, 5-μm particles; Mobile Phase A: 5:95 acetonitrile: water with 10 mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile: water with 10 mM ammonium acetate; Gradient: a 0-minute hold at 3% B, 3-43% B over 25 minutes, then a 0-minute hold at 100% B; Flow Rate: 20 mL/min; Column Temperature: 25 °C. Fraction collection was triggered by MS signals. Fractions containing the desired product were combined and dried via centrifugal evaporation to give compound **864** (7.3 mg, 48 % yield). LC/MS conditions C. LC RT: 0.8 min. LCMS (M+H) =426.17.

[00231] Additional compounds according to this disclosure can be made following this Procedure, *mutatis mutandis*.

Procedure 8 – Compounds per FIG. 8

[00232] This Procedure and companion **FIG. 8** illustrate another method for making compounds disclosed herein, using compound **866** as an exemplar.

[00233] *Compound 70.* A solution of compound **68** (307 mg, 0.922 mmol) in acetonitrile (0.9 mL) was treated with compound **69** (321 mg, 1.01 mmol) and stirred at RT for 72 h. The reaction mixture was then heated to 60 °C for 4 h, re-cooled to RT and filtered. The collected solid was rinsed with acetonitrile and dried *in vacuo*. The filtrate was concentrated *in vacuo* and the residue purified by column chromatography (12g SiO₂, 0 to 30% EtOAc-hexane, gradient

elution) to give a white solid, which was combined with the solid isolated by filtration to give compound **70** (392 mg, 74%). LC/MS conditions B: LC RT: 1.21 min. LCMS (M+H) =576.9.

[00234] Compound **71**. A solution of compound **70** (144 mg, 0.251 mmol) in MeOH (1.2 mL) was treated with NaOMe (81 mg, 1.5 mmol) and stirred at RT. After 96 h, the reaction mixture was diluted with H₂O and extracted with EtOAc (3X). The combined organic layers were dried over Na₂SO₄, filtered and concentrated in vacuo to give the compound **71** (108 mg, 100% yield). ¹H NMR (400 MHz, DMSO-d₆) δ 11.62 - 11.59 (m, 1H), 10.85 - 10.82 (m, 1H), 7.91 (s, 1H), 7.51 (d, *J*=1.4 Hz, 1H), 7.47 (dd, *J*=7.9, 1.4 Hz, 1H), 6.69 (d, *J*=7.9 Hz, 1H), 5.75 (s, 2H), 3.89 (s, 3H), 3.84 (s, 3H), 1.50 (s, 9H). LC/MS conditions B: LC RT: 0.89 min. LCMS (M+H) =430.6.

[00235] Compound **72**. A solution of compound **71** (294 mg, 0.685 mmol) in DMSO (3.4 mL) was treated with (*S*)-1-((*tert*-butyldiphenylsilyl)oxy)hexan-3-amine (**71a**) hydrochloride (322 mg, 0.822 mmol), BOP (364 mg, 0.822 mmol) and DBU (516 μL, 3.43 mmol) and stirred at RT. After 3 h, the reaction mixture diluted with EtOAc and washed with H₂O. The organic layer concentrated *in vacuo* and the residue was purified via column chromatography (24g SiO₂; 0 to 25% EtOAc-DCM, gradient elution) to give compound **72** (227.8 mg, 43%). ¹H NMR (400 MHz, DMSO-d₆) δ 9.00 - 8.93 (m, 1H), 7.92 (s, 1H), 7.53 (dd, *J*=8.0, 1.4 Hz, 2H), 7.46 (s, 2H), 7.44 (d, *J*=1.3 Hz, 1H), 7.42 - 7.37 (m, 1H), 7.37 - 7.31 (m, 3H), 7.24 - 7.20 (m, 2H), 7.20 - 7.16 (m, 1H), 6.28 (d, *J*=7.9 Hz, 1H), 6.20 (d, *J*=8.5 Hz, 1H), 5.83 - 5.72 (m, 2H), 4.60 - 4.46 (m, 1H), 3.85 (s, 3H), 3.76 (s, 3H), 3.55 - 3.43 (m, 2H), 1.83 - 1.73 (m, 1H), 1.73 - 1.65 (m, 1H), 1.46 (br d, *J*=13.6 Hz, 2H), 1.41 (s, 9H), 1.15 - 1.04 (m, 2H), 0.91 (s, 9H), 0.74 (t, *J*=7.3 Hz, 3H). LC/MS conditions B: LC RT: 1.07 min. LCMS (M+H) =767.4.

[00236] Compound **73**. A solution of methyl ester **72** (227 mg, 0.297 mmol) in THF (4.2 mL) was cooled to 0 °C and treated with LiAlH₄ (1M in THF, 327 μL, 0.327 mmol). After 10 min, additional LiAlH₄ (1M in THF, 150 μL, 0.150 mmol) added. After 30 min, the reaction was quenched with MeOH and Rochelle's salt (sat aq soln) and stirred at RT for 30 minutes. The mixture was extracted with EtOAc (3X). The combined organic layers were washed with H₂O, and concentrated *in vacuo*. The residue was purified via column chromatography (12g SiO₂; 0 to 100% EtOAc-hexane, gradient elution) to give compound **73** (91.5 mg, 42%). LC/MS conditions B: LC RT: 1.02 min. LCMS (M+H) =739.7.

[00237] Compound **74**. A solution of compound **73** (91.5 mg, 0.124 mmol) in THF (1.2 mL) was treated with thionyl chloride (45 μL, 0.61 mmol) and stirred at RT. After 15 min, the

reaction mixture concentrated in vacuo, the residue was redissolved in DCM and concentrated *in vacuo* to provide compound **74** (94 mg, 100 %). LC/MS conditions B: LC RT: 1.09 min. LCMS (M+H) = 757.3.

[00238] *Compound 75.* A solution of compound **74** (20 mg, 0.027 mmol) in DMF (0.5 mL) was treated with DIEA (70 μ L, 0.40 mmol) and 3-(tert-butyl)cyclobutan-1-amine **74a** (34.1 mg, 0.268 mmol) and heated to 70 °C for 1h. The reaction mixture was cooled to RT and concentrated *in vacuo*. The residue was dissolved in EtOAc and washed with sat. aq NaHCO₃ soln. The organic layer was concentrated *in vacuo* to give afford compound **75** (22 mg, 97%), which was used without further purification. LC/MS conditions B: LC RT: 0.95 min. LCMS (M+H) = 848.6.

[00239] *Compound 866.* A solution of compound **75** (25 mg, 0.029 mmol) in MeOH (0.6 mL) was treated with HCl (37% aq soln, 0.3 mL, 3.7 mmol) and stirred at RT for 6 h. The reaction mixture was neutralized with NaHCO₃ and extracted with DCM (3x). The combined organic layers were concentrated *in vacuo*. The residue was redissolved in DMF and filtered through a PTFE filter. The crude product was purified via preparative HPLC/MS conditions A-1: Fraction collection was triggered by MS signals. Fractions containing the desired product were combined and dried via centrifugal evaporation to give compound **866** (3.3 mg, 22 % yield). LC/MS conditions C: LC RT = 1.23 min. LCMS (M+H) = 510.23.

[00240] Additional compounds according to this disclosure can be made following this Procedure, *mutatis mutandis*.

Procedure 9 – Compounds per FIG. 9

[00241] This Procedure and companion **FIG. 9** illustrate another method for making compounds disclosed herein, using compounds **853** and **870** as exemplars.

[00242] *Compound 76.* A solution of compound **55** (400 mg, 1.40 mmol) and cesium carbonate (914 mg, 2.8 mmol) in DMF/acetonitrile (5 mL/5 mL) was cooled in an ice bath. A solution of methyl 4-(bromomethyl)-3-fluorobenzoate **55a** (277 mg, 1.12 mmol) in acetonitrile (5 mL) was added, and the reaction stirred at 0 °C for 30 min, then at RT for a further hour. The acetonitrile was evaporated from the reaction mixture and purified using reverse-phase flash chromatography (100 g column, 10 to 60% MeCN in water containing 0.05% TFA) to give compound **76** (482 mg, 1.07 mmol, 35 % purity (contaminated with the N2-regioisomer, 27 % yield) as a solid. LC-MS (ES, *m/z*): [M+H]⁺ = 451.1, 453.2.

[00243] *Compound 77.* Compound **76** (470 mg, 1.04 mmol, 35% purity (contaminated with the N2-regioisomer) was dissolved in ethanol (50 mL). 10 % Pd/C (20 mg) was added, and the reaction evacuated and purged with hydrogen six times, then stirred under a hydrogen atmosphere for 90 min. The reaction mixture was filtered through CELITE®, washed with EtOH (100 mL), and evaporated to dryness, giving compound **77** (370 mg, 0.99 mmol, 35 % purity (contaminated with the N2-regioisomer), 95 % yield) as a solid. LC-MS (ES, m/z): $[M+H]^+ = 373.3$.

[00244] *Compound 78.* A stirred suspension of compound **77** (370 mg, 0.99 mmol, 35 % purity contaminated with the N2-regioisomer) in THF (100 mL) was cooled in an ice bath. LiAlH₄ (754 mg, 1.98 mmol) was added portion wise over 5 min, and the reaction was stirred at 0 °C for 20 minutes. NaOH (1N, 50 mL) was added, and the reaction stirred for 10 min at RT, transferred to a separatory funnel and extracted with EtOAc (3 x 40 mL). The combined organic phases were washed with brine (3 x 30 mL), dried (MgSO₄), filtered and concentrated. Flash chromatography (40 g column, 0 to 25 % MeOH in DCM) yielded compound **78** (74 mg, 0.215 mmol, 21.63 % yield) as a solid. LC-MS (ES, m/z): $[M+H]^+ = 345.3$.

[00245] *Compound 853.* A 20 mL scintillation vial was charged with compound **78** (25 mg, 0.073 mmol) and THF (4 mL). 3 drops of thionyl chloride were added, and the reaction mixture was stirred for 1 hour. The reaction mixture was evaporated to dryness and the residue was dissolved in acetonitrile (5 mL) and evaporated twice. The residue was dissolved in DMF (1.5 mL). Cyclobutanamine (20.7 mg, 0.29 mmol) was added, and the reaction mixture stirred at RT overnight. The reaction mixture was filtered and purified via preparative HPLC/MS conditions A-1: Fraction collection was triggered by MS and UV signals. Fractions containing the desired product were combined and dried via centrifugal evaporation to give compound **853** (19.5 mg, 0.03 mmol, 42 % yield).

[00246] *Compound 870.* A 20 mL scintillation vial was charged with compound **78** (50 mg, 0.15 mmol) and THF (4 mL). 3 Drops of thionyl chloride were added, and the reaction mixture stirred for 1 h. The reaction mixture was evaporated to dryness. The residue was dissolved in acetonitrile (5 mL) and evaporated twice. The residue was dissolved in DMF (2 mL). 2-(piperazin-1-yl)ethan-1-ol (38 mg, 0.29 mmol) was added, followed by DIPEA (0.10 mL, 0.58 mmol), and the reaction mixture stirred at 50 °C for 1 h. After cooling, the reaction mixture was filtered and purified via preparative HPLC/MS conditions A-1: Fraction collection was triggered

by MS and UV signals. Fractions containing the desired product were combined and dried via centrifugal evaporation, giving compound **870** (41 mg, 0.06 mmol, 42 % yield).

[00247] Additional compounds according to this disclosure can be made following this Procedure, *mutatis mutandis*.

5 *Procedure 10 – Compounds per FIG. 10*

[00248] This Procedure and companion **FIG. 10** illustrate another method for making compounds disclosed herein, using compound **873** as an exemplar.

[00249] *Compound 80.* A 40 mL scintillation vial was charged with compound **79** (250 mg, 1.55 mmol), NBS (331 mg, 1.86 mmol), AIBN (50.9 mg, 0.31 mmol) and CCl₄ (5 mL). The
10 reaction mixture was stirred at 70 °C for 2 h. After cooling, the reaction mixture was evaporated to dryness. Flash chromatography (24 g column, 0 to 40 % EtOAc in hexanes) gave compound **80** (189 mg, 0.787 mmol, 51 % yield) as a solid. LC-MS (ES, *m/z*): No ion detected. ¹H NMR (400 MHz, CDCl₃) δ 7.33 (d, *J*=7.7 Hz, 1H), 6.88 (d, *J*=7.7 Hz, 1H), 6.84 (s, 1H), 4.53 (s, 2H), 3.92 (s, 3H), 3.74 (s, 2H).

15 [00250] *Compound 81.* To a stirred suspension of methyl (7-(butylamino)-1H-pyrazolo[4,3-d]pyrimidin-5-yl)carbamate (6 g, 22.7 mmol) in DMF (10 mL) and was added a solution of NBS (4.44 g, 25.0 mmol) in acetonitrile (20 mL). The reaction mixture was stirred at RT for 1 h. Water (50 mL) was added. The reaction mixture filtered. The residue was washed with water (3 x 30 mL) and air dried overnight to yield compound **81** (5.112 g, 14.9 mmol, 66 % yield) as a
20 solid. LC-MS (ES, *m/z*): [M+H]⁺ = 343.0, 345.0. ¹H NMR (400 MHz, DMSO-d₆) δ 12.87 (br s, 1H), 9.80 (s, 1H), 7.56 (br s, 1H), 3.62 (s, 3H), 3.54 (q, *J*=6.6 Hz, 2H), 1.62 (quin, *J*=7.2 Hz, 2H), 1.40 (dq, *J*=14.8, 7.4 Hz, 2H), 0.94 (t, *J*=7.4 Hz, 3H).

[00251] *Compound 82.* Compound **81** (1g, 2.91 mmol) was dissolved in DMF (10 mL) and cooled in an ice bath. Cesium carbonate (1.899 g, 5.83 mmol) was added, followed by
25 compound **80** (0.560 g, 2.33 mmol). The reaction mixture was stirred at RT for 5 h and then poured into saturated NaHCO₃ solution (50 mL) and extracted with EtOAc (3 x 40 mL). The combined organic phases were washed with brine (4 x 40 mL), dried (MgSO₄), filtered and concentrated. Flash chromatography (40 g column, 0 to 85% EtOAc in hexane) gave compound **82** (219 mg, 0.44 mmol, 15 % yield) as a solid. LC-MS (ES, *m/z*): [M+H]⁺ 502.2, 504.2. ¹H
30 NMR (400 MHz, CDCl₃) δ 7.25 - 7.19 (m, 1H), 6.98 (s, 1H), 6.97 - 6.91 (m, 1H), 5.70 (s, 2H),

5.28 (s, 1H), 3.98 (s, 3H), 3.84 (s, 3H), 3.78 - 3.60 (m, 4H), 1.72 - 1.41 (m, 2H), 1.41 - 1.20 (m, 2H), 0.94 (t, $J=7.3$ Hz, 3H).

[00252] *Compound 83*. Compound **82** (219 mg, 0.44 mmol) was dissolved in EtOH (10 mL) and 10 % Pd/C (20 mg) was added. The reaction vessel was evacuated and purged with H₂ six times, then stirred under an H₂ atmosphere for 2 h. The reaction mixture was filtered and evaporated to dryness, giving compound **83** (188 mg, 0.44 mmol, 100 % yield) as a solid. LC-MS (ES, m/z): $[M+H]^+$ 424.4. ¹H NMR (400 MHz, DMSO-*d*₆) δ 11.71 (br s, 1H), 8.67 (br s, 1H), 8.04 (s, 1H), 7.05 (s, 1H), 6.89 (s, 2H), 5.77 (s, 2H), 4.01 (s, 2H), 3.83 (s, 3H), 3.76 (s, 3H), 3.69 - 3.58 (m, 2H), 1.72 - 1.48 (m, 2H), 1.41 - 1.17 (m, 2H), 0.90 (t, $J=7.4$ Hz, 3H).

[00253] *Compound 873*. Compound **83** (25 mg, 0.059 mmol) was dissolved in dioxane (2 mL); sodium hydroxide (0.354 mL, 1.77 mmol) was added. The reaction mixture was stirred at 80 °C for 3 h. After cooling, the reaction was neutralized with 5N HCl, then evaporated to dryness. The residue was dissolved in DMF (2 mL), filtered and purified via preparative HPLC/MS conditions A-2: Fraction collection was triggered by MS signals. Fractions containing the desired product were combined and dried via centrifugal evaporation to give compound **873** (6.2 mg, 0.013 mmol, 22%).

[00254] Additional compounds according to this disclosure can be made following this Procedure, *mutatis mutandis*.

Procedure 11 – Compounds per FIG. 11

[00255] This Procedure and companion **FIG. 11** illustrate another method for making compounds disclosed herein, using compound **855** as an exemplar.

[00256] *Compound 85*. To a solution of methyl 5-methoxy-6-methylnicotinate **84** (300 mg, 1656 μ mol) and NBS (413 mg, 2318 μ mol) in CCl₄ (3 mL), AIBN (54.4 mg, 331 μ mol) was added. The reaction mixture was stirred at 80 °C for 30 min. LCMS analysis showed the reaction was complete. The reaction mixture was cooled down and diluted with DCM (2 mL). The resulting solution was purified on a 40 g RediSepRf Gold Silica column. Mobile phase A: hexanes; Mobile phase B: Ethyl acetate; Gradient: 1 min at 0% B, 15 min at 0-50% B; Flow rate: 40 mL/min; Column Temperature: 25 °C. Fraction collection was triggered by UV signals at 254 nm. The fractions containing expected product were combined, concentrated and dried under high vacuum to give compound **85** (215 mg, 50%). LC/MS conditions E: LC RT: 1.57 min. $[M+H]^+/Z=260.0$

[00257] *Compound 86*. To a solution of compound **30** (427 mg, 2070 μ mol) in DMF (2 mL), Cs_2CO (701 mg, 2152 μ mol) was added. The reaction mixture was stirred at RT for 10 min. A solution of compound **85** (215 mg, 0.827 mmol) in acetonitrile (2 mL) was added to the reaction mixture slowly. The reaction mixture was stirred at RT for 30 min. LCMS analysis showed 3 peaks corresponding product m/z. The reaction mixture was neutralized with acetic acid (0.3 mL), diluted with water and purified by preparative HPLC/MS conditions A-3: Fraction collection was triggered by UV signals. The fractions corresponding to the three peaks were freeze-dried separately. The NMR analysis confirmed that compound corresponding to the latest peak was the desired compound **86** (76 mg, 11.9%). LC/MS conditions E: LC-RT: 1.89 min. $[\text{M}+\text{H}]^+/\text{Z}=386.2$. ^1H NMR (500 MHz, $\text{DMSO}-d_6$) δ 8.57 (t, $J=5.7$ Hz, 1H), 8.50 (d, $J=1.6$ Hz, 1H), 7.88 (d, $J=1.6$ Hz, 1H), 7.83 (s, 1H), 7.76 (s, 1H), 5.95 (s, 2H), 4.00 (s, 3H), 3.89 (s, 3H), 3.55 (q, $J=6.8$ Hz, 2H), 1.59 – 1.48 (m, 2H), 1.30 – 1.14 (m, 2H), 0.86 (t, $J=7.4$ Hz, 3H).

[00258] *Compound 87*. To a solution of compound **86** (38 mg, 0.099 mmol) in THF (1 mL), LiAlH_4 in THF (0.079 mL, 0.197 mmol) was added. The reaction mixture was stirred at RT for 10 min. LCMS analysis showed the reaction was complete. The reaction mixture was neutralized with acetic acid (0.2 mL), diluted with water (3 mL) and purified on HPLC/MS conditions A-3: Fraction collection was triggered by UV signals. The fractions containing expected product were combined and freeze-dried to give compound **87** (28 mg, 79%). LC/MS conditions E: LC-RT: 1.26 min. $[\text{M}+\text{H}]^+/\text{Z}=357.2$.

[00259] *Compound 855*. To a solution of compound **87** (28 mg, 0.078 mmol) in DCM (1 mL), SOCl_2 (0.144 mL, 1.972 mmol) was added. The reaction mixture was stirred at RT overnight. The reaction mixture was concentrated and co-evaporated with DCM (3x20 mL) to form crude N7-butyl-1-((5-(chloromethyl)-3-methoxypyridin-2-yl)methyl)-1H-pyrazolo[4,3-d]pyrimidine-5,7-diamine (41 mg), which was used for next step immediately without purification.

[00260] To a solution of the preceding compound (41 mg, 0.109 mmol, crude) in DMF (1 mL), cyclobutanamine (388 mg, 5.45 mmol) was added. The reaction mixture was stirred at RT for 3 h. LCMS analysis showed the reaction was complete. The reaction mixture was freeze-dried with acetonitrile and water. The crude material was purified via preparative HPLC with the following conditions: Column: XBridge C18, 200 mm x 19 mm, 5- μ m particles; Mobile Phase A: 5:95 acetonitrile: water with 10-mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile: water with 10-mM ammonium acetate; Gradient: a 0-minute hold at 8% B, 8-48% B over 20

minutes, then a 0-minute hold at 100% B; Flow rate: 20 mL/min; Column Temperature: 25 °C. Fraction collection was triggered by MS and UV signals. Fractions containing the desired product were combined and dried via centrifugal evaporation to give 6.6 mg (14.8%) of compound **855** (6.6 mg, 14.8%). LC/MS conditions: Column: Waters Acquity BEH C18, 2.1 mm x 50 mm, 1.7 µm particles; Mobile Phase A: 5:95 acetonitrile: water with 10 mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile: water with 10 mM ammonium acetate; Temperature: 50 °C; Gradient: 0 %B to 100 %B over 3 min, then a 0.50 min hold at 100 %B; Flow rate: 1mL/min; Detection: MS and UV (220 nm). LC RT = 1.36 min. (M+H) = 411.1

[00261] Additional compounds according to this disclosure can be made following this Procedure, *mutatis mutandis*.

Procedure 12 – Compounds per FIG. 12

[00262] This Procedure and companion **FIG. 12** illustrate another method for making compounds disclosed herein, using compound **867** as an exemplar.

[00263] *Compound 90.* To a solution of compound **89** (300 mg, 0.722 mmol) dissolved in DCM (3 mL) at -78 °C was added ethyl magnesium bromide (0.633 mL, 2.165 mmol). 2-methyltetrahydrofuran was added slowly to the reaction mixture and stirred at -78 °C for 1 hr and then 0 °C for 1 h. The reaction mixture was quenched with saturated ammonium chloride solution (1 mL) and brought to RT, then diluted with DCM (10 mL), washed with water (5 mL), then followed by brine solution (5 mL). The organic layer was dried over sodium sulphate, filtered, concentrated, purified on silicagel with ethyl acetate/hexane. The product containing fractions were concentrated to afford compound **90** as thick oil (204 mg, 63.4% yield). ¹H NMR (400 MHz, Chloroform-*d*) δ 7.58 (m, 4H), 7.42 – 7.26 (m, 6H), 3.75 – 3.57 (m, 2H), 3.31 (d, *J* = 7.8 Hz, 1H), 2.93 (d, *J* = 7.5 Hz, 1H), 1.75 (m, 1H), 1.68 – 1.47 (m, 3H), 1.06 (s, 9H), 0.98 (s, 9H), 0.87 (t, *J* = 7.4 Hz, 3H). LCMS: *M/Z* = 446.2.

[00264] *Compound 91.* Hydrochloric acid (194 µL, 0.774 mmol, 4 M in dioxane) was added to a solution of compound **90** (203 mg, 0.455 mmol) in diethyl ether (4554 µL) and MeOH (55.3 µL, 1.366 mmol). The mixture was stirred at RT for 1 h. The solution was concentrated to a thick oil. 20 mL of hexane was then added to the oil and the flask was kept in the freezer at -20 °C for 1 h. The white solid was collected and washed with cold hexanes, then dried under vacuum to give compound **91** (116 mg, 0.307 mmol, 67.4 % yield) as a white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ 7.85 (s, 3H), 7.63 (ddd, *J* = 7.7, 3.0, 1.7 Hz, 4H), 7.56 – 7.40 (m, 6H), 3.92 – 3.65

(m, 2H), 3.18 (p, $J = 6.3$ Hz, 1H), 1.86 (dq, $J = 13.0, 6.5$ Hz, 1H), 1.76 (dq, $J = 13.4, 6.4$ Hz, 1H), 1.64 – 1.47 (m, 2H), 1.01 (s, 9H), 0.89 (t, $J = 7.5$ Hz, 3H). LCMS: $M/Z = 342.2$.

[00265] *Compound 867.* A solution of compound **88** (30 mg, 0.068 mmol) in DMSO (0.75 mL) was treated with compound **91** (51.3 mg, 0.136 mmol), DBU (51.1 μ L, 0.339 mmol) followed by BOP (60.0 mg, 0.136 mmol) and heated at 70 °C for 2 h to give compound **92**, which was not isolated. 10M aq. solution of sodium hydroxide (250 μ L, 2.500 mmol) was added to the reaction mixture of compound **92** and stirred at 75 °C for overnight. The reaction mixture concentrated *in vacuo* and the residue was treated with MeOH (0.3 mL) and HCl (37% aq. solution, 0.3 mL, 3.7 mmol), stirred at RT for 30 min and concentrated. The crude product was dissolved in DMF, filtered through a PTFE frit, and purified via preparative HPLC conditions A-1. Fraction collection was triggered by MS signals. Fractions containing the desired product were combined and dried via centrifugal evaporation to yield compound **867** as white solid (13 mg, 40% yield).

[00266] Additional compounds according to this disclosure can be made following this Procedure, *mutatis mutandis*.

Procedure 13 – Compounds per FIG. 13

[00267] This Procedure and companion **FIG. 13** illustrate another method for making compounds disclosed herein, using compound **851** as an exemplar.

[00268] Methyl 6-(hydroxymethyl)nicotinate **94** was coupled with compound **55** and then taken to compound **851**, following the reaction conditions described hereinabove for the various steps, *mutatis mutandis*.

[00269] Additional compounds according to this disclosure can be made following this Procedure, *mutatis mutandis*.


Procedure 14 – Compounds per FIG. 14

[00270] This Procedure and companion **FIG. 14** illustrate another method for making compounds disclosed herein, using compound **877** as an exemplar.

[00271] *Compound 102.* A solution of methyl 4-nitro-1H-pyrazole-5-carboxylate **100** (1.00 g, 5.61 mmol) and K_2CO_3 (0.93 g, 6.73 mmol) in DMF (5.9 mL) was cooled to 0 °C and methyl 4-(bromomethyl)benzoate **101** (1.29 g, 5.61 mmol) was added in portions. The reaction mixture was allowed to warm to RT and stirred for 4 h. The reaction mixture was concentrated *in vacuo*.

The residue was dissolved EtOAc and washed with sat. NaHCO_3 and H_2O (2x). The organic layer was concentrated in vacuo. The residue was dissolved in DCM and purified via column chromatography (80g SiO_2 , 0 to 50% EtOAc-hexane gradient) to give compound **102** (0.37 g, 21%). ^1H NMR (400 MHz, CHCl_3 -d) δ 8.10 - 8.08 (m, 1H), 8.06 - 8.01 (m, 2H), 7.32 (d, $J=8.6$ Hz, 2H), 5.55 (s, 2H), 3.93 (s, 3H), 3.92 - 3.92 (m, 3H). LC/MS condition B. LC RT: 0.95 min. LCMS (M+H) = 320.1.

[00272] In the preceding reaction, some of the N2 regioisomer was produced, which was removed during the SiO_2 chromatography:



[00273] **Compound 103.** Ammonium formate (292 mg, 4.64 mmol) and zinc (189 mg, 2.9 mmol) were added to a solution of compound **102** (370 mg, 1.16 mmol), in THF (1.5 ml)/MeOH (1.5 ml) at RT. The reaction was stirred at RT for 3 h and additional portions of ammonium formate (100 mg, 1.59 mmol) and zinc (100 mg, 2.04 mmol) were added. After 30 min, the reaction mixture filtered through a pad of CELITETM, and the filtrate was concentrated *in vacuo* to afford a white solid. The solid was suspended in EtOAc, stirred for 30 minutes and filtered. The organic filtrate was then concentrated in vacuo to give compound **103** (335 mg, 100 %). ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 7.93 - 7.86 (m, 2H), 7.19 - 7.15 (m, 3H), 5.59 (s, 2H), 5.13 (s, 2H), 3.83 (s, 3H), 3.73 (s, 3H). LC/MS condition B: LC RT: 0.78 min. LCMS (M+H) = 290.1.

[00274] **Compound 104.** 1,3-bis(Methoxycarbonyl)-2-methyl-thiopseudourea **1** (271 mg, 1.27 mmol) and acetic acid (0.994 mL, 17.37 mmol) were added to a solution of compound **103** (335 mg, 1.16 mmol) in MeOH (14 mL) at RT. The reaction mixture was stirred at RT for 3 h and an additional portion of HOAc (0.5 mL, 8.7 mmol) was added. After 16 h at RT another portion of HOAc (0.3 mL, 5.2 mmol) was added. After 72 h, sodium methoxide solution (7.94 mL, 34.7 mmol, 25% in MeOH) was added to the reaction mixture. After stirring for 2 h, the reaction mixture was acidified with HOAc (3 mL) and the resulting slurry was filtered. The resulting solid was washed with H_2O and MeOH, and dried overnight to afford compound **104** (383 mg, 93%). ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 11.52 - 11.22 (m, 1H), 7.94 - 7.88 (m, 3H), 7.33 (d,

$J=8.3$ Hz, 2H), 5.79 (s, 2H), 3.83 (s, 3H), 3.74 (s, 3H). One proton not visible, likely due to proton exchange. LC/MS condition B: LC RT: 0.80 min. LCMS (M+H) =358.2.

[00275] *Compound 105.* (S)-1-((tert-Butyldiphenylsilyl)oxy)hexan-3-amine (**71a**)

hydrochloride (840 mg, 2.14 mmol), BOP (711 mg, 1.61 mmol) and DBU (808 μ L, 5.36 mmol)

5 were added sequentially to a RT solution of compound **104** (383 mg, 1.07 mmol) in DMF (5.4 mL). The reaction mixture was stirred for 16 h. At the end of the reaction, the mixture was diluted with EtOAc and washed with H₂O (2X). The organic layer was concentrated *in vacuo*. The residue was dissolved in DCM and purified via column chromatography (40g SiO₂, 0 to 80% EtOAc-hexane gradient) to give provide compound **105** (424 mg, 57 %). ¹H NMR (400
10 MHz, DMSO-*d*₆) δ 9.53 - 9.49 (m, 1H), 7.97 (s, 1H), 7.66 (d, $J=8.4$ Hz, 2H), 7.64 - 7.59 (m, 1H), 7.54 - 7.50 (m, 2H), 7.47 - 7.44 (m, 1H), 7.42 - 7.39 (m, 2H), 7.36 - 7.31 (m, 2H), 7.31 (br t, $J=1.4$ Hz, 1H), 7.19 - 7.12 (m, 2H), 6.94 (d, $J=8.4$ Hz, 2H), 6.32 (d, $J=8.6$ Hz, 1H), 6.03 - 5.84 (m, 2H), 4.56 (td, $J=8.4, 4.4$ Hz, 1H), 3.72 (s, 3H), 3.56 (s, 3H), 3.49 - 3.38 (m, 1H), 1.84 - 1.68 (m, 2H), 1.55 - 1.39 (m, 2H), 1.36 - 1.21 (m, 1H), 1.18 - 1.07 (m, 1H), 0.91 - 0.86 (m, 9H), 0.74
15 (t, $J=7.3$ Hz, 3H). LC/MS condition B: LC RT: 1.08 min. LCMS (M+H) =695.6.

[00276] *Compound 106.* A solution of compound **105** (424 mg, 0.610 mmol) in THF (8.7 mL) was cooled to -15 °C and LiAlH₄ (1M in THF, 1.1 mL, 1.1 mmol) was added. After 15 min an additional portion of LiAlH₄ (1M in THF, 0.3 mL, 0.3 mmol) was added. After 10 min the reaction was quenched with MeOH and Rochelle's salt (sat. soln) and was stirred at RT for 30
20 min. The mixture was extracted with EtOAc (3x). The combined organic layers were washed with H₂O, and concentrated *in vacuo*. The residue was dissolved in DCM/MeOH, absorbed onto CELITE™ and purified via column chromatography (24g SiO₂; 0 to 100% EtOAc-hexane gradient elution) to afford compound **106** (181 mg, 44%). ¹H NMR (400 MHz, DMSO-*d*₆) δ 9.47 (s, 1H), 7.91 (s, 1H), 7.62 (ddt, $J=5.7, 3.6, 1.8$ Hz, 1H), 7.56 (dd, $J=7.9, 1.5$ Hz, 2H), 7.48 - 7.43
25 (m, 3H), 7.39 - 7.32 (m, 3H), 7.24 - 7.20 (m, 2H), 7.08 (d, $J=8.1$ Hz, 2H), 6.91 (d, $J=8.1$ Hz, 2H), 6.29 (d, $J=8.6$ Hz, 1H), 5.78 (d, $J=1.9$ Hz, 2H), 5.06 (t, $J=5.6$ Hz, 1H), 4.63 - 4.54 (m, 1H), 4.32 (d, $J=5.4$ Hz, 2H), 3.57 (s, 3H), 3.55 - 3.49 (m, 1H), 1.85 - 1.76 (m, 2H), 1.55 - 1.40 (m, 2H), 1.20 - 1.02 (m, 2H), 0.91 (s, 9H), 0.78 (t, $J=7.3$ Hz, 3H). LC/MS condition B: LC RT: 0.95 min. LCMS (M+H) =667.6.

30 **[00277]** *Compound 107.* Thionyl chloride (99 μ L, 1.4 mmol) was added to a RT solution of methyl compound **106** (181 mg, 0.224 mmol) in THF (2.7 mL). After stirring for 10 min, the reaction mixture was concentrated *in vacuo*. The residue was redissolved in DCM and

concentrated in vacuo to give compound **107** (172.2 mg, 93%). LC/MS condition B: LC RT: 1.11 min. LCMS (M+H) = 685.6.

[00278] *Compound 108.* Compound **107** (23 mg, 0.034 mmol) was dissolved in DMF (0.7 mL) at RT and was treated with DIEA (88 μ L, 0.50 mmol) and 3-methoxyazetidine (**26a**), as its
5 hydrochloride (21 mg, 0.17 mmol). After stirring for 2 h at 70 °C, the reaction mixture was concentrated in vacuo to give crude compound **108**, which was used without further purification. LC/MS condition B: LC RT: 0.89 min. LCMS (M+H) = 736.7.


[00279] *Compound 877.* A solution of compound **108** (25 mg, 0.034 mmol) in dioxane (0.7 mL) at RT was treated with NaOH (10M aq. soln, 0.1 mL, 1.0 mmol). The reaction was heated to
10 75 °C for 2 h, before the addition of another portion of NaOH (10M aq. soln, 0.15 mL, 1.5 mmol). After 4 h heating at 80 °C, the reaction mixture was concentrated in vacuo. The residue was treated with MeOH (0.5 mL), HCl (37% aq. soln, 0.4 mL, 4.9 mmol) was added, stirred at RT for 60 min, and concentrated. The crude product was dissolved in DMF, filtered through a PTFE frit, and purified via preparative LC/MS Condition A-2. Fraction collection was triggered
15 by MS signals. Fractions containing the desired product were combined and dried via centrifugal evaporation to give a residue which was further purified via preparative LC/MS Conditions A-1. Fraction collection was triggered by MS signals. Fractions containing the desired product were combined and dried via centrifugal evaporation to give compound **877**, as its TFA salt (5.7 mg, 38%). LC/MS condition C: LC RT: 1.0 min. LCMS (M+H) = 440.2.

[00280] *Compound 874.* A solution of compound **106** (20 mg, 0.030 mmol) in dioxane (0.15 mL) at RT was treated with NaOH (10M aq. soln, 0.2 mL, 2.0 mmol) and the reaction was heated to 75 °C for 1 h, before the addition of another portion of NaOH (10M aq. soln, 0.2 mL, 2.0 mmol). After 3 h heating at 75 °C, the reaction mixture was concentrated in vacuo. The residue was treated with MeOH (0.5 mL) and HCl (37% aq. soln, 0.4 mL, 4.9 mmol), stirred at
25 RT for 30 min and concentrated. The crude product was dissolved in DMF, filtered through a PTFE frit, and purified via preparative LC/MS conditions A-2. Fraction collection was triggered by MS signals. Fractions containing the desired product were combined and dried via centrifugal evaporation to give compound **874**. LC/MS conditions C: LC RT: 1.07 min. LCMS (M+H) = 371.2.

[00281] Additional compounds according to this disclosure can be made following this Procedure, *mutatis mutandis*.

Procedure 15 – Compound 829

[00282] This procedure relates to the preparation of compounds **829** and its regioisomer. These compounds were prepared by reacting compounds **36** and **37** with MeMgCl Grignard reagent.



5

[00283] To a mixture of compounds **36** and **37** (60 mg, 0.134 mmol) in THF (1 mL) was added MeMgCl (0.171 mL, 0.513 mmol) at 0 °C. After 1 hr, LCMS showed reaction was completed. The mixture was purified via preparative HPLC/MS with the following conditions: Column: XBridge C18, 200 mm x 19 mm, 5- μ m particles; Mobile Phase A: 5:95 acetonitrile: water with 0.1% TFA; Mobile Phase B: 95:5 acetonitrile: water with 0.1% TFA; Gradient: a 0-minute hold at 10% B, 10-45% B over 20 minutes, then a 4-minute hold at 100% B; Flow Rate: 20mL/min; Column Temperature: 25 °C. Fraction collection was triggered by MS signals. Fractions containing the desired product were combined and dried via centrifugal evaporation.

10

PROPERTIES

[00284] Analytical data for compounds of this disclosure are provided in following Table B, along with their human TLR7 (hTLR7) agonism data. In some instances, the reported activity agonism value is the average of plural assays. The association of a particular compound with a particular Procedure is illustrative, and not exhaustive. A compound could be made by one of the other Procedures and, conversely, the same Procedure could be used to make other compounds of this disclosure. The RT (retention time) column refers to the retention time per LCMS procedure B/C/D/E above, as applicable.

15

20

Table B					
Cpd. No.	Procedure	hTLR7 EC ₅₀ (nM)	LC/MS [M+H] ⁺	RT (min)	¹ H NMR (500 MHz, DMSO-d ₆)
800	1	58.3	409.5	1.05	δ 7.55 (s, 1H), 7.04 (s, 1H), 6.78 (d, <i>J</i> = 7.7 Hz, 1H), 6.43 (dd, <i>J</i> = 21.5, 6.9 Hz, 2H), 5.61 (d, <i>J</i> = 11.9 Hz, 4H), 3.84 (s, 3H), 3.61 (s, 1H), 3.43 – 3.37 (m, 1H), 3.18 (t, <i>J</i> = 7.8 Hz, 1H), 2.55 (s, 1H), 2.09 – 2.02 (m, 2H), 1.91 (s, 1H), 1.77 – 1.69 (m, 2H), 1.67 – 1.59 (m, 1H), 1.58 – 1.43 (m, 3H), 1.20 (p, <i>J</i> = 7.4 Hz, 2H), 0.85 (t, <i>J</i> = 7.4 Hz, 3H)
801	2	160	439.5	0.87	δ 8.22 (s, 1H), 7.73 (s, 1H), 7.18 (s, 1H), 7.01 (d, <i>J</i> = 8.0 Hz, 1H), 6.91 (d, <i>J</i> = 7.6 Hz, 1H), 5.71 (s, 2H), 4.13 (s, 2H), 3.92 (d, <i>J</i> = 9.8 Hz, 2H), 3.77 (s, 1H), 3.64 (s, 1H), 3.57 (d, <i>J</i> = 6.6 Hz, 1H), 3.30 (t, <i>J</i> = 11.6 Hz, 3H), 2.89 (s, 1H), 2.73 (s, 1H), 1.99 (d, <i>J</i> = 12.3 Hz, 2H), 1.63 – 1.52 (m, 4H), 1.28 (h, <i>J</i> = 7.4 Hz, 2H), 0.88 (t, <i>J</i> = 7.3 Hz, 3H)
802	4, 6	43.8	492.2	1.21	δ 7.55 (s, 1H), 7.36 (d, <i>J</i> = 8.5 Hz, 2H), 6.95 (d, <i>J</i> = 8.5 Hz, 2H), 6.76 (d, <i>J</i> = 2.1 Hz, 1H), 6.52 (d, <i>J</i> = 8.5 Hz, 1H), 6.49 – 6.43 (m, 1H), 6.40 (dd, <i>J</i> = 8.4, 2.3 Hz, 1H), 5.64 (s, 2H), 5.60 (s, 2H), 3.80 (s, 3H), 3.78 (s, 2H), 2.65 (t, <i>J</i> = 5.6 Hz, 2H), 1.56 – 1.42 (m, 2H), 1.29 – 1.16 (m, 2H), 0.87 (t, <i>J</i> = 7.5 Hz, 3H).
803	4, 6	569	449.1	1.58	δ 7.74 (s, 1H), 7.33 (br d, <i>J</i> = 8.2 Hz, 2H), 6.97 (d, <i>J</i> = 8.2 Hz, 2H), 6.82 (d, <i>J</i> = 8.2 Hz, 1H), 6.74 (d, <i>J</i> = 2.1 Hz, 1H), 6.47 – 6.41 (m, 1H), 5.68 (s, 2H), 4.48 (br s, 2H), 3.73 (s, 3H), 3.64 – 3.53 (m, 2H), 1.59 (dt, <i>J</i> = 14.6, 7.3 Hz, 2H), 1.27 (dt, <i>J</i> = 14.9, 7.4 Hz, 2H), 0.90 (t, <i>J</i> = 7.3 Hz, 3H)
804	2	43.4	406.4	0.91	δ 8.90 (s, 1H), 8.26 (s, 1H), 7.95 (s, 1H), 7.86 (s, 1H), 7.74 (s, 1H), 7.64 (s, 1H), 7.50 (s, 1H), 7.15 (s, 1H), 6.88 (d, <i>J</i> = 7.8 Hz, 1H), 6.82 (d, <i>J</i> = 7.9 Hz, 1H), 5.71 (s, 2H), 5.33 (s, 2H), 3.77 (s, 3H), 2.90 (s, 1H), 2.73 (d, <i>J</i> = 9.5 Hz, 1H), 1.56 (p, <i>J</i> = 7.3 Hz, 2H), 1.23 (q, <i>J</i> = 7.3 Hz, 2H), 0.85 (t, <i>J</i> = 7.4 Hz, 3H)
805	2	41.4	427.5	0.94	δ 8.18 (s, 1H), 7.95 (s, 1H), 7.75 (s, 1H), 7.26 (s, 1H), 7.02 (d, <i>J</i> = 7.9 Hz, 1H), 6.82 (d, <i>J</i> = 7.6 Hz, 1H), 5.73 (s, 2H), 4.13 (s, 2H), 3.79 (s, 3H), 3.56 (d, <i>J</i> = 7.0 Hz, 1H), 2.90 (s, 1H), 2.72 (d, <i>J</i> = 17.1 Hz, 3H), 1.58 (p, <i>J</i> = 7.5 Hz, 2H), 1.28 (dd, <i>J</i> = 14.9, 7.5 Hz, 2H), 1.16 (s, 5H), 0.89 (t, <i>J</i> = 7.4 Hz, 3H)

Table B					
Cpd. No.	Proce- dure	hTLR7 EC ₅₀ (nM)	LC/MS [M+H] ⁺	RT (min)	¹ H NMR (500 MHz, DMSO-d ₆)
806	2	41.4	453.5	0.82	δ 8.28 (s, 1H), 7.82 (s, 1H), 7.76 (d, <i>J</i> = 12.9 Hz, 1H), 7.21 (s, 1H), 7.01 (d, <i>J</i> = 7.8 Hz, 1H), 6.90 (d, <i>J</i> = 7.7 Hz, 1H), 5.74 (s, 2H), 4.13 (s, 1H), 3.78 (s, 3H), 3.58 (q, <i>J</i> = 6.7 Hz, 1H), 3.42 (s, 0H), 2.96 (s, 1H), 2.72 (s, 1H), 2.08 (d, <i>J</i> = 12.0 Hz, 2H), 1.89 (d, <i>J</i> = 12.8 Hz, 2H), 1.59 (h, <i>J</i> = 7.6 Hz, 2H), 1.45 – 1.23 (m, 4H), 1.16 (q, <i>J</i> = 11.1 Hz, 2H), 0.91 (t, <i>J</i> = 7.3 Hz, 3H)
807	2	2548	439.5	0.97	δ 7.55 (s, 1H), 7.03 (s, 1H), 6.76 (d, <i>J</i> = 7.8 Hz, 1H), 6.45 (d, <i>J</i> = 7.8 Hz, 1H), 6.39 (s, 1H), 5.61 (d, <i>J</i> = 13.7 Hz, 3H), 3.89 (d, <i>J</i> = 19.6 Hz, 3H), 3.84 (s, 2H), 3.40 (d, <i>J</i> = 6.7 Hz, 1H), 3.18 (s, 1H), 2.44 (s, 1H), 2.23 (d, <i>J</i> = 8.6 Hz, 2H), 1.86 (s, 1H), 1.75 (s, 1H), 1.48 (t, <i>J</i> = 7.4 Hz, 2H), 1.41 (d, <i>J</i> = 9.6 Hz, 2H), 1.20 (q, <i>J</i> = 7.5 Hz, 2H), 0.85 (t, <i>J</i> = 7.3 Hz, 3H)
808	4, 6	157	506.2	1.22	δ 7.74 (br s, 1H), 7.51 (br d, <i>J</i> = 8.5 Hz, 2H), 7.05 (br d, <i>J</i> = 8.5 Hz, 2H), 6.84 - 6.78 (m, 2H), 6.47 (dd, <i>J</i> = 7.8, 2.0 Hz, 1H), 5.70 (s, 2H), 4.14 (br s, 2H), 3.75 (s, 3H), 3.61 - 3.57 (m, 2H), 3.12 - 3.06 (m, 2H), 1.62 - 1.56 (m, 2H), 1.32 - 1.26 (m, 2H), 0.90 (br t, <i>J</i> = 7.3 Hz, 3H).
809	4, 6	74.5	531.2	1.43	δ 7.76 (s, 1H), 7.37 - 7.31 (m, 2H), 7.02 - 6.94 (m, 2H), 6.85 (d, <i>J</i> = 7.9 Hz, 1H), 6.77 (s, 1H), 6.46 - 6.41 (m, 1H), 5.72 - 5.69 (m, 2H), 3.73 (s, 3H), 3.62 - 3.58 (m, 2H), 1.64 - 1.57 (m, 2H), 1.32 - 1.26 (m, 2H), 0.90 (t, <i>J</i> = 7.3 Hz, 3H).
810	4, 6	245	561.4	1.0	δ 7.74 (s, 1H), 7.38 - 7.23 (m, 2H), 6.98 (br d, <i>J</i> = 8.7 Hz, 2H), 6.82 (d, <i>J</i> = 8.5 Hz, 1H), 6.75 (s, 1H), 6.42 (br d, <i>J</i> = 7.0 Hz, 1H), 5.68 (s, 2H), 3.50 (s, 3H), 3.17 (s, 2H), 3.08 (br dd, <i>J</i> = 6.3, 2.2 Hz, 2H), 2.97 - 2.88 (m, 6H), 2.65 (br s, 2H), 1.63 - 1.52 (m, 2H), 1.28 - 1.24 (m, 2H), 0.93 - 0.81 (m, 3H).
811	2	138	425.2	0.8	δ 7.54 (s, 1H), 7.00 (s, 1H), 6.77 – 6.72 (m, 1H), 6.49 – 6.40 (m, 2H), 5.59 (d, <i>J</i> = 9.5 Hz, 3H), 4.23 (t, <i>J</i> = 6.1 Hz, 1H), 3.82 (s, 3H), 3.38 (q, <i>J</i> = 6.5 Hz, 2H), 3.18 (d, <i>J</i> = 13.2 Hz, 2H), 1.95 (t, <i>J</i> = 5.8 Hz, 2H), 1.89 (dd, <i>J</i> = 7.5, 4.9 Hz, 2H), 1.84 (s, 8H), 1.50 – 1.43 (m, 2H), 1.18 (q, <i>J</i> = 7.4 Hz, 2H), 0.84 (t, <i>J</i> = 7.3 Hz, 3H)

Table B					
Cpd. No.	Proce- dure	hTLR7 EC ₅₀ (nM)	LC/MS [M+H] ⁺	RT (min)	¹ H NMR (500 MHz, DMSO-d ₆)
812	2	102	450.5	0.77	δ 8.32 (s, 1H), 7.95 (s, 1H), 7.77 (s, 1H), 7.15 (s, 1H), 6.96 (d, <i>J</i> = 7.7 Hz, 1H), 6.86 (d, <i>J</i> = 7.6 Hz, 1H), 5.74 (s, 2H), 4.22 (s, 1H), 3.78 (s, 2H), 2.90 (s, 3H), 2.55 (s, 1H), 1.58 (p, <i>J</i> = 7.3 Hz, 2H), 1.40 (s, 1H), 1.26 (q, <i>J</i> = 7.5 Hz, 2H), 0.88 (t, <i>J</i> = 7.3 Hz, 3H)
813	2	23.8	424.5	0.78	δ 8.28 (s, 1H), 7.96 (s, 1H), 7.90 (s, 0H), 7.76 (s, 1H), 7.27 (s, 0H), 7.17 (s, 0H), 7.06 (d, <i>J</i> = 13.9 Hz, 1H), 6.89 (d, <i>J</i> = 7.8 Hz, 1H), 6.81 (d, <i>J</i> = 7.6 Hz, 1H), 5.72 (s, 2H), 3.77 (s, 2H), 3.73 (s, 1H), 3.58 (d, <i>J</i> = 6.9 Hz, 1H), 3.17 (d, <i>J</i> = 6.4 Hz, 2H), 2.90 (s, 3H), 2.55 (s, 1H), 1.58 (p, <i>J</i> = 7.1 Hz, 2H), 1.26 (q, <i>J</i> = 7.5 Hz, 2H), 0.88 (t, <i>J</i> = 7.3 Hz, 3H)
814	2	97.6	411.5	0.83	δ 8.28 (s, 1H), 7.84 (s, 1H), 7.76 (d, <i>J</i> = 9.0 Hz, 1H), 7.19 (s, 1H), 6.98 (d, <i>J</i> = 7.7 Hz, 1H), 6.87 (d, <i>J</i> = 7.6 Hz, 1H), 5.74 (s, 2H), 4.66 (t, <i>J</i> = 7.4 Hz, 2H), 4.56 (t, <i>J</i> = 6.6 Hz, 2H), 4.36 (q, <i>J</i> = 6.5 Hz, 1H), 4.23 (d, <i>J</i> = 14.0 Hz, 1H), 4.07 (s, 1H), 3.79 (s, 3H), 3.58 (d, <i>J</i> = 6.9 Hz, 2H), 2.51 (s, 8H), 1.60 (q, <i>J</i> = 7.4 Hz, 2H), 1.28 (dt, <i>J</i> = 15.3, 7.6 Hz, 2H), 0.90 (t, <i>J</i> = 7.3 Hz, 3H)
815	2	33.2	439.5	1.1	δ 8.29 (d, <i>J</i> = 5.7 Hz, 1H), 7.96 (s, 1H), 7.89 (s, 1H), 7.77 (d, <i>J</i> = 5.7 Hz, 1H), 7.15 (s, 1H), 6.97 (d, <i>J</i> = 8.0 Hz, 1H), 6.85 (d, <i>J</i> = 7.7 Hz, 1H), 5.75 (d, <i>J</i> = 10.6 Hz, 2H), 4.35 (s, 1H), 4.29 (s, 1H), 4.25 (s, 1H), 4.07 (s, 1H), 4.00 (s, 1H), 3.79 (d, <i>J</i> = 5.5 Hz, 3H), 3.57 (q, <i>J</i> = 6.7 Hz, 1H), 3.43 (s, 1H), 2.90 (s, 2H), 2.73 (d, <i>J</i> = 9.7 Hz, 3H), 2.55 (s, 1H), 1.73 (s, 1H), 1.58 (p, <i>J</i> = 7.4 Hz, 2H), 1.27 (q, <i>J</i> = 7.4 Hz, 2H), 0.88 (td, <i>J</i> = 7.3, 4.3 Hz, 3H)
816	2	92.5	399.4	1.0	δ 8.19 (s, 1H), 7.95 (s, 1H), 7.74 (s, 1H), 7.22 (s, 1H), 7.00 (d, <i>J</i> = 7.8 Hz, 1H), 6.86 (d, <i>J</i> = 7.7 Hz, 1H), 5.73 (s, 2H), 4.14 (s, 2H), 3.90 (s, 1H), 3.78 (s, 3H), 3.66 (s, 1H), 3.57 (s, 1H), 3.46 (s, 1H), 3.18 (s, 1H), 2.95 (t, <i>J</i> = 5.5 Hz, 2H), 2.90 (s, 1H), 2.74 (s, 1H), 2.55 (s, 1H), 1.58 (p, <i>J</i> = 7.3 Hz, 2H), 1.28 (h, <i>J</i> = 7.4 Hz, 2H), 0.89 (t, <i>J</i> = 7.3 Hz, 3H)

Table B					
Cpd. No.	Proce- dure	hTLR7 EC ₅₀ (nM)	LC/MS [M+H] ⁺	RT (min)	¹ H NMR (500 MHz, DMSO-d ₆)
817	3	27.8	400.4	1.17	δ 7.73 (s, 1H), 7.64 (s, 1H), 7.33 (d, <i>J</i> = 8.5 Hz, 1H), 6.98 (s, 1H), 6.80 (d, <i>J</i> = 7.9 Hz, 1H), 6.64 (d, <i>J</i> = 7.6 Hz, 1H), 5.72 (d, <i>J</i> = 16.4 Hz, 1H), 5.64 (d, <i>J</i> = 16.3 Hz, 1H), 4.49 (d, <i>J</i> = 6.4 Hz, 1H), 4.44 (s, 2H), 3.87 (s, 1H), 3.75 (s, 3H), 3.46 (d, <i>J</i> = 11.3 Hz, 1H), 3.38 (d, <i>J</i> = 6.7 Hz, 1H), 3.14 (s, 1H), 2.52 (s, 2H), 1.68 (dq, <i>J</i> = 12.5, 6.6, 6.2 Hz, 2H), 1.47 (t, <i>J</i> = 5.8 Hz, 2H), 1.09 (q, <i>J</i> = 9.0, 8.2 Hz, 2H), 0.78 (t, <i>J</i> = 7.3 Hz, 3H)
818	2	258	356.4	1.2	8.13 (s, 1H), 7.73 (s, 2H), 6.99 (s, 1H), 6.86 – 6.76 (m, 2H), 5.69 (s, 2H), 4.47 (s, 2H), 3.76 (s, 3H), 3.57 (d, <i>J</i> = 6.7 Hz, 1H), 1.57 (p, <i>J</i> = 7.2 Hz, 2H), 1.27 (dt, <i>J</i> = 15.0, 7.5 Hz, 2H), 1.17 (t, <i>J</i> = 7.2 Hz, 1H), 0.89 (t, <i>J</i> = 7.4 Hz, 3H)
819	2	44.4	436.5	0.97	δ 8.27 (t, <i>J</i> = 5.7 Hz, 1H), 7.94 (s, 1H), 7.76 (d, <i>J</i> = 0.9 Hz, 1H), 7.30 (s, 1H), 7.19 (s, 0H), 7.09 (s, 1H), 6.93 (d, <i>J</i> = 7.8 Hz, 1H), 6.82 (d, <i>J</i> = 7.7 Hz, 1H), 5.71 (s, 2H), 4.30 (s, 1H), 4.01 (s, 1H), 3.94 (s, 1H), 3.76 (s, 3H), 3.57 (s, 1H), 3.19 (d, <i>J</i> = 15.2 Hz, 1H), 3.02 (s, 1H), 2.89 (s, 1H), 2.73 (s, 1H), 2.55 (s, 3H), 2.22 (s, 1H), 1.84 (d, <i>J</i> = 11.5 Hz, 1H), 1.57 (p, <i>J</i> = 7.2 Hz, 2H), 1.25 (h, <i>J</i> = 7.5 Hz, 2H), 0.87 (t, <i>J</i> = 7.3 Hz, 3H)
820	2	121	453.5	1.09	δ 7.72 (s, 1H), 7.21 (s, 1H), 7.01 (d, <i>J</i> = 7.8 Hz, 1H), 6.91 (d, <i>J</i> = 7.7 Hz, 1H), 5.71 (s, 2H), 4.07 (s, 2H), 3.78 (s, 3H), 3.54 (s, 1H), 2.89 (s, 1H), 2.73 (s, 1H), 2.55 (s, 4H), 1.82 – 1.71 (m, 5H), 1.59 (dd, <i>J</i> = 15.5, 7.8 Hz, 4H), 1.30 (q, <i>J</i> = 7.5 Hz, 2H), 0.90 (t, <i>J</i> = 7.4 Hz, 3H)
821	2	33.8	438.5	1.27	δ 8.30 (s, 1H), 7.94 (s, 1H), 7.77 (q, <i>J</i> = 1.5 Hz, 1H), 7.16 (s, 1H), 6.97 (d, <i>J</i> = 7.7 Hz, 1H), 6.83 (d, <i>J</i> = 7.7 Hz, 1H), 5.73 (s, 2H), 4.14 (s, 1H), 3.78 (d, <i>J</i> = 1.6 Hz, 3H), 3.57 (s, 1H), 3.23 (s, 2H), 2.89 (d, <i>J</i> = 1.5 Hz, 3H), 2.73 (d, <i>J</i> = 1.3 Hz, 3H), 2.55 (s, 2H), 2.03 (s, 2H), 1.57 (p, <i>J</i> = 7.3 Hz, 3H), 1.25 (q, <i>J</i> = 7.4 Hz, 3H), 0.87 (t, <i>J</i> = 7.3 Hz, 3H)

Table B					
Cpd. No.	Procedure	hTLR7 EC ₅₀ (nM)	LC/MS [M+H] ⁺	RT (min)	¹ H NMR (500 MHz, DMSO-d ₆)
822	2	244	475.5	1.27	δ 9.95 (s, 0H), 8.20 (d, <i>J</i> = 6.0 Hz, 1H), 7.73 (s, 1H), 7.49 (s, 1H), 7.29 (s, 1H), 7.18 (s, 1H), 7.03 (s, 1H), 6.89 – 6.83 (m, 2H), 6.46 (d, <i>J</i> = 8.3 Hz, 1H), 5.81 (s, 1H), 5.66 (s, 1H), 4.20 (s, 1H), 3.86 (s, 1H), 3.72 (s, 1H), 3.46 (t, <i>J</i> = 7.3 Hz, 1H), 2.89 (s, 1H), 2.73 (s, 0H), 2.55 (s, 3H), 1.59 – 1.52 (m, 2H), 1.24 (q, <i>J</i> = 7.4 Hz, 2H), 0.86 (t, <i>J</i> = 7.3 Hz, 3H)
823	2	21.5	468.6	1.01	δ 7.56 (s, 1H), 6.96 (s, 1H), 6.74 (d, <i>J</i> = 7.5 Hz, 1H), 6.43 (dd, <i>J</i> = 12.7, 6.8 Hz, 2H), 5.70 (s, 1H), 5.61 (s, 2H), 3.88 – 3.74 (m, 5H), 3.39 (d, <i>J</i> = 10.3 Hz, 2H), 2.59 – 2.53 (m, 9H), 2.40 (t, <i>J</i> = 6.3 Hz, 4H), 1.91 (d, <i>J</i> = 1.2 Hz, 3H), 1.45 (p, <i>J</i> = 7.2 Hz, 2H), 1.16 (h, <i>J</i> = 7.5 Hz, 2H), 0.83 (t, <i>J</i> = 7.4 Hz, 3H)
824	2	304	436.5	1.02	δ 7.55 (s, 1H), 6.90 (d, <i>J</i> = 1.5 Hz, 1H), 6.70 (d, <i>J</i> = 7.5 Hz, 1H), 6.42 (d, <i>J</i> = 7.6 Hz, 1H), 5.61 (d, <i>J</i> = 17.6 Hz, 3H), 3.83 (s, 2H), 3.72 (s, 1H), 3.39 (d, <i>J</i> = 6.1 Hz, 1H), 3.20 (s, 2H), 2.55 (s, 5H), 1.87 (s, 4H), 1.52 – 1.42 (m, 2H), 1.19 (h, <i>J</i> = 7.3 Hz, 2H), 0.85 (t, <i>J</i> = 7.3 Hz, 3H)
825	2	43.5	427.5	1.25	δ 8.24 (s, 1H), 7.94 (s, 1H), 7.81 (s, 1H), 7.76 (s, 1H), 7.21 (s, 1H), 7.00 (d, <i>J</i> = 7.8 Hz, 1H), 6.83 (d, <i>J</i> = 7.7 Hz, 1H), 5.74 (s, 2H), 4.25 (s, 1H), 3.89 (s, 1H), 3.78 (s, 3H), 3.56 (d, <i>J</i> = 6.9 Hz, 1H), 3.43 (s, 1H), 3.17 (s, 1H), 3.08 (s, 1H), 2.89 (s, 1H), 2.73 (s, 1H), 2.66 (s, 3H), 2.54 (s, 3H), 1.83 (s, 1H), 1.57 (q, <i>J</i> = 7.3 Hz, 2H), 1.25 (dt, <i>J</i> = 14.9, 7.5 Hz, 2H), 0.87 (t, <i>J</i> = 7.4 Hz, 3H)
826	2	182	413.5	0.85	δ 8.29 (s, 1H), 7.95 (s, 1H), 7.75 (s, 1H), 7.21 (s, 1H), 7.00 (d, <i>J</i> = 7.6 Hz, 1H), 6.87 (d, <i>J</i> = 7.7 Hz, 1H), 5.73 (s, 2H), 4.13 (s, 2H), 3.78 (s, 2H), 3.58 (t, <i>J</i> = 4.9 Hz, 2H), 3.29 (s, 2H), 3.07 (t, <i>J</i> = 5.1 Hz, 2H), 2.90 (s, 2H), 2.74 (s, 2H), 1.59 (p, <i>J</i> = 7.4 Hz, 2H), 1.28 (h, <i>J</i> = 7.8 Hz, 2H), 0.89 (t, <i>J</i> = 7.4 Hz, 3H)
827	2	47.6	438.5	0.89	δ 7.65 (s, 1H), 6.94 (d, <i>J</i> = 7.9 Hz, 2H), 6.82 (d, <i>J</i> = 7.6 Hz, 1H), 5.74 (s, 1H), 5.35 (s, 2H), 3.87 (d, <i>J</i> = 2.1 Hz, 2H), 3.84 (s, 9H), 3.40 (s, 2H), 2.54 (s, 3H), 2.14 (s, 3H), 1.83 (s, 1H), 1.52 (t, <i>J</i> = 7.6 Hz, 2H), 1.28 (q, <i>J</i> = 7.5 Hz, 2H), 0.85 (t, <i>J</i> = 7.4 Hz, 3H)

Table B					
Cpd. No.	Proce- dure	hTLR7 EC ₅₀ (nM)	LC/MS [M+H] ⁺	RT (min)	¹ H NMR (500 MHz, DMSO-d ₆)
828	2	98.7	411.5	0.92	δ 8.17 (s, 0H), 7.72 (d, <i>J</i> = 2.4 Hz, 1H), 7.63 (s, 0H), 7.24 (d, <i>J</i> = 4.4 Hz, 1H), 7.03 (d, <i>J</i> = 7.7 Hz, 1H), 6.92 (d, <i>J</i> = 7.7 Hz, 1H), 5.73 (s, 2H), 4.09 (s, 2H), 3.78 s, 3H), 3.61 – 3.54 (m, 1H), 3.48 (s, 2H), 2.93 (s, 1H), 2.55 (s, 1H), 1.62 (q, <i>J</i> = 7.4 Hz, 2H), 1.38 – 1.27 (m, 11H), 1.21 – 1.14 (m, 1H), 0.92 (t, <i>J</i> = 7.4 Hz, 3H)
829	15	1336	448.2		δ 8.15 (s, 1H), 7.82 (s, 1H), 7.74 (br d, <i>J</i> = 7.9 Hz, 1H), 7.59 (br s, 1H), 7.47 (d, <i>J</i> = 8.5 Hz, 2H), 7.05 - 6.93 (m, 3H), 5.53 (br s, 1H), 5.42 (s, 2H), 1.55 (br t, <i>J</i> = 7.5 Hz, 2H), 1.43 (s, 6H), 1.36 - 1.25 (m, 2H), 0.89 (br t, <i>J</i> = 7.5 Hz, 3H)
830	2	30.2	423.5	0.92	δ 8.25 (s, 1H), 7.83 (s, 1H), 7.77 (s, 1H), 7.21 (s, 1H), 6.99 (d, <i>J</i> = 7.7 Hz, 1H), 6.82 (d, <i>J</i> = 7.7 Hz, 1H), 5.76 (s, 2H), 4.23 (s, 1H), 3.80 (s, 3H), 3.57 (d, <i>J</i> = 6.6 Hz, 1H), 2.93 (s, 1H), 2.55 (s, 4H), 1.78 (s, 1H), 1.65 (s, 1H), 1.58 (q, <i>J</i> = 7.3 Hz, 3H), 1.25 (q, <i>J</i> = 7.4 Hz, 2H), 1.17 (t, <i>J</i> = 7.2 Hz, 1H), 0.88 (t, <i>J</i> = 7.3 Hz, 3H)
831	2	104	411.5	1.0	δ 7.74 (s, 1H), 7.21 (s, 1H), 6.99 (d, <i>J</i> = 8.0 Hz, 1H), 6.86 (d, <i>J</i> = 7.7 Hz, 1H), 5.74 (s, 1H), 4.12 (s, 1H), 3.78 (s, 3H), 3.57 (d, <i>J</i> = 6.6 Hz, 1H), 3.41 (s, 1H), 2.93 (s, 3H), 2.89 (s, 1H), 2.55 (s, 3H), 1.60 (q, <i>J</i> = 7.5 Hz, 3H), 1.30 (dq, <i>J</i> = 15.5, 7.5 Hz, 3H), 1.17 (t, <i>J</i> = 7.3 Hz, 6H), 0.89 (q, <i>J</i> = 7.2 Hz, 4H)
832	2	141	425.5	0.82	δ 8.31 (t, <i>J</i> = 5.6 Hz, 1H), 7.77 (d, <i>J</i> = 0.8 Hz, 1H), 7.19 (s, 1H), 6.99 (d, <i>J</i> = 7.7 Hz, 1H), 6.85 (d, <i>J</i> = 7.7 Hz, 1H), 5.75 (s, 2H), 4.24 (s, 1H), 3.79 (s, 3H), 3.58 (t, <i>J</i> = 6.7 Hz, 1H), 3.09 (s, 2H), 2.97 – 2.88 (m, 1H), 2.55 (d, <i>J</i> = 0.8 Hz, 9H), 1.57 (p, <i>J</i> = 7.3 Hz, 2H), 1.25 (h, <i>J</i> = 7.3 Hz, 2H), 1.17 (t, <i>J</i> = 7.3 Hz, 1H), 0.88 (t, <i>J</i> = 7.3 Hz, 3H)
833	2	31.1	409.5	1.11	δ 8.22 (s, 1H), 7.76 (s, 1H), 7.22 (s, 1H), 7.01 (d, <i>J</i> = 7.5 Hz, 1H), 6.83 (d, <i>J</i> = 7.7 Hz, 1H), 5.75 (s, 2H), 4.31 (s, 2H), 3.80 (s, 3H), 3.61 – 3.54 (m, 1H), 2.93 (s, 1H), 2.55 (s, 8H), 1.57 (p, <i>J</i> = 7.2 Hz, 2H), 1.27 (dt, <i>J</i> = 14.7, 7.5 Hz, 2H), 1.17 (t, <i>J</i> = 7.2 Hz, 1H), 0.88 (t, <i>J</i> = 7.3 Hz, 3H)

Table B					
Cpd. No.	Proce- dure	hTLR7 EC ₅₀ (nM)	LC/MS [M+H] ⁺	RT (min)	¹ H NMR (500 MHz, DMSO-d ₆)
834	3	29.9	494.3	0.89	δ 7.79 (s, 1H), 7.60 (d, <i>J</i> = 8.5 Hz, 1H), 7.13 (s, 1H), 6.93 (d, <i>J</i> = 7.8 Hz, 1H), 6.70 (d, <i>J</i> = 7.7 Hz, 1H), 5.82 – 5.69 (m, 2H), 4.52 (d, <i>J</i> = 9.2 Hz, 1H), 3.80 (s, 2H), 3.52 (s, 2H), 3.38 (t, <i>J</i> = 6.5 Hz, 2H), 2.92 (d, <i>J</i> = 6.0 Hz, 1H), 2.55 (s, 10H), 1.71 (q, <i>J</i> = 6.3 Hz, 2H), 1.53 (d, <i>J</i> = 8.7 Hz, 2H), 1.16 (td, <i>J</i> = 8.1, 7.7, 2.7 Hz, 4H), 0.81 (t, <i>J</i> = 7.3 Hz, 3H)
835	3	89	480.9	1	δ 7.57 (s, 1H), 6.91 (s, 1H), 6.70 (d, <i>J</i> = 7.8 Hz, 1H), 6.35 (d, <i>J</i> = 7.7 Hz, 1H), 5.71 – 5.61 (m, 3H), 5.55 (d, <i>J</i> = 17.0 Hz, 1H), 4.31 (d, <i>J</i> = 9.9 Hz, 1H), 3.84 (s, 2H), 3.79 (s, 2H), 3.44 (s, 1H), 3.29 (d, <i>J</i> = 7.1 Hz, 1H), 3.26 (d, <i>J</i> = 48.2 Hz, 5H), 3.17 (s, 0H), 2.55 (s, 6H), 1.84 (s, 5H), 1.63 (dd, <i>J</i> = 13.7, 6.6 Hz, 1H), 1.53 – 1.47 (m, 1H), 1.37 (dt, <i>J</i> = 34.6, 7.6 Hz, 2H), 1.08 – 1.01 (m, 2H), 0.76 (t, <i>J</i> = 7.3 Hz, 3H)
836	3	15.3	451.2	0.83	δ 8.63 (s, 1H), 7.76 (s, 1H), 7.52 (d, <i>J</i> = 7.2 Hz, 2H), 7.35 (s, 1H), 7.14 (s, 1H), 6.85 (d, <i>J</i> = 7.7 Hz, 1H), 6.69 (d, <i>J</i> = 7.8 Hz, 1H), 5.77 (d, <i>J</i> = 16.5 Hz, 1H), 5.69 (d, <i>J</i> = 16.4 Hz, 1H), 5.29 (s, 2H), 4.52 (d, <i>J</i> = 7.0 Hz, 1H), 3.79 (s, 3H), 3.38 (d, <i>J</i> = 6.7 Hz, 1H), 3.18 (s, 0H), 2.93 (s, 2H), 2.55 (s, 6H), 1.71 (p, <i>J</i> = 6.1 Hz, 2H), 1.50 (q, <i>J</i> = 7.2 Hz, 2H), 1.13 (dt, <i>J</i> = 35.1, 7.5 Hz, 5H), 0.78 (t, <i>J</i> = 7.3 Hz, 3H)
837	3	2.4	491.2	0.71	δ 8.67 (d, <i>J</i> = 5.1 Hz, 2H), 7.91 (s, 0H), 7.78 (s, 1H), 7.71 (d, <i>J</i> = 8.3 Hz, 1H), 7.53 (d, <i>J</i> = 5.1 Hz, 2H), 7.22 (s, 1H), 7.00 (d, <i>J</i> = 7.6 Hz, 1H), 6.79 (d, <i>J</i> = 7.7 Hz, 1H), 5.82 – 5.71 (m, 2H), 4.56 (d, <i>J</i> = 7.2 Hz, 1H), 4.22 (d, <i>J</i> = 19.9 Hz, 4H), 3.79 (s, 3H), 3.41 (d, <i>J</i> = 6.3 Hz, 0H), 2.93 (q, <i>J</i> = 6.7 Hz, 1H), 2.55 (s, 0H), 1.79 – 1.72 (m, 2H), 1.56 (p, <i>J</i> = 8.0, 7.4 Hz, 2H), 1.23 (d, <i>J</i> = 10.9 Hz, 1H), 1.18 (q, <i>J</i> = 8.3, 7.4 Hz, 4H), 0.84 (t, <i>J</i> = 7.3 Hz, 3H)
838	3	39.6	483.1	0.7	δ 7.80 (s, 1H), 7.59 (d, <i>J</i> = 8.5 Hz, 1H), 7.19 (s, 1H), 6.95 (d, <i>J</i> = 7.9 Hz, 1H), 6.68 (d, <i>J</i> = 7.7 Hz, 1H), 5.79 (d, <i>J</i> = 16.8 Hz, 1H), 5.74 (d, <i>J</i> = 16.7 Hz, 1H), 4.57 – 4.51 (m, 1H), 3.81 (s, 3H), 3.40 (d, <i>J</i> = 17.5 Hz, 1H), 3.22 (s, 1H), 2.97 – 2.89 (m, 2H), 2.55 (s, 1H), 2.02 (s, 1H), 1.79 – 1.68 (m, 2H), 1.56 – 1.50 (m, 2H), 1.16 (dt, <i>J</i> = 12.8, 7.3 Hz, 5H), 0.82 (t, <i>J</i> = 7.3 Hz, 3H)

Table B					
Cpd. No.	Proce- dure	hTLR7 EC ₅₀ (nM)	LC/MS [M+H] ⁺	RT (min)	¹ H NMR (500 MHz, DMSO-d ₆)
839	3	242	481.1	0.74	δ 7.57 (s, 1H), 7.01 (s, 1H), 6.78 (d, <i>J</i> = 7.9 Hz, 1H), 6.37 (d, <i>J</i> = 7.7 Hz, 1H), 5.74 – 5.66 (m, 1H), 5.64 (s, 2H), 5.55 (d, <i>J</i> = 17.1 Hz, 1H), 4.31 (s, 1H), 3.84 (s, 2H), 3.63 (d, <i>J</i> = 8.6 Hz, 7H), 3.60 (d, <i>J</i> = 6.0 Hz, 6H), 3.37 (s, 1H), 3.30 (q, <i>J</i> = 7.9, 7.1 Hz, 2H), 3.16 (d, <i>J</i> = 12.7 Hz, 1H), 2.81 (s, 1H), 2.70 (d, <i>J</i> = 10.3 Hz, 1H), 2.55 (s, 7H), 1.81 (s, 3H), 1.63 (dd, <i>J</i> = 13.1, 6.4 Hz, 1H), 1.51 (dd, <i>J</i> = 13.3, 6.3 Hz, 2H), 1.41 (d, <i>J</i> = 6.8 Hz, 1H), 1.34 (t, <i>J</i> = 7.4 Hz, 1H), 1.03 (d, <i>J</i> = 8.0 Hz, 2H), 0.75 (t, <i>J</i> = 7.3 Hz, 3H)
840	3	14.7	484.2	0.82	δ 8.97 (s, 2H), 7.85 (s, 2H), 7.77 (s, 1H), 7.70 (d, <i>J</i> = 8.3 Hz, 1H), 7.24 (d, <i>J</i> = 1.5 Hz, 1H), 7.02 (dd, <i>J</i> = 7.7, 1.5 Hz, 1H), 5.76 (d, <i>J</i> = 2.9 Hz, 2H), 4.57 (dq, <i>J</i> = 14.2, 6.8 Hz, 2H), 4.17 (s, 2H), 3.93 (dd, <i>J</i> = 11.3, 3.9 Hz, 2H), 3.80 (s, 3H), 3.53 – 3.16 (m, 5H), 2.07 – 1.92 (m, 2H), 1.75 (q, <i>J</i> = 6.6 Hz, 2H), 1.68 – 1.46 (m, 4H), 1.21 (h, <i>J</i> = 7.3 Hz, 2H), 0.85 (t, <i>J</i> = 7.3 Hz, 3H)
841	3	9.7	454.2	0.83	δ 7.92 (s, 1H), 7.56 (s, 1H), 7.05 (s, 1H), 6.78 (d, <i>J</i> = 7.9 Hz, 1H), 6.40 (d, <i>J</i> = 7.8 Hz, 1H), 5.73 (d, <i>J</i> = 8.9 Hz, 0H), 5.64 (d, <i>J</i> = 18.8 Hz, 2H), 5.55 (d, <i>J</i> = 17.0 Hz, 1H), 4.30 (s, 1H), 3.84 (s, 1H), 3.76 – 3.56 (m, 3H), 3.29 (t, <i>J</i> = 6.5 Hz, 2H), 3.21 – 3.15 (m, 1H), 2.89 (s, 1H), 2.73 (s, 1H), 2.55 (s, 1H), 2.03 (d, <i>J</i> = 9.1 Hz, 2H), 1.74 (t, <i>J</i> = 9.7 Hz, 2H), 1.62 (t, <i>J</i> = 10.0 Hz, 2H), 1.52 (dt, <i>J</i> = 16.0, 8.1 Hz, 2H), 1.37 (dt, <i>J</i> = 33.8, 7.5 Hz, 2H), 1.09 – 1.02 (m, 2H), 0.75 (t, <i>J</i> = 7.3 Hz, 3H)
842	3	28.3	484.3	0.77	δ 7.74 (s, 1H), 7.41 (s, 1H), 7.08 (s, 1H), 6.92 (d, <i>J</i> = 7.9 Hz, 1H), 6.71 (d, <i>J</i> = 7.9 Hz, 1H), 5.74 (d, <i>J</i> = 16.7 Hz, 1H), 5.65 (d, <i>J</i> = 16.5 Hz, 1H), 4.49 (s, 1H), 4.07 (s, 5H), 4.05 (s, 9H), 3.78 (s, 3H), 3.38 (t, <i>J</i> = 6.1 Hz, 4H), 2.89 (s, 1H), 2.83 (s, 1H), 2.55 (s, 13H), 1.71 (s, 2H), 1.65 (d, <i>J</i> = 6.2 Hz, 1H), 1.50 – 1.44 (m, 2H), 1.18 – 1.00 (m, 4H), 0.76 (t, <i>J</i> = 7.3 Hz, 3H)

Table B					
Cpd. No.	Proce- dure	hTLR7 EC ₅₀ (nM)	LC/MS [M+H] ⁺	RT (min)	¹ H NMR (500 MHz, DMSO-d ₆)
843	3	55.9	481.2	1.1	δ 7.57 (s, 1H), 7.01 (s, 1H), 6.78 (d, <i>J</i> = 7.9 Hz, 1H), 6.37 (d, <i>J</i> = 7.7 Hz, 1H), 5.74 – 5.66 (m, 1H), 5.64 (s, 2H), 5.55 (d, <i>J</i> = 17.1 Hz, 1H), 4.31 (s, 1H), 3.84 (s, 2H), 3.63 (d, <i>J</i> = 8.6 Hz, 7H), 3.60 (d, <i>J</i> = 6.0 Hz, 6H), 3.37 (s, 1H), 3.30 (q, <i>J</i> = 7.9, 7.1 Hz, 2H), 3.16 (d, <i>J</i> = 12.7 Hz, 1H), 2.81 (s, 1H), 2.70 (d, <i>J</i> = 10.3 Hz, 1H), 2.55 (s, 7H), 1.81 (s, 3H), 1.63 (dd, <i>J</i> = 13.1, 6.4 Hz, 1H), 1.51 (dd, <i>J</i> = 13.3, 6.3 Hz, 2H), 1.41 (d, <i>J</i> = 6.8 Hz, 1H), 1.34 (t, <i>J</i> = 7.4 Hz, 1H), 1.03 (d, <i>J</i> = 8.0 Hz, 2H), 0.75 (t, <i>J</i> = 7.3 Hz, 3H)
844	3	4.6	517.4	0.73	δ 8.27 (s, 1H), 8.20 (d, <i>J</i> = 5.0 Hz, 1H), 7.91 (s, 0H), 7.58 (s, 1H), 7.07 – 7.01 (m, 2H), 6.82 (d, <i>J</i> = 7.8 Hz, 1H), 6.41 (d, <i>J</i> = 7.7 Hz, 1H), 5.78 (d, <i>J</i> = 8.5 Hz, 1H), 5.71 – 5.64 (m, 2H), 5.55 (d, <i>J</i> = 17.1 Hz, 1H), 4.30 (s, 1H), 3.80 (d, <i>J</i> = 30.8 Hz, 4H), 3.60 (s, 1H), 3.53 (s, 1H), 3.35 – 3.29 (m, 2H), 2.88 (s, 1H), 2.77 (d, <i>J</i> = 5.9 Hz, 2H), 2.72 (s, 1H), 2.66 (d, <i>J</i> = 6.5 Hz, 2H), 2.55 (s, 1H), 1.90 (s, 4H), 1.63 (d, <i>J</i> = 8.6 Hz, 1H), 1.51 (s, 1H), 1.39 (s, 1H), 1.35 – 1.28 (m, 1H), 1.01 (d, <i>J</i> = 12.4 Hz, 2H), 0.71 (t, <i>J</i> = 7.4 Hz, 3H)
845	2	21.2	439.0	0.92	δ 8.29 (s, 1H), 7.76 (s, 1H), 7.17 (s, 1H), 6.98 (d, <i>J</i> = 7.8 Hz, 1H), 6.84 (d, <i>J</i> = 7.6 Hz, 1H), 5.73 (s, 2H), 4.19 (s, 1H), 3.78 (s, 2H), 3.55 (s, 1H), 3.40 (d, <i>J</i> = 33.6 Hz, 1H), 3.23 (s, 1H), 3.16 (s, 1H), 2.99 (s, 1H), 2.55 (s, 9H), 2.05 (s, 1H), 1.60 – 1.53 (m, 2H), 1.25 (q, <i>J</i> = 7.4 Hz, 2H), 0.87 (t, <i>J</i> = 7.4 Hz, 3H)
846	5	198	525.2	0.96	δ 7.82 (s, 1H), 7.76 (s, 1H), 7.58 (d, <i>J</i> = 8.6 Hz, 1H), 7.20 (s, 1H), 6.99 (d, <i>J</i> = 8.3 Hz, 1H), 6.79 (d, <i>J</i> = 7.7 Hz, 1H), 5.82 (d, <i>J</i> = 16.4 Hz, 1H), 5.75 (d, <i>J</i> = 16.6 Hz, 1H), 4.49 (s, 1H), 4.13 (s, 2H), 3.95 – 3.88 (m, 2H), 3.80 – 3.76 (m, 2H), 3.56 (d, <i>J</i> = 29.7 Hz, 1H), 3.29 (t, <i>J</i> = 11.8 Hz, 3H), 2.98 (d, <i>J</i> = 6.8 Hz, 2H), 2.92 (s, 1H), 2.51 (s, 8H), 1.99 (d, <i>J</i> = 11.9 Hz, 2H), 1.78 (s, 3H), 1.72 (d, <i>J</i> = 8.7 Hz, 1H), 1.62 – 1.49 (m, 4H), 1.16 (t, <i>J</i> = 7.1 Hz, 3H), 0.82 (t, <i>J</i> = 7.2 Hz, 3H)

Table B					
Cpd. No.	Procedure	hTLR7 EC ₅₀ (nM)	LC/MS [M+H] ⁺	RT (min)	¹ H NMR (500 MHz, DMSO-d ₆)
847	5	187	539.1	0.81	δ 7.89 (d, <i>J</i> = 6.5 Hz, 1H), 7.76 (d, <i>J</i> = 1.2 Hz, 1H), 7.64 (d, <i>J</i> = 8.6 Hz, 1H), 7.18 (d, <i>J</i> = 11.6 Hz, 1H), 7.06 – 6.98 (m, 1H), 6.83 (d, <i>J</i> = 7.8 Hz, 1H), 5.81 (d, <i>J</i> = 16.1 Hz, 1H), 5.74 (d, <i>J</i> = 18.4 Hz, 1H), 4.50 (s, 1H), 4.09 (s, 2H), 3.83 (d, <i>J</i> = 8.8 Hz, 2H), 3.79 – 3.72 (m, 9H), 3.69 (s, 1H), 3.47 (t, <i>J</i> = 11.9 Hz, 2H), 2.98 (d, <i>J</i> = 5.8 Hz, 2H), 1.85 (s, 2H), 1.78 (s, 3H), 1.73 (d, <i>J</i> = 12.3 Hz, 4H), 1.53 (dt, <i>J</i> = 13.9, 7.5 Hz, 2H), 1.48 (s, 3H), 1.18 (q, <i>J</i> = 7.6 Hz, 2H), 0.82 (t, <i>J</i> = 7.3 Hz, 3H)
848	3	33.0	497.9	1.02	δ 7.57 (s, 1H), 7.12 (s, 1H), 6.86 (d, <i>J</i> = 7.8 Hz, 1H), 6.43 (d, <i>J</i> = 7.8 Hz, 1H), 5.74 (d, <i>J</i> = 8.2 Hz, 1H), 5.69 – 5.62 (m, 3H), 5.57 (d, <i>J</i> = 16.9 Hz, 1H), 4.32 (s, 1H), 3.86 (s, 3H), 3.74 – 3.66 (m, 3H), 3.55 (s, 4H), 3.29 (t, <i>J</i> = 6.5 Hz, 2H), 2.55 (s, 5H), 1.91 (s, 2H), 1.65 (dd, <i>J</i> = 13.3, 6.0 Hz, 1H), 1.57 (s, 2H), 1.49 (s, 2H), 1.39 (dq, <i>J</i> = 22.4, 7.8 Hz, 3H), 1.17 (s, 3H), 1.07 (q, <i>J</i> = 7.6 Hz, 2H), 0.78 (t, <i>J</i> = 7.3 Hz, 3H)
849	13	2030	440.1	0.97	δ 8.45 (d, <i>J</i> = 1.5 Hz, 1H), 7.73 (dd, <i>J</i> = 8.1, 2.0 Hz, 1H), 7.61 (br t, <i>J</i> = 4.9 Hz, 1H), 7.55 (s, 1H), 7.18 (d, <i>J</i> = 7.9 Hz, 1H), 5.70 (s, 2H), 5.65 (s, 2H), 3.91 (s, 1H), 3.51 - 3.31 (m, 6H), 2.48 - 2.08 (m, 8H), 1.65 - 1.51 (m, 2H), 1.37 - 1.26 (m, 2H), 0.91 (t, <i>J</i> = 7.3 Hz, 3H)
850	13	1616	396.2	1.06	δ 8.45 (d, <i>J</i> = 1.5 Hz, 1H), 7.74 (dd, <i>J</i> = 7.8, 2.0 Hz, 1H), 7.64 - 7.57 (m, 1H), 7.55 (s, 1H), 7.18 (d, <i>J</i> = 7.9 Hz, 1H), 5.70 (s, 2H), 5.64 (s, 2H), 2.71 (br t, <i>J</i> = 4.4 Hz, 4H), 2.30 (br s, 4H), 1.66 - 1.51 (m, 2H), 1.37 - 1.26 (m, 2H), 0.91 (t, <i>J</i> = 7.3 Hz, 3H)
851	13	1770	381.1	1.38	δ 8.52 (s, 1H), 7.96 (br d, <i>J</i> = 4.0 Hz, 1H), 7.83 (dd, <i>J</i> = 8.0, 1.7 Hz, 1H), 7.61 (s, 1H), 7.25 (d, <i>J</i> = 8.0 Hz, 1H), 6.19 (br d, <i>J</i> = 2.1 Hz, 2H), 5.76 (s, 2H), 3.86 (br s, 2H), 3.56 - 3.39 (m, 2H), 2.68 (br s, 4H), 1.76 (br s, 4H), 1.59 (quin, <i>J</i> = 7.3 Hz, 2H), 1.36 - 1.25 (m, 2H), 0.90 (t, <i>J</i> = 7.4 Hz, 3H)

Table B					
Cpd. No.	Proce- dure	hTLR7 EC ₅₀ (nM)	LC/MS [M+H] ⁺	RT (min)	¹ H NMR (500 MHz, DMSO-d ₆)
852	13	3170	408.0	1.24	δ 8.52 (s, 1H), 7.90 (dd, <i>J</i> =8.1, 1.7 Hz, 1H), 7.78 (s, 1H), 7.48 (d, <i>J</i> =7.9 Hz, 1H), 5.86 (s, 2H), 4.09 - 3.88 (m, 2H), 3.65 - 3.55 (m, 2H), 3.23 - 3.08 (m, 4H), 3.07 - 2.91 (m, 2H), 2.18 (br d, <i>J</i> =10.7 Hz, 1H), 1.82 (br d, <i>J</i> =11.3 Hz, 1H), 1.64 (quin, <i>J</i> =7.2 Hz, 2H), 1.32 (sxt, <i>J</i> =7.4 Hz, 2H), 0.91 (t, <i>J</i> =7.3 Hz, 3H).
853	9	420	397.9	1.35	δ 8.46 (br s, 1H), 7.88 (br s, 1H), 7.81 (s, 1H), 7.40 (d, <i>J</i> =11.2 Hz, 1H), 7.27 (br d, <i>J</i> =7.6 Hz, 1H), 7.06 (t, <i>J</i> =7.9 Hz, 1H), 5.90 (s, 2H), 4.04 (s, 2H), 3.67 (br t, <i>J</i> =8.1 Hz, 1H), 3.58 (br d, <i>J</i> =6.1 Hz, 2H), 2.19 - 2.10 (m, 4H), 2.08 (s, 1H), 1.85 - 1.69 (m, 2H), 1.60 (quin, <i>J</i> =7.3 Hz, 2H), 1.35 - 1.21 (m, 2H), 0.90 (t, <i>J</i> =7.3 Hz, 3H)
854	2	46.8	437.0	0.71	δ 7.55 (s, 1H), 6.99 (s, 1H), 6.80 - 6.74 (m, 1H), 6.43 (d, <i>J</i> = 7.7 Hz, 1H), 5.65 (s, 1H), 5.59 (s, 2H), 3.82 (s, 3H), 3.63 (s, 1H), 3.39 (d, <i>J</i> = 6.3 Hz, 2H), 3.19 (d, <i>J</i> = 13.3 Hz, 1H), 2.91 - 2.83 (m, 1H), 2.75 - 2.67 (m, 1H), 2.55 (s, 5H), 1.81 (d, <i>J</i> = 1.7 Hz, 5H), 1.57 (d, <i>J</i> = 10.1 Hz, 1H), 1.46 (p, <i>J</i> = 7.2 Hz, 2H), 1.17 (h, <i>J</i> = 7.5 Hz, 2H), 0.83 (t, <i>J</i> = 7.3 Hz, 3H).
855	11	640	411.1	1.36	δ 8.03 (t, <i>J</i> = 5.4 Hz, 1H), 8.02 (s, 1H), 7.51 (s, 1H), 7.46 (s, 1H), 5.65 (s, 2H), 5.60 (s, 1H), 3.88 (s, 3H), 3.64 (s, 1H), 3.18 (s, 2H), 3.16 - 3.10 (m, 1H), 2.10 - 1.99 (m, 2H), 1.92 (s, 3H), 1.76 - 1.45 (m, 6H), 1.39 (h, <i>J</i> = 7.4 Hz, 2H), 0.94 (t, <i>J</i> = 7.4 Hz, 3H)
856	11	1160	441.3	1.28	δ 8.06 (d, <i>J</i> = 1.6 Hz, 1H), 7.56 (d, <i>J</i> = 1.5 Hz, 1H), 7.47 (s, 1H), 5.65 (d, <i>J</i> = 6.9 Hz, 3H), 3.88 (s, 2H), 3.82 (d, <i>J</i> = 12.6 Hz, 3H), 3.30 - 3.20 (m, 2H), 3.18 (s, 1H), 3.00 (s, 1H), 2.64 (s, 1H), 2.55 (s, 3H), 1.92 (s, 1H), 1.78 (d, <i>J</i> = 12.8 Hz, 2H), 1.64 (p, <i>J</i> = 7.2 Hz, 2H), 1.39 (h, <i>J</i> = 7.4 Hz, 2H), 1.34 - 1.22 (m, 2H), 0.94 (t, <i>J</i> = 7.4 Hz, 3H).
857	4, 6	11.5	519.9	1.48	δ 8.22 (br t, <i>J</i> =6.0 Hz, 1H), 7.76 (s, 1H), 7.55 (d, <i>J</i> =8.5 Hz, 2H), 7.05 (d, <i>J</i> =8.5 Hz, 2H), 6.86 (d, <i>J</i> =8.2 Hz, 1H), 6.78 (d, <i>J</i> =2.1 Hz, 1H), 6.48 (dd, <i>J</i> =8.2, 2.1 Hz, 1H), 5.71 (s, 2H), 4.14 (s, 2H), 3.74 (s, 3H), 3.59 (q, <i>J</i> =6.5 Hz, 2H), 2.76 (s, 2H), 1.59 (quin, <i>J</i> =7.3 Hz, 2H), 1.34 - 1.23 (m, 2H), 1.17 (s, 6H), 0.90 (t, <i>J</i> =7.5 Hz, 3H)

Table B					
Cpd. No.	Procedure	hTLR7 EC ₅₀ (nM)	LC/MS [M+H] ⁺	RT (min)	¹ H NMR (500 MHz, DMSO-d ₆)
858	4, 6	10.8	532.2	1.38	δ 7.55 (s, 1H), 7.34 (d, <i>J</i> =8.2 Hz, 2H), 6.93 (d, <i>J</i> =8.5 Hz, 2H), 6.75 (d, <i>J</i> =1.8 Hz, 1H), 6.52 (d, <i>J</i> =8.2 Hz, 1H), 6.46 (br t, <i>J</i> =5.2 Hz, 1H), 6.39 (dd, <i>J</i> =8.2, 2.1 Hz, 1H), 5.64 (s, 2H), 5.60 (s, 2H), 3.71 (s, 3H), 3.42 (br d, <i>J</i> =5.8 Hz, 2H), 3.26 (td, <i>J</i> =11.4, 2.0 Hz, 4H), 2.63 - 2.57 (m, 1H), 1.80 - 1.73 (m, 2H), 1.55 - 1.46 (m, 2H), 1.32 - 1.18 (m, 4H), 0.87 (t, <i>J</i> =7.3 Hz, 3H).
859	4, 6	13.1	531.9	1.41	δ 7.55 (s, 1H), 7.26 (d, <i>J</i> =8.5 Hz, 2H), 6.92 (d, <i>J</i> =8.5 Hz, 2H), 6.76 (d, <i>J</i> =2.1 Hz, 1H), 6.53 (d, <i>J</i> =8.2 Hz, 1H), 6.47 (br t, <i>J</i> =4.0 Hz, 1H), 6.40 (dd, <i>J</i> =8.5, 2.1 Hz, 1H), 5.64 (s, 2H), 5.60 (s, 2H), 3.80 (s, 3H), 3.46 - 3.35 (m, 1H), 2.69 - 2.60 (m, 2H), 2.02 (br t, <i>J</i> =10.4 Hz, 2H), 1.72 - 1.64 (m, 2H), 1.50 (quin, <i>J</i> =7.2 Hz, 2H), 1.42 - 1.33 (m, 2H), 1.22 (dq, <i>J</i> =14.8, 7.4 Hz, 2H), 0.86 (t, <i>J</i> =7.3 Hz, 3H).
860	4, 6	19.5	502.2	1.2	δ 7.55 (s, 1H), 7.32 (d, <i>J</i> =8.4 Hz, 2H), 6.93 (d, <i>J</i> =8.4 Hz, 2H), 6.75 (d, <i>J</i> =1.9 Hz, 1H), 6.55 - 6.43 (m, 2H), 6.39 (dd, <i>J</i> =8.5, 2.0 Hz, 1H), 5.65 (s, 2H), 5.60 (s, 2H), 3.79 (s, 3H), 3.61 (s, 2H), 3.18 (br d, <i>J</i> =4.7 Hz, 1H), 2.06 (br d, <i>J</i> =7.7 Hz, 2H), 1.78 - 1.46 (m, 6H), 1.27 - 1.18 (m, 2H), 0.87 (t, <i>J</i> =7.3 Hz, 3H).
861	3	1.2	470.3	0.82	δ 7.90 - 7.82 (m, 2H), 7.78 (s, 1H), 7.62 - 7.55 (m, 1H), 7.17 (s, 1H), 6.95 (br d, <i>J</i> =7.0 Hz, 1H), 6.68 (d, <i>J</i> =7.6 Hz, 1H), 5.84 - 5.70 (m, 2H), 4.64 - 4.55 (m, 1H), 4.54 - 4.48 (m, 1H), 4.32 (s, 2H), 4.25 - 4.21 (m, 2H), 4.20 (br s, 1H), 3.91 (br d, <i>J</i> =6.3 Hz, 2H), 3.80 (s, 3H), 3.23 (s, 3H), 1.75 - 1.68 (m, 2H), 1.57 - 1.48 (m, 2H), 1.15 (sxt, <i>J</i> =7.4 Hz, 2H), 0.81 (t, <i>J</i> =7.3 Hz, 3H).
862	3	11.0	476.04	0.86	δ 7.57 - 7.55 (m, 1H), 6.98 (s, 1H), 6.76 (d, <i>J</i> =7.7 Hz, 1H), 6.38 (d, <i>J</i> =8.0 Hz, 1H), 5.71 (br d, <i>J</i> =8.5 Hz, 1H), 5.68 - 5.62 (m, 3H), 5.59 - 5.52 (m, 1H), 4.45 - 4.37 (m, 1H), 4.36 - 4.27 (m, 1H), 3.85 (s, 3H), 3.66 (s, 2H), 3.56 (br t, <i>J</i> =12.5 Hz, 4H), 3.33 - 3.28 (m, <i>J</i> =6.3 Hz, 2H), 1.68 - 1.58 (m, 1H), 1.54 - 1.46 (m, 1H), 1.45 - 1.30 (m, 2H), 1.09 - 1.00 (m, 2H), 0.75 (t, <i>J</i> =7.4 Hz, 3H)

Table B					
Cpd. No.	Proce- dure	hTLR7 EC ₅₀ (nM)	LC/MS [M+H] ⁺	RT (min)	¹ H NMR (500 MHz, DMSO-d ₆)
863	3	9.5	456.2	0.77	δ 7.58 - 7.56 (m, 1H), 6.94 (s, 1H), 6.71 (br d, <i>J</i> =7.6 Hz, 1H), 6.36 (d, <i>J</i> =7.7 Hz, 1H), 5.70 - 5.65 (m, 2H), 5.65 (s, 2H), 5.58 - 5.52 (m, 1H), 5.35 - 5.29 (m, 1H), 4.32 (br dd, <i>J</i> =8.3, 4.3 Hz, 1H), 4.16 (br d, <i>J</i> =5.1 Hz, 1H), 3.85 (s, 3H), 3.50 (s, 2H), 3.48 - 3.46 (m, 2H), 3.33 - 3.31 (m, 2H), 2.72 (br t, <i>J</i> =6.0 Hz, 2H), 1.68 - 1.59 (m, 1H), 1.55 - 1.46 (m, 1H), 1.45 - 1.38 (m, 1H), 1.37 - 1.30 (m, 1H), 1.09 - 0.99 (m, 2H), 0.76 (t, <i>J</i> =7.2 Hz, 3H)
864	7	216	426.17	0.8	δ 7.56 - 7.52 (m, 1H), 7.01 (s, 1H), 6.77 (br d, <i>J</i> =7.6 Hz, 1H), 6.57 (br d, <i>J</i> =7.6 Hz, 1H), 5.66 (s, 2H), 5.55 (s, 2H), 3.83 (s, 3H), 3.63 - 3.54 (m, 2H), 3.19 - 3.11 (m, 1H), 2.07 - 2.00 (m, 2H), 1.75 - 1.65 (m, 2H), 1.65 - 1.56 (m, 1H), 1.56 - 1.46 (m, 1H), 1.05 (t, <i>J</i> =6.9 Hz, 3H)
865	7	959	412.2	0.90	δ 7.56 - 7.52 (m, 1H), 6.99 (s, 1H), 6.76 (br d, <i>J</i> =7.6 Hz, 1H), 6.62 - 6.53 (m, 1H), 5.65 (s, 2H), 5.54 (s, 2H), 3.82 (s, 3H), 3.58 (q, <i>J</i> =5.8 Hz, 1H), 3.21 (s, 2H), 3.13 - 3.05 (m, 1H), 2.06 - 1.98 (m, 2H), 1.70 - 1.61 (m, 2H), 1.60 - 1.55 (m, 1H), 1.54 - 1.45 (m, 1H)
866	8	19.5	510.23	1.23	δ 9.28 - 9.02 (m, 1H), 7.84 - 7.77 (m, 1H), 7.75 (s, 1H), 7.68 - 7.59 (m, 1H), 7.19 (s, 1H), 6.96 (d, <i>J</i> =7.7 Hz, 1H), 6.77 (d, <i>J</i> =7.7 Hz, 1H), 5.80 - 5.66 (m, 2H), 4.60 - 4.49 (m, 1H), 3.99 (br s, 2H), 3.78 (s, 3H), 3.42 - 3.40 (m, 2H), 2.99 - 2.97 (m, 1H), 2.22 (br d, <i>J</i> =1.7 Hz, 1H), 2.07 - 2.00 (m, 1H), 1.84 - 1.80 (m, 1H), 1.76 - 1.71 (m, 1H), 1.57 - 1.51 (m, 1H), 1.21 - 1.13 (m, 2H), 0.83 (t, <i>J</i> =7.3 Hz, 3H), 0.80 - 0.75 (m, 9H)
867	12	302	470.4	0.71	δ 8.96 (s, 1H), 7.85 (s, 1H), 7.78 (s, 1H), 7.73 (d, <i>J</i> =8.1 Hz, 1H), 7.19 (d, <i>J</i> =19.6 Hz, 1H), 7.02 (d, <i>J</i> =7.7 Hz, 1H), 6.84 (d, <i>J</i> =7.7 Hz, 1H), 5.82 - 5.70 (m, 2H), 4.46 (m, 1H), 4.16 (s, 2H), 3.94 (d, <i>J</i> =11.4 Hz, 2H), 3.80 (s, 2H), 3.56 (s, 1H), 3.31 (t, <i>J</i> =11.7 Hz, 3H), 2.00 (d, <i>J</i> =12.5 Hz, 2H), 1.76 (p, <i>J</i> =6.9 Hz, 2H), 1.62 (tt, <i>J</i> =13.2, 5.8 Hz, 4H), 0.80 (t, <i>J</i> =7.4 Hz, 3H)

Table B					
Cpd. No.	Procedure	hTLR7 EC ₅₀ (nM)	LC/MS [M+H] ⁺	RT (min)	¹ H NMR (500 MHz, DMSO-d ₆)
868	3	1.4	498.21	0.95	δ 7.59 - 7.51 (m, 1H), 6.94 (s, 1H), 6.79 - 6.66 (m, 1H), 6.36 (d, <i>J</i> =7.7 Hz, 1H), 5.69 - 5.65 (m, 1H), 5.63 (s, 2H), 5.55 - 5.50 (m, 1H), 4.34 - 4.27 (m, 1H), 4.06 (quin, <i>J</i> =6.1 Hz, 1H), 3.84 (s, 3H), 3.51 - 3.49 (m, 4H), 3.30 (m, 2H), 2.78 - 2.73 (m, 2H), 1.90 (s, 1H), 1.66 - 1.59 (m, 1H), 1.54 - 1.45 (m, 1H), 1.43 - 1.36 (m, 1H), 1.36 - 1.29 (m, 1H), 1.05 - 1.03 (m, 2H), 1.02 (s, 3H), 1.01 (s, 3H), 0.74 (t, <i>J</i> =7.3 Hz, 3H)
869	12	897	484.1	1.13	δ 7.59 (s, 1H), 7.08 (s, 1H), 6.79 (d, <i>J</i> = 7.7 Hz, 1H), 6.30 (d, <i>J</i> = 7.8 Hz, 1H), 5.67 (d, <i>J</i> = 17.3 Hz, 1H), 5.62 (d, <i>J</i> = 10.8 Hz, 2H), 5.55 (d, <i>J</i> = 17.2 Hz, 1H), 5.43 (d, <i>J</i> = 8.9 Hz, 1H), 4.16 (s, 1H), 3.89 (m, 4H), 3.82 (s, 3H), 3.76 (s, 1H), 3.70 (s, 1H), 3.25 - 3.15 (m, 4H), 1.88 (s, 1H), 1.73 (m, 3H), 1.62 (m, 2H), 1.52 (m, 1H), 1.23 (m, 2H), 0.67 (dd, <i>J</i> = 6.9, 2.8 Hz, 6H)
870	9	1796	457.3	1.23	δ 8.45 (br t, <i>J</i> =5.6 Hz, 1H), 7.81 (s, 1H), 7.21 (d, <i>J</i> =11.0 Hz, 1H), 7.16 - 7.07 (m, 1H), 6.96 (t, <i>J</i> =7.9 Hz, 1H), 5.87 (s, 2H), 3.72 (t, <i>J</i> =5.2 Hz, 2H), 3.20 - 3.10 (m, 2H), 2.55 (s, 4H), 1.63 - 1.50 (m, 2H), 1.29 - 1.18 (m, 2H), 0.87 (t, <i>J</i> =7.3 Hz, 3H)
871	12	61	469.9	1.04	δ 7.57 (s, 1H), 7.08 (s, 1H), 6.81 (d, <i>J</i> = 7.7 Hz, 1H), 6.48 (d, <i>J</i> = 7.7 Hz, 1H), 5.71 (d, <i>J</i> = 16.9 Hz, 1H), 5.63 (s, 2H), 5.48 (d, <i>J</i> = 16.9 Hz, 1H), 4.30 - 4.18 (m, 1H), 3.85 (s, 3H), 3.80 (d, <i>J</i> = 12.0 Hz, 2H), 3.71 (s, 2H), 3.60 - 3.52 (m, 1H), 3.45 - 3.33 (m, 1H), 3.22 (t, <i>J</i> = 11.7 Hz, 1H), 1.83 - 1.70 (m, 3H), 1.49 (m, 1H), 1.34 - 1.19 (m, 4H), 1.09 - 1.03 (m, 2H), 1.03 - 0.94 (m, 2H), 0.76 (t, <i>J</i> = 7.3 Hz, 3H)
872	3	32.7	454.16	1.09	δ 7.57 - 7.54 (m, 1H), 7.05 - 7.01 (m, 1H), 6.76 (d, <i>J</i> =7.7 Hz, 1H), 6.40 - 6.37 (m, 1H), 5.66 - 5.64 (m, 1H), 5.63 - 5.61 (m, 2H), 5.57 - 5.52 (m, 1H), 4.35 - 4.27 (m, 1H), 3.84 (s, 3H), 3.56 (s, 2H), 3.29 (br t, <i>J</i> =6.5 Hz, 2H), 3.18 - 3.06 (m, 2H), 2.07 - 2.00 (m, 2H), 1.90 (s, 2H), 1.71 - 1.64 (m, 2H), 1.63 - 1.57 (m, 2H), 1.54 - 1.46 (m, 2H), 1.44 - 1.37 (m, 1H), 1.36 - 1.30 (m, 1H), 1.10 - 1.01 (m, 2H), 0.76 (t, <i>J</i> =7.3 Hz, 3H)

Table B					
Cpd. No.	Procedure	hTLR7 EC ₅₀ (nM)	LC/MS [M+H] ⁺	RT (min)	¹ H NMR (500 MHz, DMSO-d ₆)
873	10	253	366.3	1.37	δ 7.57 (s, 1H), 7.03 (s, 1H), 6.82 (d, <i>J</i> =7.9 Hz, 1H), 6.59 (br s, 1H), 6.48 (d, <i>J</i> =7.7 Hz, 1H), 5.78 (br s, 2H), 5.63 (s, 2H), 3.98 (s, 2H), 3.84 (s, 3H), 3.38 (br. m, 2H), 1.48 (quin, <i>J</i> =7.3 Hz, 2H), 1.25 - 1.12 (m, 2H), 0.85 (t, <i>J</i> =7.3 Hz, 3H)
874	14	2048	371.15	1.07	δ 7.32 - 7.17 (m, 2H), 6.96 (br d, <i>J</i> =7.2 Hz, 2H), 6.48 - 6.39 (m, 1H), 6.39 - 6.09 (m, 1H), 5.85 - 5.69 (m, 2H), 5.39 - 5.06 (m, 1H), 4.63 - 4.50 (m, 1H), 4.46 - 4.40 (m, 2H), 4.39 - 4.31 (m, 1H), 3.36 - 3.32 (m, 2H), 1.73 - 1.58 (m, 2H), 1.41 (br d, <i>J</i> =7.1 Hz, 2H), 1.08 - 0.89 (m, 2H), 0.83 - 0.66 (m, 3H)
875	14	58	423.91	1.03	δ 7.82 - 7.78 (m, 1H), 7.42 (br d, <i>J</i> =8.5 Hz, 1H), 7.37 (br d, <i>J</i> =7.9 Hz, 2H), 7.01 (br d, <i>J</i> =8.2 Hz, 2H), 5.85 (s, 2H), 4.47 - 4.40 (m, 1H), 3.63 - 3.54 (m, 1H), 3.28 (br t, <i>J</i> =6.3 Hz, 2H), 2.16 - 2.09 (m, 2H), 2.08 - 2.00 (m, 2H), 1.74 (br dd, <i>J</i> =15.3, 8.9 Hz, 2H), 1.70 - 1.62 (m, 2H), 1.50 - 1.40 (m, 2H), 1.06 - 0.94 (m, 2H), 0.74 (t, <i>J</i> =7.3 Hz, 3H)
876	14	1270	453.99	0.98	δ 7.63 - 7.56 (m, 1H), 7.26 (br d, <i>J</i> =7.9 Hz, 2H), 6.94 (br d, <i>J</i> =7.9 Hz, 2H), 5.97 (br d, <i>J</i> =8.2 Hz, 1H), 5.69 (br d, <i>J</i> =7.0 Hz, 2H), 5.59 (s, 2H), 4.35 - 4.26 (m, 1H), 3.79 (br d, <i>J</i> =11.6 Hz, 2H), 3.69 (s, 1H), 3.28 (br t, <i>J</i> =6.3 Hz, 2H), 3.25 - 3.16 (m, 2H), 2.67 - 2.58 (m, 1H), 1.79 - 1.70 (m, 2H), 1.67 - 1.52 (m, 2H), 1.44 - 1.35 (m, 2H), 1.31 - 1.20 (m, 2H), 1.08 - 0.96 (m, 2H), 0.75 (t, <i>J</i> =7.3 Hz, 3H)
877	14	190	440.23	1.0	δ 7.83 (s, 1H), 7.49 (br d, <i>J</i> =8.2 Hz, 1H), 7.39 (br d, <i>J</i> =8.2 Hz, 2H), 7.01 (br d, <i>J</i> =7.9 Hz, 2H), 5.89 (br s, 2H), 4.52 - 4.39 (m, 1H), 4.28 (s, 2H), 4.22 - 4.18 (m, 2H), 4.18 - 4.14 (m, 1H), 3.86 (br d, <i>J</i> =7.6 Hz, 1H), 3.33 - 3.26 (m, 1H), 3.26 - 3.21 (m, 1H), 3.20 (s, 3H), 1.70 - 1.63 (m, 2H), 1.50 - 1.40 (m, 2H), 1.05 - 0.94 (m, 2H), 0.74 (t, <i>J</i> =7.3 Hz, 3H)

Table B					
Cpd. No.	Proce- dure	hTLR7 EC ₅₀ (nM)	LC/MS [M+H] ⁺	RT (min)	¹ H NMR (500 MHz, DMSO-d ₆)
878	14	1107	426.19	1.07	δ 7.60 - 7.56 (m, 1H), 7.16 (br d, <i>J</i> =7.9 Hz, 2H), 6.91 (br d, <i>J</i> =8.2 Hz, 2H), 5.92 (br d, <i>J</i> =8.5 Hz, 1H), 5.75 - 5.63 (m, 2H), 5.59 (s, 2H), 4.35 - 4.26 (m, 1H), 4.17 - 4.10 (m, 1H), 3.33 - 3.27 (m, 1H), 3.16 (s, 1H), 2.98 (s, 1H), 2.70 (br t, <i>J</i> =6.1 Hz, 2H), 1.67 - 1.53 (m, 2H), 1.42 - 1.33 (m, 2H), 1.02 - 0.94 (m, 2H), 0.73 (t, <i>J</i> =7.3 Hz, 3H)
879	14	370	483.25	1.13	δ 7.92 - 7.87 (m, 1H), 7.86 (s, 1H), 7.55 (br d, <i>J</i> =8.3 Hz, 1H), 7.34 - 7.28 (m, 3H), 7.01 (d, <i>J</i> =8.0 Hz, 2H), 5.91 (br s, 2H), 4.54 - 4.44 (m, 1H), 3.72 - 3.70 (m, 2H), 3.64 (br s, 2H), 3.34 (dt, <i>J</i> =10.9, 5.6 Hz, 2H), 3.30 - 3.24 (m, 2H), 3.12 (br s, 2H), 1.71 (q, <i>J</i> =6.1 Hz, 2H), 1.54 - 1.44 (m, 2H), 1.09 - 0.96 (m, 2H), 0.77 (t, <i>J</i> =7.3 Hz, 3H)

[00285] The foregoing detailed description of the invention includes passages that are chiefly or exclusively concerned with particular parts or aspects of the invention. It is to be understood that this is for clarity and convenience, that a particular feature may be relevant in more than just the passage in which it is disclosed, and that the disclosure herein includes all the appropriate combinations of information found in the different passages. Similarly, although the various figures and descriptions herein relate to specific embodiments of the invention, it is to be understood that where a specific feature is disclosed in the context of a particular figure or embodiment, such feature can also be used, to the extent appropriate, in the context of another figure or embodiment, in combination with another feature, or in the invention in general.

[00286] Further, while the present invention has been particularly described in terms of certain preferred embodiments, the invention is not limited to such preferred embodiments. Rather, the scope of the invention is defined by the appended claims.

ACRONYMS AND ABBREVIATIONS

[00287] Table C provides a list of acronyms and abbreviations used in this specification, along with their meanings.

Table C	
ACRONYM OR ABBREVIATION	MEANING OR DEFINITION
AIBN	Azobisisobutyronitrile
Aq.	Aqueous
Boc	<i>t</i> -Butyloxycarbonyl
BOP	(Benzotriazol-1-yloxy)tris(dimethylamino)-phosphonium hexafluorophosphate (V)
DBU	1,8-Diazabicyclo[5.4.0]undec-7-ene
DCM	Dichloromethane
DIAD	Diisopropyl azodicarboxylate
DIPEA, DIEA	N,N-diisopropylethylamine, also known as Hünig's base
DMF	N,N-dimethylformamide
DMSO	Dimethyl sulfoxide
Fmoc	Fluorenylmethyloxycarbonyl
HATU	Hexafluorophosphate Azabenzotriazole Tetramethyl Uronium; 1-[Bis(dimethylamino)-methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate
Hünig's base	See DIPEA, DIEA
HPLC	High pressure liquid chromatography
LCMS, LC-MS, LC/MS	Liquid chromatography-mass spectrometry
MS	Mass spectrometry
MsCl	Methanesulfonyl chloride, mesyl chloride
NBS	N-Bromosuccinimide
NMR	Nuclear magnetic resonance
PEG	Poly(ethylene glycol)
PTFE	Poly(tetrafluoroethylene)
RT (in the context of reaction conditions)	Room (ambient) temperature, circa 25 °C
RT (in context of liquid chromatography)	Retention time, in min
Sat.	Saturated
Soln	Solution
TBDPS	tert-Butyldiphenylsilyl
TEAA	Triethylammonium acetate
TFA	Trifluoroacetic acid
THF	Tetrahydrofuran

REFERENCES

[00288] Full citations for the following references cited in abbreviated fashion by first author (or inventor) and date earlier in this specification are provided below. Each of these references is incorporated herein by reference for all purposes.

- 5 [00289] Akinbobuyi *et al.*, *Tetrahedron Lett.* **2015**, 56, 458, “Facile syntheses of functionalized toll-like receptor 7 agonists”.

[00290] Akinbobuyi *et al.*, *Bioorg. Med. Chem. Lett.* **2016**, 26, 4246, “Synthesis and immunostimulatory activity of substituted TLR7 agonists.”

[00291] Barberis *et al.*, US 2012/0003298 A1 (2012).

- 10 [00292] Beesu *et al.*, *J. Med. Chem.* **2017**, 60, 2084, “Identification of High-Potency Human TLR8 and Dual TLR7/TLR8 Agonists in Pyrimidine-2,4-diamines.”

[00293] Berghöfer *et al.*, *J. Immunol.* **2007**, 178, 4072, “Natural and Synthetic TLR7 Ligands Inhibit CpG-A- and CpG-C-Oligodeoxynucleotide-Induced IFN- α Production.”

[00294] Bonfanti *et al.*, US 2014/0323441 A1 (2015) [2015a].

- 15 [00295] Bonfanti *et al.*, US 2015/0299221 A1 (2015) [2015b].

[00296] Bonfanti *et al.*, US 2016/0304531 A1 (2016).

[00297] Carson *et al.*, US 2013/0202629 A1 (2013).

[00298] Carson *et al.*, US 8,729,088 B2 (2014).

[00299] Carson *et al.*, US 9,050,376 B2 (2015).

- 20 [00300] Carson *et al.*, US 2016/0199499 A1 (2016).

[00301] Chan *et al.*, *Bioconjugate Chem.* **2009**, 20, 1194, “Synthesis and Immunological Characterization of Toll-Like Receptor 7 Agonistic Conjugates.”

[00302] Chan *et al.*, *Bioconjugate Chem.* **2011**, 22, 445, “Synthesis and Characterization of PEGylated Toll Like Receptor 7 Ligands.”

- 25 [00303] Chen *et al.*, US 7,919,498 B2 (2011).

[00304] Coe *et al.*, US 9,662,336 B2 (2017).

- [00305] Cortez and Va, *Medicinal Chem. Rev.* **2018**, 53, 481, “Recent Advances in Small-Molecule TLR7 Agonists for Drug Discovery”.
- [00306] Cortez *et al.*, US 2017/0121421 A1 (2017).
- [00307] Cortez *et al.*, US 9,944,649 B2 (2018).
- 5 [00308] Dellaria *et al.*, WO 2007/028129 A1 (2007).
- [00309] Desai *et al.*, US 9,127,006 B2 (2015).
- [00310] Ding *et al.*, WO 2016/107536 A1 (2016).
- [00311] Ding *et al.*, US 2017/0273983 A1 (2017) [2017a].
- [00312] Ding *et al.*, WO 2017/076346 A1 (2017) [2017b].
- 10 [00313] Gadd *et al.*, *Bioconjugate Chem.* **2015**, 26, 1743, “Targeted Activation of Toll-Like Receptors: Conjugation of a Toll-Like Receptor 7 Agonist to a Monoclonal Antibody Maintains Antigen Binding and Specificity.”
- [00314] Graupe *et al.*, US 8,993,755 B2 (2015).
- [00315] Embrechts *et al.*, *J. Med. Chem.* **2018**, 61, 6236, “2,4-Diaminoquinazolines as Dual
15 Toll Like Receptor (TLR) 7/8 Modulators for the Treatment of Hepatitis B Virus.”
- [00316] Halcomb *et al.*, US 9,161,934 B2 (2015).
- [00317] Hashimoto *et al.*, US 2009/0118263 A1 (2009).
- [00318] He *et al.*, US 2019/0055246 A1 (2019) [2019a].
- [00319] He *et al.*, US 2019/0055247 A1 (2019) [2019b].
- 20 [00320] Hirota *et al.*, US 6,028,076 (2000).
- [00321] Holidack *et al.*, US 2012/0083473 A1 (2012).
- [00322] Isobe *et al.*, US 6,376,501 B1 (2002).
- [00323] Isobe *et al.*, JP 2004137157 (2004).
- [00324] Isobe *et al.*, *J. Med. Chem.* **2006**, 49 (6), 2088, “Synthesis and Biological Evaluation
25 of Novel 9-Substituted-8-Hydroxyadenine Derivatives as Potent Interferon Inducers.”
- [00325] Isobe *et al.*, US 7,521,454 B2 (2009) [2009a].
- [00326] Isobe *et al.*, US 2009/0105212 A1 (2009) [2009b].


- [00327] Isobe *et al.*, US 2011/0028715 A1 (2011).
- [00328] Isobe *et al.*, US 8,148,371 B2 (2012).
- [00329] Jensen *et al.*, WO 2015/036044 A1 (2015).
- [00330] Jones *et al.*, US 7,691,877 B2 (2010).
- 5 [00331] Jones *et al.*, US 2012/0302598 A1 (2012).
- [00332] Kasibhatla *et al.*, US 7,241,890 B2 (2007).
- [00333] Koga-Yamakawa *et al.*, *Int. J. Cancer* **2013**, 132 (3), 580, "Intratracheal and oral administration of SM-276001: A selective TLR7 agonist, leads to antitumor efficacy in primary and metastatic models of cancer."
- 10 [00334] Li *et al.*, US 9,902,730 B2 (2018).
- [00335] Lioux *et al.*, US 9,295,732 B2 (2016).
- [00336] Lund *et al.*, *Proc. Nat'l Acad. Sci (USA)* **2004**, 101 (15), 5598, "Recognition of single-stranded RNA viruses by Toll-like receptor 7."
- [00337] Maj *et al.*, US 9,173,935 B2 (2015).
- 15 [00338] McGowan *et al.*, US 2016/0168150 A1 (2016) [2016a].
- [00339] McGowan *et al.*, US 9,499,549 B2 (2016) [2016b].
- [00340] McGowan *et al.*, *J. Med. Chem.* **2017**, 60, 6137, "Identification and Optimization of Pyrrolo[3,2-d]pyrimidine Toll-like Receptor 7 (TLR7) Selective Agonists for the Treatment of Hepatitis B."
- 20 [00341] Musmuca *et al.*, *J. Chem. Information & Modeling* **2009**, 49 (7), 1777, "Small-Molecule Interferon Inducers. Toward the Comprehension of the Molecular Determinants through Ligand-Based Approaches."
- [00342] Nakamura *et al.*, *Bioorg. Med. Chem. Lett.* **2013**, 13, 669, "Synthesis and evaluation of 8-oxoadenine derivatives as potent Toll-like receptor agonists with high water solubility."
- 25 [00343] Ogita *et al.*, US 2007/0225303 A1 (2007).
- [00344] Ota *et al.*, WO 2019/124500 A1 (2019).
- [00345] Pilatte *et al.*, WO 2017/216293 A1 (2017).

- [00346] Poudel *et al.*, US 2019/0055243 A1 (2019) [2019a].
- [00347] Poudel *et al.*, US 2019/0055245 A1 (2019) [2019b].
- [00348] Purandare *et al.*, PCT Application Ser. No. PCT/US19/28697, filed April 23, 2019.
- [00349] Pryde, US 7,642,350 B2 (2010).
- 5 [00350] Sato-Kaneko *et al.*, *JCI Insight* **2017**, 2, e93397, “Combination Immunotherapy with TLR Agonists and Checkpoint Inhibitors Suppresses Head and Neck Cancer”.
- [00351] Smits *et al.*, *The Oncologist* **2008**, 13, 859, “The Use of TLR7 and TLR8 Ligands for the Enhancement of Cancer Immunotherapy”.
- [00352] Vasilakos and Tomai, *Expert Rev. Vaccines* **2013**, 12, 809, “The Use of Toll-like
10 Receptor 7/8 Agonists as Vaccine Adjuvants”.
- [00353] Vernejoul *et al.*, US 2014/0141033 A1 (2014).
- [00354] Young *et al.*, US 2019/0055244 A1 (2019).
- [00355] Yu *et al.*, *PLoS One* **2013**, 8 (3), e56514, “Toll-Like Receptor 7 Agonists: Chemical Feature Based Pharmacophore Identification and Molecular Docking Studies.”
- 15 [00356] Zhang *et al.*, *Immunity* **2016**, 45, 737, “Structural Analysis Reveals that Toll-like Receptor 7 Is a Dual Receptor for Guanosine and Single-Stranded RNA.”
- [00357] Zhang *et al.*, WO 2018/095426 A1 (2018)>
- [00358] Zurawski *et al.*, US 2012/0231023 A1 (2012).

CLAIMS

What is claimed is:

1. A compound having a structure according to formula I




5 wherein

each X^1 is independently N or CR^2 ;


X^2 is O, CH_2 , NH, S, or $N(C_1-C_3 \text{ alkyl})$;

R^1 is H, $CH_3(CH_2)_{1-3}$, $CH_3(CH_2)_{0-1}O(CH_2)_{2-3}$, $CH_3(CH_2)_{0-3}C(=O)$, $CH_3(CH_2)_{0-1}O(CH_2)_{2-3}C(=O)$,



R^2 is H, $O(C_1-C_3 \text{ alkyl})$, $C_1-C_3 \text{ alkyl}$, Cl, F, or CN;

R^3 is H, halo, OH, CN, NH_2 , $NH(C_1-C_5 \text{ alkyl})$, $N(C_1-C_5 \text{ alkyl})_2$, $NH(CH_2)_{0-1}(C_3-C_6 \text{ cycloalkyl})$, $NH(C_4-C_8 \text{ bicycloalkyl})$, $NH(C_6-C_{10} \text{ spirocycloalkyl})$, $N(C_3-C_6 \text{ cycloalkyl})_2$, $NH(CH_2)_{1-3}(\text{aryl})$, $N((CH_2)_{1-3}(\text{aryl}))_2$, a cyclic amine moiety having the structure




wherein


an alkyl, cycloalkyl, bicycloalkyl, spirocycloalkyl, cyclic amine, 6-membered aromatic or heteroaromatic, or 5-membered heteroaromatic moiety is optionally substituted with one or more substituents selected from OH, halo, CN, $(C_1-C_3 \text{ alkyl})$, $O(C_1-C_3 \text{ alkyl})$, $C(=O)(Me)$, $SO_2(C_1-C_3 \text{ alkyl})$, $C(=O)(Et)$, NH_2 , $NH(Me)$, $N(Me)_2$, $NH(Et)$, $N(Et)_2$, and $N(C_1-C_3 \text{ alkyl})$, $(CH_2)_{1-2}OH$, $(CH_2)_{1-2}OMe$; and a cycloalkyl, bicycloalkyl, spirocycloalkyl, or cyclic amine moiety may have a CH_2 group replaced by O, S, NH, $N(C_1-C_3 \text{ alkyl})$, or N(Boc);


20

5. A compound according to claim 1, wherein the moiety




6. A compound according to claim 1, wherein the group R^3 is selected from the group consisting of Cl, H,







7. A compound according to claim 1, wherein R^3 is a moiety




selected from the group consisting of




8. A compound according to claim 1, having a structure according to formula (I')




9. A compound according to claim 1, having a structure according to formula Ia







10. A compound according to claim 9, wherein R^1 is



11. A compound according to claim 1, having a structure according to formula Ib



12. A compound according to claim 11, wherein



5

13. A compound according to claim 1, which is covalently bonded to a poly(ethylene glycol) moiety between 2 kDa and 40 kDa in size.

14. A method of treating a cancer, comprising administering to a patient suffering from such cancer a therapeutically effective combination of an anti-cancer immunotherapy agent and a compound according to claim 1.

10


15. A method according to claim 16, wherein the anti-cancer immunotherapy agent is an antagonistic anti-CTLA-4, anti-PD-1, or anti-PD-L1 antibody.

16. A method according to claim 15, wherein the cancer is lung cancer (including non-small cell lung cancer), pancreatic cancer, kidney cancer, head and neck cancer, lymphoma (including Hodgkin's lymphoma), skin cancer (including melanoma and Merkel skin cancer), urothelial cancer (including bladder cancer), gastric cancer, hepatocellular cancer, or colorectal cancer.


15

17. A method according to claim 15, wherein the anti-cancer immunotherapy agent is ipilimumab, nivolumab, or pembrolizumab.


1/20

FIG. 1


2/20

FIG. 2A


3/20

FIG. 2B


4/20

FIG. 3A


5/20

FIG. 3B


6/20

FIG. 4A


7/20

FIG. 4B


8/20

FIG. 5


9/20

FIG. 6A


10/20

FIG. 6B


11/20

FIG. 7


12/20

FIG. 8


13/20

FIG. 9


14/20

FIG. 10


15/20

FIG. 11


16/20

FIG. 12


17/20

FIG. 13

18/20

FIG. 14

19/20

FIG. 15

20/20

FIG. 16